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CHAPTER 1 INTRODUCTION 
Chronic kidney disease (CKD) in Bangladesh 
Bangladesh is a small but heavily populous country in the world. It is as big as the 
state of Iowa in USA, with a population density of almost 3000 persons per square mile, 
while the population density of Iowa state is only 50 persons per square mile. Revised version 
of world population prospectus in 2019 stated that, in 2016, the total population in 
Bangladesh was 161,376,708. This makes it the 8th most populous country in the world [1]. 
Dhaka is the capital and largest city of Bangladesh and in 2018,World Bank reported that, the 
population in Dhaka could be as high as 20 million by 2015 [2]. Therefore, in 2016, it was 18 
million and in 2020, the population reaches to 21 million. In past decades, communicable 
diseases were responsible for majority of morbidity and mortality in Bangladesh. For that 
reason, much of health care costs in Bangladesh is invested in poverty alleviation, birth 
control, clean drinking water supply, maternal and child health, and the removal of infectious 
and communicable disease [3]. However, due to epidemiological transition, the disease 
pattern changed from communicable and infectious diseases to non-communicable diseases 
like hypertension, diabetes, cardiovascular disease and CKD [4]. Due to the higher burden of 
treatment cost and existing government policy, the treatment for CKD is given a low priority 
in this region despite the fact that, the prevalence of CKD is 18 million among people living 
in both rural and urban settings in Bangladesh[3].  
About 35,000-40,000 people reach end stage renal disease (ESRD) and 40,000 
patients die due to CKD each year in Bangladesh. In 2004, kidney disease care was available 
in 6 out of 13 government hospitals and dialysis facilities were available in 4 of the 13 
university hospitals. There were also 10 private hospitals that provide treatment facilities for 





private sector [5]. In 2014, there were around 84 dialysis centers in Bangladesh, of which, 
half were situated in Dhaka city. Remaining were in other six large cities of the country. 
However, at that time, available facilities could hardly cover only 9000 to 10,000 new 
patients (one-third) for twice weekly dialysis and the remaining 66% of patients had no 
access to hemodialysis [6]. As the treatment of ESRD is very expensive and off limits for the 
majority of Bangladeshi people, 70% of patients start on dialysis and stop treatment after 3 to 
6 months because they can no longer afford it [3]. However, the current capacity of both 
public and private hospitals can provide facilities to only 10% of the affected people. The 
remaining patients die without any prior treatment and due to inaccessibility and 
unaffordability of services. In October 2017, ‘Bangladesh Tribune’- an online Newspaper 
published that, around 20 million people in Bangladesh are suffering from kidney disease, of 
which, 8 lacs (800,000) require dialysis but only 30 thousand were able to receive it. Based 
on their report, there were 101 dialysis centers across Bangladesh in 2017 with around 1300 
to 1500 non-functional dialysis machines, but the number is very low, and at least 1,000 more 
centers with fully functional machines are needed to treat the large number of patients.  
In this chapter, there will be a brief introduction of the organ-Kidney, its structure and 
function, abnormalities in its function and different types of kidney diseases with an emphasis 
on CKD, ESRD and its complications and current scenario in Bangladesh.  
Kidney-its structure and functions 
The kidneys are a pair of bean-shaped organs-each weighing about 150 g in male and 
135g in female. Both kidneys lie in the retroperitoneal space, left one on a slightly upper 
position than the right one. It is a complex organ with highly specialized cells. Its functional 
unit is called, “nephron”, where each kidney has about 1 to 1.3 million of nephrons. Each 





distinct parts-proximal tubule, loop of Henle, distal tubule, and collecting duct (Figure 1-1). 
Major functions of nephrons are-a) Filtration-Glomeruli generates ultrafiltrate of the plasma, 
b) Reabsorption-Tubules selectively reabsorb substances from the ultrafiltrate, and c) 
Secretion- Tubules secretes substances into the urine. Major function of the kidneys is the 
correction of the composition and volume of body fluid that deviate from the normal range 
due to food intake, metabolism, exercise and environmental factors, which in case of a 
normal individual could take place within an hour or so. Another important function is the 
excretion of urea, toxin and foreign metabolites and the formation of urine [7]. Typically, 
kidneys receive 1700 L of blood per day for filtration where large and negatively charged 
molecules are restricted. Then glomeruli form 180 L of urine per day, of which, 99% is 
reabsorbed by the tubules (sodium, potassium and glucose), thus each day, 1 to 2 L of urine 
with other waste products, toxins, organic acids and extra minerals are excreted from the 
body via kidneys. Kidneys are also responsible for the production of hormones and enzymes, 
such as-renin (catalyze angiotensin, a vasoconstrictor peptide and regulate blood pressure), 
erythropoietin (a glycosylated protein with 165 amino acids that stimulates the maturation of 
red blood cells in bone marrow), and activation of the most active form of vitamin D, 1-25-
Dihydroxy Calciferol (D3) that aid in calcium and phosphate balance in the body and 
maintain bone health. Kidneys help to regulate ion concentration (sodium, potassium and 
calcium) to maintain homeostasis balance, regulate pH of blood plasma via excretion of 
excretion of hydrogen ion and reabsorption of bicarbonate ion to maintain acid-base balance 
in the body [7-9] (Table 1-1). 
Different Types of kidney diseases 
There are various types of kidney disease such as-urinary tract infection (UTI) with 





azotemia with an elevation of blood urea nitrogen (BUN) and creatinine level, nephrotic 
syndrome with damages the filtering unit that allow them to leak protein into the urine, focal 
segmental glomerulosclerosis (FSGS), and uremia with a raised level of urea and other 
nitrogenous wastes in the blood [7]. In 2012, KDIGO (Kidney Disease: Improving Global 
Outcomes) defines acute kidney injury (AKI) as an increase in serum creatinine level by 
more than 0.3 mg/dl within 48 hours or urine volume of less than 0.5 ml/kg body weight/hour 
for more than 6 hours with sudden, temporary, or sometimes fatal loss of kidney function. It 
occurs due to injury, surgery, NSAIDS overdose or myocardial infarction (MI). The 
condition is often reversible with short term treatment and kidney function improves [10].  
Chronic Kidney Disease (CKD) 
Definition and classification: CKD is considered as one of the major public health 
problems worldwide. In developed countries, the mortality rate due to CKD is alarmingly 
high. It is a gradual, progressive and irreversible loss of kidney function over a long period, 
classified based on glomerular filtration rate (GFR) or albuminuria, when a patient’s GFR 
falls below 60 ml per minute per 1.73 m2 for more than 3 months or when a patient’s urine 
albumin-to-creatinine ratio is over 30 mg of albumin for each gram of creatinine (Figure 1-2) 
[11]. According to the National Kidney Foundation (NKF) Kidney Disease Outcome Quality 
Initiative (K/DOQI) guidelines, CKD is defined as, “ a chronic disease state in that 
irreversible, structural, or functional abnormalities of the kidney, with or without a 
decreased glomerular filtration rate (GFR), are present for at least three consecutive 
months” [12]. Based on CKD-EPI  (chronic kidney disease epidemiology collaboration) 
equation, which is better than MDRD (modification of diet in renal disease study) equation 
for a clinical setting, estimated GFR (eGFR) is used to classify different stages of CKD[13]. 





stage 5 or ESRD or a complete renal failure with a GFR of less than 15 ml/min/1.73m2 
(Figure 1-3). When CKD reaches to stage 5 or ESRD, patients require renal replacement 
therapy (RRT) either by dialysis or transplantation as a life-saving approach. ESRD is a 
devastating medical, economic and social problem.  
Incidence and prevalence: Globally, the incidence of CKD was 214.63 per million 
population in 1990, which was increased to 288.53 per million population in 2016 [14]. In 
developed countries (e.g. USA), the incidence of ESRD was 378 per million population and 
the prevalence was 2128 per million in 2015[15]. The incidence of ESRD in developing 
countries was 34 (Algeria) to 240 (South Africa) per million population in 1999 [16]. USRDS 
report revealed that, in 2016, the incidence rate of ESRD in the United States (US) was 373.4 
per million population (pmp) per year, a total of 124,675 new cases reported to have ESRD. 
The prevalence rate of ESRD was 2160.7 pmp, a total of 726,331 prevalent cases of ESRD 
based on December 31, 2016 data in the US. Overall, CKD stages 1 to 5 increase from 13.6% 
in 2012 to 16.1% and CKD stages 3 to 5 rises from 6.2 to 7.5% in 2016 (Figure 1-4)[15]. 
Studies done in rural and urban areas of Bangladesh to assess the prevalence of CKD are 
combined in table 1-2, where, in one study, prevalence of CKD in Bangladesh was reported 
as 26%[17]. In 2015, Das et al. showed that, prevalence of stage 2 CKD was 24% and mostly 
in female.[18]. Although the prevalence of ESRD in Bangladesh is unknown, it could be 200 
to 250 per million population per year and the incidence rate will be higher than the 
prevalence rate [6].  The prevalence of CKD among urban Bangladeshi population has been 
estimated at 16% to 18% [17], and of them 11% were in stage III to V [19]. In Bangladesh, 
incidence of ESRD could be 100 per million or 16100 new patients develop ESRD each year 





Accurate assessment of the incidence and prevalence of ESRD becomes difficult in 
Bangladesh due to lack of proper renal registries of patients.  
Etiology: Based on United States Renal Data System (USRDS) Annual report, 
prevalence of CKD among diabetics is 36% (2013-2016) and 31% among hypertensive 
individual (2013-2016)[15]. Highest correlation was observed between age and eGFR and 
between hypertension (HTN) and albuminuria. Among adult NHANES participants in 2013-
2016, prevalence of CKD was highest (21%) among individuals aged more than 60 years, 
followed by self-reported cardiovascular disease (SR-CVD) (26.3%), DM (18.7%), HTN 
(16%) and higher BMI (7.3%). An albumin-creatinine ratio (ACR) of more than 30 mg/g was 
most common among individuals with DM (27%), followed by those with HTN (21%), 
aged+ 60years (17.3%), with SR CVD (14.8%), and of higher BMI (12%). The presence of 
both eGFR <60 and ACR ≥30 was most common with SR-CVD, at 11%, followed by DM at 
8.5%, those aged 60+ years (6%), with HTN (5.6%), and with higher BMI (2.6%) (Figure 1-
5)[15]. One study conducted in Bangladesh among ESRD patients, not on dialysis showed 
that, 18.3% had ischemic heart disease, 38% had heart failure and 9% had left ventricular 
hypertrophy. Patients with DM experienced more CVD events compared to their non-diabetic 
counterparts [20]. Another screening study conducted in a public place in Dhaka city, 
Bangladesh among 634 normal individuals showed that, 12.8% of individuals participated in 
the study had CKD, of which, 6% were in CKD stage 3 and these patients had a higher body 
mass index and systolic blood pressure, and majority of them were aged above 60 years[21]. 
In 2012, Ahmed et. Al. conducted a study in six hemodialysis centers in Bangladesh and 
found that, glomerulonephritis and diabetic nephropathy were the most common causes of 





conducted in rural Bangladesh showed that, microalbuminuria and overt-proteinuria are 
common among rural Bangladeshi people with hypertension [23].  
Treatment options: There are two ways to treat a patient if he has kidney failure – 
dialysis, or renal transplant. However, the number of kidneys available for transplant is very 
low. So, dialysis remains the only option for a patient to survive until he got a transplant. In 
2016, 35% of new ESRD patients in the US were reported to receive little or no pre-ESRD 
nephrology care[15]. Options for renal replacement therapy include either dialysis 
hemodialysis (HD) or peritoneal dialysis (PD) or transplantation of kidney (best treatment 
option) (Figure 1-6). A patient can also choose “no renal replacement therapy or comfort 
care” that leads to certain death within a few months and also known as “conservative kidney 
management” [24]. USRDS revealed that, in 2016, 63% of patients received HD (98% of 
which was on in-center and 2% on home HD), 7% received PD and 29.6% received kidney 
transplantation as treatment option[15]. In Bangladesh, treatment facilities are available only 
in major cities and many patients travel a long distance to seek care.[25]. Around 80% of 
kidney failure patients cannot afford the treatment cost of profitable centers and 
approximately 66% patients have no access to any kind of treatment facilities as the existing 
facilities can hardly accommodate only 9,000-10,000 new patients [6]. Even though there is 
improvement in dialysis technique and patient care [15], patients are reported to have poor 
quality of life [26]. In Bangladesh, outcome of that small number of patients who can access 
hemodialysis is not great. Survival of HD patients was estimated in a study which showed 1, 
3 and 5 year survival rate of 90%, 75% and 55% respectively [27].  
Complications due to CKD: Due to a reduction in the number of functional nephrons, 
kidneys become less flexible to different solutes in CKD and there is reduced renal clearance, 





oxygen species, and formation of advanced glycation end products (AGE) [28, 29]. 
Metabolic acidosis is an early symptom in patients with CKD. It gets worsen as the disease 
progresses to ESRD and may affect other organic function- cardiovascular system, central 
nervous system, pulmonary function, inflammatory process, immunity and metabolism[30]. 
Impaired oxidative balance in dialysis patients are partly due to increased production of 
reactive oxygen species, reduced clearance, and weak antioxidant defense mechanism [31]. 
Insulin resistance may occur due to reduced catabolism of insulin and glucagon[32]. Altered 
hormone production also leads to anemia[33] and mineral and bone disorder (CKD-MBD) 
[34]. Anemia with a hemoglobin level of less than 11 g/dL results in poor quality of life and 
higher cardiovascular mortality and morbidity in ESRD patients[35].  In case of CKD-MBD, 
as GFR declines, 1-α-Hydroxylase enzyme, responsible for the conversion of vitamin D into 
its active form became inactive, results in increased production of parathyroid hormone 
(hyperparathyroidism), diminished absorption of calcium ion from the intestine, 
overproduction of phosphorous in blood (hyperphosphatemia), all of which lead to the release 
of calcium from bone and leads to mineral-bone disorder (MBD) [36]. Malnutrition and 
chronic infection, common in dialysis patients also triggers anemia, that eventually induce 
inflammation, oxidative stress, and cardiovascular complication in the long run[37, 38].  
Hypoalbuminemia is another important risk factor for these patients and a serum albumin 
level of less than 3.8 g/dl is associated with malnutrition [39, 40]. It is also associated with 
high rate of CVD mortality [41]. Several non-nutritional factors are also associated with 
hypoalbuminemia (infection, inflammation, fluid overload, inadequate dialysis and metabolic 
acidosis). Additionally, around 20% of ESRD patients die due to treatment complication[42]. 
One study conducted in Bangladesh in 2012 showed that, prevalence of anemia was almost 





CKD stage 5 patients, not on dialysis. 23% of these patients also had an elevated calcium-
phosphate product [20]. It has been also noted that, cardiovascular (CVD), cerebrovascular, 
and peripheral vascular diseases are more common causes of high rates of morbidity and 
mortality among CKD patients [43]. Patients with CKD have a higher risk of developing 
CVD, stroke and dyslipidemia, a compromised antioxidant system, metabolic abnormalities 
and early death [44]. Mortality among dialysis patients and the possible causes behind it have 
been studied in different countries and shows markedly different patterns based on to timely 
access to pre-ESRD medical care, management of biochemical abnormalities in advanced 
CKD, access to quality of ESRD medical care, and ESRD education and support service [45]. 
The situation is even worse in Bangladesh, where little focus is given to prevent the 
occurrence of chronic disease. More focus is given on eradication of infectious and 
communicable disease, birth control, and maternal and childhood mortality [3]. There is 
limited access to treatment facilities, and little government support is available for patients 
with CKD. 
Inflammation: Inflammation is a physiological response, defined as, “ a localized 
adaptive response, elicited by injury or destruction of tissues that serves to destroy, dilute, or 
sequester both the injurious agent and the injured tissue” [46]. It may arise due to prolonged 
poor appetite, skeletal muscle wasting, hypercatabolism, hormonal imbalance, and 
atherosclerosis, all of which are common in dialysis patients [47]. Assessment of 
inflammation in case of Bangladeshi ESRD patients was not properly documented to the best 
of our knowledge, only in one study, it was reported that, C-reactive protein (CRP) was 
present in 78% of CKD stage 5 (not on dialysis) pateints, which is one of the markers of 
inflammation [20]. Another study showed that, Bangladeshi ESRD patients with a high CRP 





cardiovascular events and concluded that, inflammation may play a role in both the 
progression of cardiovascular disease and malnutrition among ESRD patients[48]. 
Dyslipidemia: Advanced CKD patients including ESRD on dialysis also develop 
dyslipidemia [49]. Dyslipidemia in CKD is characterized by increased level of  triglyceride 
(TG) and very low density lipoprotein (VLDL), varying level of LDL-C and a decreased 
level of plasma HDL-C [50]. Unlike dyslipidemia in normal individual, total cholesterol (TC) 
and low density lipoprotein (LDL-C) are within normal range or even lower among CKD 
patients with dyslipidemia. However, there was no large prospective study conducted in 
ESRD population to assess the relation between CVD risk and dyslipidemia[51]. Dialysis 
patients with lower level of TC or LDL-C are also at very high risk of all cause and 
cardiovascular mortality, likely due to inflammation and malnutrition[52]. Dyslipidemia is a 
contributing factors to the developoment of atherosclerosis [49]. In normal metabolism, 
HDL-C promotes reverse-cholesterol transport system by the uptake of cholesterol from 
extrahepatic tissue and maturation of HDL particle. However, in CKD, this system becomes 
dysfunctional and also promotes LDL-oxidation (Figure 1-7) [53]. In a cross sectional study 
conducted in Bangladesh in 2012, it was found that, patients on maintenance hemodialysis 
(MHD) showed a different pattern of dyslipidemia-a low HDL-C, high TG and an altered TC 
to HDL-C ratio when compared to healthy control[54].  
Cardiovascular disease (CVD): The risk of developing CVD is 10 to 30 times higher 
among CKD patients compared to general population (Figure 1-8)[15]. Prevalence of some 
common types of CVD in dialysis patients include-coronary artery disease (66%), left 
ventricular hypertrophy (75%), and cardiac failure (40%) [15, 55]. CVD risk is also higher 
among patients undergoing HD (Figure 1-9)[15]. There are both traditional and non 





factors include-diabetes melitus, hypertension, sedentary lifestyle, smoking, dyslipidemia and 
family history whereas non-traditional risk factors include-inflammation, malnutrition, 
oxidative stress, endothelial dysfunction, uremic toxin, and altered mineral metabolism 
(Figure 1-10) [53]. Various exposures that increase the cardiovascular disease burden in 
ESRD patients involve-comorbidities, inflammmation and oxidative stress, nutrient loss due 
to dialysis process itself, limited intakes of antioxidents due to dietary restrictions as well as 
genetic attributes [56]. One study showed that, prevalence of ischemic heart disease, heart 
failure, arrhythmia and left ventricular hypertrophy was 18.3%, 38%, 4.7% and 9% among 
Bangladeshi CKD stage 5 patients not on dialysis[20]. 
Malnutrition: Malnutrition among renal patient is termed as either ‘Uremic 
malnutrition’, or “Renal Cachexia’ or ‘Protein-energy wasting (PEW)’ or ‘malnutrition-
inflammation complex syndrome (MICS)’, malnutrition inflammation atherosclerosis (MIA) 
syndrome, kidney disease wasting’ and is associated with the prevalence of morbidity and 
mortality among these patients [57]. Malnutrition or PEW is considered as a common 
problem among adult HD patients [58]. The concept of PEW was proposed in 2007 by the 
International Society of Renal Nutrition and Metabolism (ISRNM) “as a state of nutritional 
and metabolic derangements in patients with CKD characterized by simultaneous loss of 
systematic body protein and energy stores, leading ultimately to loss of muscle and fat mass 
and cachexia” [57]. Studies suggested that, patients undergoing dialysis have reduced muscle 
mass and fuel reserves [59]. In a recent study, ISRNM proposed a “PEW” score, which if 
high, could indicates systemic inflammation, muscle wasting and malnutrition among MHD 
patients [60]. One-third of MHD patients having malnutrition have a high mortality risk [40]. 
Causes of PEW in CKD include decreased protein and energy intake, hypermetabolism, 





dialysis related factors which is shown in Table 1-3 [59]. Figure 1-11 shows that, as the CKD 
progresses from stage 1 to stage 5 and GFR decreases, complications, such as malnutrition, 
hyper catabolism, uremic toxin, and inflammation increase, all of which will lead to PEW 
and further complications which may cause even death [57]. Figure 1-12 shows that, PEW is 
related with increased frailty and depression, cardiovascular disease and infection-all of 
which may create volume overload, oxidative stress, endocrine disorder, anemia, anorexia, 
acidosis, poor nutrient intake and more nutrient loss during dialysis[57]. One study, 
conducted in Saudi Arabia revealed that HD patients have a tendency toward developing 
malnutrition and are at high risk of both morbidity and mortality [61]. Another study 
conducted in 2018 showed that, prevalence of malnutrition among Bangladeshi ESRD 
patients on MHD was 16.9%[62]. Global prevalence of PEW, based on a meta-analysis of 90 
studies from 34 countries including 16,434 patients, has been estimated at between 28-54% 
(25th-75th percentile) [63]. However, data on prevalence of PEW in different countries around 
the world are poorly defined due to lack of gold-standard methods/definition to diagnose 
PEW (Table 1-4). Combination of MICS, along with inflammation and dyslipidemia are 
responsible for increased incidence of atherosclerosis among hemodialysis patients [64]. 
Importance of the Nutritional Management in CKD 
A common trend seen among dialysis patient is that, dietary intake becomes 
inadequate during transition from non-dialysis to dialysis period. Often patients don’t meet 
their recommended intake, based on NKF/KDOQI guidelines for HD patients. Transition 
from non-dialysis dependent CKD to dialysis dependent ESRD is a critical phase for each 
patient and requires a combination of clinical, nutritional, and psychological assessments 





outcomes. Therefore, careful and appropriate selection of food is crucial to address such 
problems.  
Several epidemiological studies done in different countries showed that patients with 
kidney disease have limited understanding of their illness and know little about renal specific 
diet practice, where, patients with abnormal laboratory values for serum albumin, 
phosphorus, potassium, low body mass index (BMI) (<23 kg/m2), poor muscle mass and 
muscle strength and poor dietary intake were considered as patients having poor existing 
renal-specific nutrition knowledge [66]. Studies have also shown promising results for 
educational intervention among dialysis patients in fluid management, exercise and 
adaptation to treatment [44], and also showed better results in controlling diet-related 
incidence of hypertension, hyperphosphatemia, hyper/hypokalemia and protein-energy 
wasting, thus reduce further deterioration in renal function[67]. One study showed that, 
dialysis patients who received one diet counseling session by a registered dietitian showed 
significant improvement in their health status as assessed by their body mass index and 
biochemical parameters compared to patients who did not receive any nutrition support [68]. 
Another study from Taiwan showed that, provision of nutrition education among predialysis 
patients helped to keep stable or improve their physiologcal status and reduced further 
deterioration of renal function by eliminating patients’s delusion about the use of Chinese 
herbs [69]. A study recently conducted in Bangladesh also mentioned that, illiteracy might be 
a reason for increased prevalence of malnutrition among renal patients [62].  
Inadequate nutrient intake is a major contributing factor to the development of PEW 
among ESRD patients on MHD[12]. Nutritional management involves maintaining a good 
nutritional status as well as establishing normal serum chemistry via adequate intakes of all 





clinicians since the outcomes of  dialysis depends on the adequacy of both the dialysis 
treatment and the dietary intake and nutritional status of the patient [70]. Various dietary 
restrictions are traditionally imposed on dialysis patients, whereas little evidence exists to 
their benefits [71]. The goals for nutrition therapy for dialysis patient is to provide them with 
an attractive and palatable diet, control edema and serum electrolytes, prevent nutritional 
deficiencies, renal osteodystrophy, and cardiovascular complications. Aims of dietetic 
intervention among dialysis patients should be to optimise their nutritional status, keep renal 
biochemistry within safe limits, control blood pressure, blood glucose, and fluid overload, 
and thus make dietary advice as practical as possible to aid compliance. For this reason, all 
renal patients should have adequate renal specific dietetic or nutritional support [72].  
Protein: According to a simplified historical scheme on main focus in diets for CKD 
patients it has shown that, in the first Era, "Potassium" was considered to be the main killer 
with “Hyperkalemia” being the main concern. Therefore, fruits and vegetables were regarded 
as the forbidden foods. In the second Era, as soon as dialysis become efficient and survival 
rates increased, "Hyperphosphatemia" was identified as the main enemy and milk and its 
products were banned from the diet for these patients to avaoid vascular calcification. Then, 
in the third or present Era, "Protein-energy-wasting" or malnutrition was identified as the 
compromised health status. Thus a diet high in both calorie and protein is recommended 
(Table 1-5) [73].  
A high blood urea level may increase protein carbamylation and production of 
reactive oxygen species, thus leads to oxidative stress, inflammation, endothelial dysfunction, 
and cardiovascular disease [74]. A diet containing 0.6 to 0.8 g/Kg body weight/day of protein 
where, half of the protein comes from high biological value protein sources such as-dairy 





with moderate to advanced CKD [75]. To reduce the prevalence of PEW among children and 
malnourished patients, a protein intake of at least 0.8 g/Kg body weight/day is recommended 
[76]. A randomized controlled clinical trial conducted in CKD stage 3 to stage 5 patients in 
Brazil showed that, patients’ adherence to a low protein diet can be improved with provision 
of nutrition education[76]. A prospective cohort study (ARIC) assessed the association 
between the dietary protein sources and incident CKD and during a follow up of 23 years 
showed that, high intake of red and processd meat was associated with a high risk of CKD, 
compared to a diet rich in nuts, legumes and low-fat dairies using a 66-item food frequency 
questionnaire (FFQ) [77].  
However, a low-protein diet should not be prescribed to CKD stage 4 and stage 5 
patients with poor appetite and weight loss [78]. To manage increase loss of protein due to 
ongoing dialysis procedure, K/DOQI recommended around 1.2 to 1.3 g of protein/Kg body 
weight/day for a typical hemodialysis patient [79]. 
Phosphorus: A major role of kidney is to maintain phosphorus homeostasis. In 
individuals with CKD, high dietary phosphorus burden could worsen hyperparathyroidism 
and renal osteodystrophy, promote vascular calcification, and cardiovascular events, and thus 
increase mortality. Hyperphosphatemia is defined as an abnormal high serum phosphorus 
level of more than 1.46 mmol/L, a common metabolic anomalis in advanced CKD [80]. It is 
associated with coronary artery calcification, development of secondary hyperparathyroidism, 
left ventricular hypertrophy, mineral bone disorder and cardiovascular and all-cause mortality 
[81]. When phosphorus builds up in blood, it also pulled calcium from bones and cause weak 
and fragile bones. It also forms crystals which accumulates in joint, muscle, skin, blood 
vessels and heart and cause pain in bones, poor blood circulation, and damage heart [80]. In a 





altered mineral metabolism (laboratory values for serum albumin, calcium, potassium, 
sodium, phosphorus, hemoglobin, vitamin D, urea, creatinine fall both above or below the 
K/DOQI recommended range) is related with high mortality rate among patient. The 
appropriate use of dialysate calcium concentration, use of food items with low Phosphorus to 
protein ration, phosphorus binders, vitamin D supplementation will improve patients’ 
outcome [82].  
The quantity and bioavailability of phosphorus differs with the type of dietary protein 
intake. Gastrointestinal absorption of phosphorus is lower for plant due to phytates than for 
meat [83], also processed foods have higher phosphorus burden due to the use of food 
additives [84]. Organic phosphate in fresh plant food has an absorption rate of 20% to 50% 
and in animal-based food, it is 40% to 50%, whereas, the absorption rate is more than 90% in 
inorganic phosphate from processed foods and carbonated drinks. Thus type of phosphate 
(organic or inorganic) is an important consideration for patients’ education [85, 86]. 
Restriction of dietary phosphorus to less than 800 mg/day is recommended for CKD patients 
[79]. However, controlling hyperphosphatemia is associated with poor outcomes among 
dialysis patients who are at high risk of protein-energy wasting, and an individualized dietary 
approach incorporating the use of phophate binders should be recommended for dialysis 
patients [75]. Controling dietary phosphorus is quite challenging in real-life settings. 
Effective strategies include restriction of phosphorus rich food, selection of fresh food mostly 
from plant origin, adoption of boiling as a prefered cooking method, avoid foods with 
preservatives, fast food, and street food. Boiling causes demineralization of food by reducing 
phosphorus as well as sodium, potasium, and calcium content in both vegetables and animal-
derived products. The degree of mineral los is proportional to the amount of boiling water 





Studies showed that, boiling reduces 51% of P from vegetables, 48% from legumes, and 38% 
from meat [87]. 
Phosphorus (P) to Protein (Pro) ratio (mg of P/g of Pro): Ideally, a beneficial diet 
for a hemodialysis patient should be high in protein and low in bioavailable phosphorus. 
Because, PEW results from a reduction in protein intake due to the  restriction of dietary 
phosphorus intake. Both low dietary protein (Pro) intake, high dietary phosphorus (P) intake 
and high ratio of dietary P/Pro intake are associated with increased mortality in hemodialysis 
patients [88]. A favorable P to Pro ratio of 10 to 12 mg/g is recommended by NKF KDOQI 
[89]. It has been showed that, a P/Pro ratio of a whole egg is more than 14 mg/g of protein, 
whereas, the ratio is less than 2 mg/g of protein in case of a egg white [90]. Nutrition 
education is necessary in this regard. To help in selecting foods with lower phosphorus 
content via different cooking methods, phosphorus bioavailability, a phosphorus pyramid is 
developed by National Kidney Foundation considering loss of phosphorus via different 
cooking methods, phosphorus bioavailability, and P to Pro ratio and is widley used as a 
popular, visual nutrition education tool for CKD patients (Figure1-13)[91]. 
Sodium and Fluid: Hypernatremia takes place when dietary sodium intake is high, 
that may lead to fluid retention, rise in blood pressure, and shortness of breath. In patients 
with CKD, dietary sodium restriction is recommended to control fluid retention and 
hypertension and to improve cardiovascular risks [92]. A dietary sodium intake of less than 
4g/day is recommended for overall management of CKD and a sodium intake of less than 
3g/day is recommended for specific management of fluid retention and hyponatremia. 
Additionally, patients with stage 3 and above should limit fluid intake to less than 1.5 L/day. 
Adjustment should be made based on hot climate and other associated condition of fluid loss 





Common cooking practice showed the use of excess dietary salt due to poor health literacy 
and unawareness among Bangladeshi CKD patients in East London [94]. K/DOQI 
recommended a dietary sodium intake of 750 to 2000 mg a day and fluid intake of 750 to 
1500 ml a day for a typical hemodialysis patients [89].  
Potassium: Potassium imbalance is another common cause of morbidity among 
dialysis patients. For most people, fresh fruits and vegetables, rich in potassium are 
considered as healthy choice due to high fiber and vitamin content and low acidogenecity 
[95]. In epidemiological studies, both low (<4.0 mmol/L:hypokalemia) and high (>5.5 
mmol/L:hyperkalemia) plasma potassium levels are related to rapid progression of kidney 
disease [96]. Though hypokalamia is more commong among hospitalized patients or patients 
undergoing peritonial dialysis, hyperkalamia is most common among hemodialysis patients 
due to excess intake and inadequate removal. Regulating dietary intake of potassium is 
difficult for patients who are also told to reduce intakes of phosphorus, sodium, water, and 
carbohydrates while having diabetes as a comorbidity. Excessive dietary potassium 
restriction can expose patients to less heart-healthy and more atherogenic diet and 
constipation [97]. Appropriate cooking method in order to leach potassium from fruits and 
vegetables should be adopted to avoid hyperkalemia. In hemodialysis patients with 
hyperkalemia, a dietary potassium intake of less than 3 g/day with a balanced intake of fiber-










Summary with Specific Aims 
There is a rising trend in the incidence and prevalence of CKD in Bangladesh. Every 
year around 35,000-40,000 people reach ESRD and about 40,000 people die from kidney 
disease. Malnutrition and inflammation contributes to the high rates of mortality among 
dialysis patients. HD patients have a greater risk for cardiovascular disease, stroke and 
dyslipidemia, a compromized antioxident system, cognitive dysfunction, metabolic 
abnormalities, hospitalization, and all cause mortality. The main goals of treating patients 
with CKD are to slow down disease progression and prevent CVD and atherosclerotic 
complications. Nutrition and life-style modifications might play a key role to improve the 
outcomes. However, no single method can assess the overall nutritional and health status of a 
patient undergoing HD and a combination of multiple approaches should be employed to 
understand this issue. One such approach could be to assess the impact of improved nutrition 
knowledge on the nutritional and health status of HD-CKD patients. Therefore, by providing 
patients a renal-specific nutrition and health related counseling, it may be possible to improve 
dialysis outcomes as well as nutrition and health status of this population group in a resource-
poor setting. To the best of our knowledge,  no study has been done in Bangladesh to assess 
the current nutrition and health status of hemodialysis patients and see the impact of renal-
specific nutrition knowledge on their overall quality of life.  
The goal of this Ph.D. proposal is to document the extent of nutrition and health 
status of patients undergoing HD in a resource poor setting. The central hypothesis is that, 
high morbidity and mortality in HD patients in Bangladesh is in part attributed to poor 
nutrition and nutritional knowledge. The rationale for this research proposal is that, once the 
basis for poor nutrition and lack of nutrition knowledge has been established, appropriate 





in an improvement in their quality of life. The information will also serve as a basis for 
training support staff to disseminate nutrition information in dialysis units across Bangladesh.  
To test my hypothesis I proposed the following specific aims: 
Specific Aim I:  
To assess the current nutrition and health status of hemodialysis patients in a specialized renal 
hospital in Dhaka, Bangladesh. 
Specific Aim II: 
To document the prevalence of protein energy wasting (PEW) based on criteria from the 
International Society for Renal Nutrition and Metabolism (ISRNM) among the existing 
hemodialysis patients. 
Specific Aim III:  
To develop culturally acceptable renal-specific nutrition information and evaluate its impact 













Tables and Figures 
Tables 
Table 1-1. Kidney Functions [9]. 




Waste elimination Removal of metabolic waste products (urea, creatinine, uric acid) 
and elimination and detoxification of drugs and toxins 
Fluid balance Involve in removal and reabsorption of water to maintain fluid 




Involve in secretion, excretion and reabsorption of H+, HCO3-, NH4+, 
PO4++ to maintain blood pH 
Electrolyte balance Involve in excretion and reabsorption of electrolytes such as sodium, 
potassium, chloride, and bicarbonate to maintain homeostasis 
Mineral 
metabolism 
Control of mineral metabolism through endocrine synthesis (1,25-
dihydroxycholecalciferol and 24, 25-dihydroxycholecalciferol) and 
excretion of phosphorous 
Endocrine 
functions 
Regulation of systemic blood pressure (renin, angiotensin, 
prostaglandin, nitric oxide, sodium homeostasis and production of 
erythropoietin 
Metabolic process Regulation of metabolic process (gluconeogenesis, lipid metabolism) 
Degradation and catabolism of peptide hormones (insulin, glucagon, 
parathyroid hormone) and low molecular weight protein (β2-





Table 1-2. Prevalence of Chronic Kidney Disease (CKD) in Bangladesh 























































634 12.8 Screening 
Anand et 
al.[17] 


















MDRD: modification of diet in renal disease, C-G: Cockcroft-Gault formula, eGFR: estimated glomerular 











Table 1-3. Causes of PEW in CKD patients [59] 
 
Causes of PEW in CKD patients 
1 Decreased protein and energy intake 
a Anorexia  
i. Dysregulation in circulating appetite mediators  
ii. Hypothalamic amino acid sensing  
iii. Nitrogen-based uremic toxins 
b Dietary restrictions 
c Alterations in organs involved in nutrient intake 
d Depression 
e Inability to obtain or prepare food 
2 Hypermetabolism 
a Increased energy expenditure  
i. Inflammation  
ii. Increased circulating proinflammatory cytokines  
iii. Insulin resistance secondary to obesity  
iv. Altered adiponectin and resisting metabolism 
b Hormonal disorders  
i. Insulin resistance of CKD  
ii. Increased glucocorticoid activity 
3 Metabolic acidosis 
4 Decreased physical activity 
5 Decreased anabolism 
a Decreased nutrient intake 
b Resistance to GH/IGF-1 
c Testosterone deficiency 
d Low thyroid hormone levels 
6 Comorbidities and lifestyle 
a Comorbidities (diabetes mellitus, CHF, depression, coronary artery disease, 
peripheral vascular disease) 
7 Dialysis 
a Nutrient losses into dialysate 
b Dialysis-related inflammation 
c Dialysis-related hypermetabolism 
d Loss of residual renal function 
Source: Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from 








Table 1-4: Prevalence of malnutrition among HD patients in different countries 
Author Country Sample Size Prevalence (%) 
Campbell et. Al. 2013[102] Australia 213 23.5 
Alharabi et.al. 2012[103] Saudi Arabia 269 48.7 
Harvinder et.al. 2016[104] Malaysia 155 59 
Srivastava et al. 2012[105] India 135 43.0 
Wardani et al. 2019[106] Indonesia 71 66 

























The Risks Dietary Indications 
First Era Potassium Hyperkalemia can be deadly Restrictions on fruits and 
vegetables 
Second Era Phosphate Vascular calcification, 
vascular ageing 
Restrictions on cheese, 
milk and derivatives 
Third Era Malnutrition Risk of death is higher in 
malnourished patients 
Increased protein and 
calorie intake 
The definition of each period is approximate, as each one merges with the next, and the first warnings on 
malnutrition are as old as dialysis itself, while we should always keep in mind the short-term risks of 

















Figure 1-1. Overview of Kidney Structure 
 











Figure 1-2. Percentage of NHANES 2013-2016 participants, in the various CKD (eGFR 
and albuminuria) risk categories (KDIGO 2012)[15] 
 
Data source: USRDS Annual Data Report, 2018 [15].National Health and Nutrition Examination Survey 
(NHANES), 2001-2004, 2005-2008, 2009-2012 & 2013-2016 participants aged 20 and older. Single-sample 
estimates of eGFR and ACR; eGFR calculated using the CKD-EPI equation. Low risk: eGFR ≥60 ml/min/1.73 
m
2 
and ACR <30 mg/g; moderately high risk: eGFR 45-59 ml/min/1.73 m
2
 or eGFR ≥60 ml/min/1.73 m
2
 and 
ACR 30-300 mg/g; high risk: eGFR 30-44 ml/min/1.73 m
2 
or eGFR 45-59 ml/min/1.73 m
2
 and ACR 30-300 
mg/g or eGFR ≥60 ml/min/1.73 m
2
 and ACR >300 mg/g; very high risk: eGFR <30 ml/min/1.73 m
2
 or eGFR 
30-44 ml/min/1.73 m
2
 and ACR 30-300 mg/g or eGFR ≥60 ml/min/1.73 m
2
 and ACR >300 mg/g. 
Abbreviations: ACR, urine albumin/creatinine ratio; CKD, chronic kidney disease; eGFR, estimated glomerular 











Figure 1-3. Stages of Chronic Kidney Disease[107] 
 















Figure 1-4: Prevalence of CKD by stages among NHANES participants (2001-2016)[15] 
Data Source: National Health and Nutrition Examination Survey (NHANES), 2001-2004, 2005-2008, 2009-
2012 & 2013–2016 [15], participants aged 20 & older. Whisker lines indicate 95% confidence intervals. 














Figure 1-5: Distribution of markers of CKD in NHANES participants with diabetes, 
hypertension, self-reported cardiovascular disease and obesity, 2013-2016[15] 
 
Data Source: National Health and Nutrition Examination Survey (NHANES), 2013-2016 [15], participants age 
20 & older. Single-sample estimates of eGFR & ACR; eGFR calculated using the CKD-EPI equation. 
Abbreviations: ACR, urine albumin/creatinine ratio; BMI, body mass index; CKD, chronic kidney disease; SR 













Figure 1-6: Treatment options for Renal Replacement Therapy (RRT) 
 












Figure 1-7. Changes in HDL Function mediated by CKD [53] 
 












Figure 1-8: Prevalence of common cardiovascular diseases in patients with or without CKD, 
2016 [15] 
 
Source: USRDS Annual Data Report [15]. Abbreviations: AF, atrial fibrillation; AMI, acute myocardial 
infarction; CAD, coronary artery disease; CKD, chronic kidney disease; CVA/TIA, cerebrovascular 
accident/transient ischemic attack; CVD, cardiovascular disease; HF, heart failure; PAD, peripheral arterial 
disease; SCA/VA, sudden cardiac arrest and ventricular arrhythmias; VHD, valvular heart disease; VTE/PE, 











Figure 1-9: Prevalence of cardiovascular diseases in adult ESRD patients by treatment 
modality, 2016[15] 
 
Data Source: Special analyses, USRDS ESRD Database [15]. Abbreviations: AF, atrial fibrillation; AMI, acute 
myocardial infarction; CAD, coronary artery disease; CVA/TIA, cerebrovascular accident/transient ischemic 
attack; CVD, cardiovascular disease; HF, heart failure; PAD, peripheral arterial disease; SCA/VA, sudden 













Figure 1-10: CVD Risk Factors in CKD [53] 
 
Source: Cholesterol Metabolism in CKD [53]. Chronic kidney disease (CKD) and cardiovascular disease (CVD) 
risk factors and their interplay. Traditional risk factors are found in both the CKD and non-CKD population. 
Nontraditional risk factors may result from or be worsened by CKD and negatively affect the cardiovascular 












Figure 1-11: The Conceptual Model for CKD progression, and its consequences [57] 
 













Figure 1-12: The conceptual model for etiology of PEW in CKD and direct clinical 
implications [57] 
 











Figure 1-13. The Phosphorous Pyramid [91] 
 













CHAPTER 2 METHODOLOGY 
General Study Design 
The purpose of specific aim I was to examine the current health and nutritional status 
of HD patients. A total of 133 patients on MHD from Kidney Foundation Hospital and 
Research Institute, Dhaka, Bangladesh (in 2017 and 2018) were assessed based on 
anthropometric, biochemical and clinical parameters in this cross-sectional study. Lipid and 
lipoprotein subfractions were analyzed and patients with dyslipidemia were characterized 
using triglycerides (TG) to high density lipoprotein cholesterol (HDL-C) ratios of > 3.8 and < 
3.8 as well as the Adult Treatment Panel (ATP) III, 2013 guidelines. Patients’ data were also 
analyzed based on gender and twice weekly vs thrice weekly dialysis in order to measure any 
differences between these two groups. 
The goal of specific aim II was to identify patients with poor nutritional and health 
status. Patients were assessed for protein energy wasting (PEW) based on ISRNM proposed 
diagnostic criteria. We explored prevalence of PEW at KFHRI where more than  3.5 lacs 
(3,60616) dialysis sessions were offered for patients with kidney failure over the last 16 years 
in KFHRI and  as the recent meta-analysis of global prevalence of PEW across 36 countries 
did not have any data for Bangladesh [63]. 
The goal for specific aim III was to develop an educational tool for improving renal-
specific nutrition knowledge among hemodialysis patients in the form of a “Nutrition 








Study site- Kidney Foundation Hospital and Research Institute (KFHRI) 
Kidney Foundation Hospital and Research Institute (KFHRI) is a specialized hospital 
in Dhaka, Bangladesh. Twenty-two percent of the ESRD patients received renal replacement 
therapy (RRT) and are managed with HD initially. Also, 50% of kidney transplantation are 
performed in KFB each year. The survival rate for both HD and kidney transplant patients in 
KFHRI is better than any other facilities in Bangladesh and other Asian countries [3]. 
Ethics and Human Subjects Issues 
A total of 133 MHD patients were assessed between 2017 and 2018. A pilot study in 
2017 and the clinical trial, “Palm Tocotrienol in Chronic Hemodialysis Study  (PATCH)” in 
2018 were both approved by the ethics board of both KFHRI and Wayne State University 
(WSU), while the PATCH study was further approved by the Institutional Review Board of 
Wayne State University (IRB#123314MP4F), where, 102 were enrolled in a clinical trial 
assessing the impact of supplementation with 300 mg of tocotrienols or placebo (PATCH 
clinical trial NCT 02358967) by the local hospital staffs. The data reported in the current 
study from the “PATCH participants” were collected prior to the start of their 
supplementation. Inclusion criteria was ESRD patients undergoing MHD treatment for at 
least 3 months and more than 18 years old. Informed written consent was obtained from all 
patients. Where needed consent forms and case report forms were translated into the Bangla 
language, approved by bi-lingual nephrologists and registered lawyer (Figure 3-1).  
Anthropometric assessment 
To facilitate anhtropometric data collection, two phases of training were implemented. 
Initially a training workshop was conucted at KFHRI for nurses, medical doctors and the 





research team, just prior to data collection, again involving nurses, medical doctors and 
resident nutrionists. In both sessions, training was provided by individuals who were Level 3 
certified by the International Society for Anthropometry and Kinanthropometry (ISAK) for 
anthropometric assessments. For data collection, patients were assessed by 2-3 teams of 3-4 
individals per team. Each team included a hopsital nephrologist, staff member and a research 
team member. Anthropometric assessments included measurement of height and post-dialysis 
weight, and calculating Body Mass Index (BMI) of a patient using the Quetelet’s index [108]. 
Before or after dialysis session, mid-arm circumference (MAC) was measured for each 
subject in a standing position using a non-stretchable Lufkin® tape (Apex Tool Group, LLC, 
NC, USA). Also, triceps skinfold thickness (TSF) was measured using Lange skinfold 
calipers (Lange Skinfold Calipers, Power System, Tennessee, USA). Mid-arm muscle 
circumference was then calculated using the standard formula: [MAMC=MAC-(3.14 x TSF)] 
[109]. Protocol from the International Society for Advancement of Kinanthropometry (ISAK) 
was followed. Handgrip strength for each patient was measured by taking three readings with 
a rest period of at least 1 min between trials from the non-fistula hand using a Jamar Hand-
grip dynamometer (BK-7498; Fred Sammons, Inc., Burr Ridge, IL). The measurements were 
taken to assess muscle strength of the patient. The measurement was taken before or after the 
dialysis session while the patient was in sitting position and standard protocol from the 
American Society of Hand Therapists was used [110].  
Nutritional assessment  
There is no formal dietetics program or specialized nutrition program with practicums 
in renal nutrition in Bangladesh and most nutrionists are indviduals who took some nutrition 
courses as undergraduates. ‘No’ dietitian with skills was available, routine nutrition 





circumstances, dietary data collection was a big challenge and training was given to hospital 
dietitian before data collection. For nutrition data collection, initially a training workshop was 
conucted at KFHRI for nurses, medical doctors and the local nutrionists. Afterwards, one 
member affiliated with the hospital site attended a two week training workshop in Malaysia 
with other members of the research team. During this visit, shadowing of staff in local 
dialysis units was arranged. A final training session at KFHRI was conducted by members of 
the research team, just prior to data collection. The training was provided by individuals who 
were registered dietitians (accreditation from Austalia and USA). 
In both 2017 and 2018, only one-day 24-hour diet recall data were collected and 
analyzed from all the patients. Then dietary data were analyzed using ESHA Food Processor 
Nutrition Analysis and Fitness Software, version 11.3.285. For mixed dishes, that were not in 
the existing data base, ingredients were entered in the recipe builder within the software and 
approximately 150 Bangladeshi recipes were thus prepared based on recipes available for 
some common foods in Bangladesh from “Food Composition Table for Bangladesh” (Figure 
2-2) [111] and established recipes available from online. Ingredients available in both 
"ESHA" and “Food Composition Table” were used and some were also collected from 
“online sources” and were verified by searching various food database website and 
comparing them.  
Basal Metabolic Rate (BMR) was calculated using Harris-Benedict Equation: [*men: 
66.5+(13.75 x body weight in Kg) +(5.0 x height in cm) - (6.76 x Age in years)] and 






When their weight was <95% or >115% of the standard body weight, we used 
adjusted edema-free body weight and when the value was between 95%-115%, we used 
actual body weight as recommended by NKF KDOQI (2000) guidelines[79]. 
To minimize systemic error, underreporting of dietary data was evaluated by 
calculating the ratio between reported energy intake (EI) and basal metabolic rate (BMR). 
Goldberg cut-off equations for EI: BMR (Energy Intake: Basal metabolic rate) can be used to 
determine the mean population bias in reported energy intake[114, 115]. However, as we do 
not have any physical activity value, here we directly compare energy expenditure with 
energy intake to determine under-reporters, with a ratio of EI:BMR<0.75 being used as a cut-
off for under-reporters, more than 2.4 was considered over-reporters and the ratio of 0.75 to 
2.4 being used as acceptable reporters [116]. It is often difficult to get an accurate picture of 
the dietary intake of patients due to the prevalence of high rates of underreporting among 
CKD patients and there is dispute on how to omit under-reporters while doing dietary 
evaluation especially in terms of total calorie, protein, dietary fiber, calcium and zinc 
intake[117, 118] 
Blood sampling and Lipid measurements  
Non-fasting blood smaples were collected into two sets of tubes, one containing  
Ethylene Diamine Tetraacetic Acid (EDTA) and one containing Lithium Heparin (LH). The 
use of non-fasting blood samples is consistent with recent reports and guidelines where it is 
noted that, they are valid predictors of cardiovascular disease risk [119]. Plasma samples 
were isolated by centrifugation at 3500 rpm for 10 minutes at 40C and multiple aliquots were 
immediately stored at -800C. They were subsequently transported to Wayne State University 
on dry ice via courier (World Courier Service, Bangladesh). Plasma total cholesterol (TC) 





MI, USA). HDL-C was assessed in the supernatant after precipitating apo B lipoproteins with 
dextran sulfate and magnesium ion (Point Scientific Inc.). LDL-C was calculated using the 
Friedwald formula: [LDL-C=TC-HDL-C-(TG/5)]. HDL and LDL-subfraction were analyzed 
in plasma using the LipoprintTM  polyacrylamide electrophoresis-based system (Quantimetrix 
Corporation, Redondo Beach, CA, USA) and were quantitated using the manufacturer’s 
software[120]. HDL can be separated into 10 subfractions which can be grouped into large, 
intermediate and small HDL (Figure 2-3). Similarly, LDL is separated into 7 subfractions, 
which can then be classified into three groups constituting of large, intermediate and small 
LDL (Figure 2-4). This system is certified by FDA for clinical LDL subfraction 
measurements, while values for HDL are for research purposes only. 
Sociodemographic data and medical history were collected for all patients. Data were 
also collected for different types of health-related questionnaire such as malnutrition 
inflammation score (MIS), appetite and diet analysis tool (ADAT), and health-related Quality 
of life (HR-QoL) from 102 patients in 2018. 
MIS Form (Malnutrition inflammation score)  
This is a new comprehensive scoring system with 10 components is an indicator of 
malnutrition-inflammation complex syndrome (MICS) and is also significantly correlated 
with measures of inflammation (C-Reactive Protein), anemia (Hematocrit), and nutritional 
status (Creatinine) as well as hospitalization and mortality of patients on maintenance 
hemodialysis (MHD) [46]. It combines the traditional 7 components of subjective global 
assessment along with body mass index (BMI), serum albumin level and total iron binding 
capacity (TIBC) to represent serum transferrin level. This score has validity and reliability to 
diagnose malnutrition among hemodialysis population [121]. A score >5 indicates 





(normal) to 3 (very severe). The sum of all 10 MIS components ranges from 0 (normal) to 30 
(severely malnourished); higher score reflects a more severe degree of malnutrition and 
inflammation  [46]. 
ADAT Form 
It was developed to assess the appetite and factors affecting food intake in 
hemodialysis patients in accordance with dose of dialysis provided [122]. One study 
suggested that, poor appetite is correlated with increased proportion of malnourished dialysis 
patients [123]. It is a five-point scale, where, “1=very good’, “2=good’, “3=fair’, “4=poor’, 
and “5=very poor’. The lower the score, the better the appetite of a patient [124]. Thus, 
ADAT of scale one means very good appetite whereas, ADAT of scale five means very poor 
appetite.  
Restless Leg Syndrome (RLS) Score Form 
RLS is a sensory-motor disorder, usually occurs in lower limbs of the body during 
rest or sleep time and is related to poor sleep quality and depression [125]. Higher score 
means severity of RLS, Here, “0” point means “no symptom”, 1-10 points meaning “mild 
symptom”, 11-20 points meaning “moderate symptom”, 21-30 points meaning “severe 
symptoms”, and 31-40 points meaning “very severe symptoms”. Restless leg syndrome scale: 
0, None; 1 – 10, Mild RLS; 11-20, Moderate RLS, 21-30 Severe RLS, 31-40 Very Severe 
RLS. Patients reporting score ‘0’ were excluded from analysis [126]. 
HR-QoL (Health Related Quality of life) and SF 36  
Quality of Life (QoL) was assessed using an interviewer administered 36-item Short 
Form Health Survey (SF-36) questionnaire [127]. The KDQOL-36 is comprised of five 
subscales calculated separately: 1) SF-12 physical component summary (PCS), 2) SF-12 





disease, and 5) effects of kidney disease. The two domains in SF-36, PCS used for assessing 
physical health status and MCS used for assessing emotional and psychological function 
contribute to the total QoL score [128]. It is an easy to use tool that can be use in the outcome 
assessment programs for dialysis patients [129]. KD- QoL Subscale scores range from 0 to 
100, with lower scores indicating poor self-reported QOL [130]. It is also a clinically 
adequate and inexpensive method that gives a balanced estimation of nutritional status in 
dialysis patients [131]. The lower the score, the more malnourished the patient will be and it 
is a good way of assessing morbidity and mortality of HD patients. 
Assessment of PEW patients (Specific Aim II) 
PEW was diagnosed in the study patients based on anthropometric and biochemical 
measures as described by the International Society for Renal Nutrition and Metabolism 
(ISRNM)  (Figure 2-5) [57]. Data were utilized from four criteria with pre-established values 
- serum chemistry (albumin, prealbumin or cholesterol), body mass (BMI, unintentional 
weight loss over time or fat percentage), muscle mass (muscle wasting over time, MAMC or 
creatinine appearance) and dietary intake (using measures of DPI or DEI). If measures for 3 
out of 4 major criteria were encountered, a patient was diagnosed as having PEW.   
Development of culturally acceptable renal-specific ‘Nutrition Booklet’ for 
Hemodialysis patients (Specific Aim III) 
The booklet was developed with input from Registered dietitians from USA and 
Malaysia, nephrologists, nutritionists, published dietary guidelines, scientific literature as 
well as the “Bangladeshi Food Composition Table” from the Institute of Nutrition and Food 
Science (INFS), University of Dhaka [111]. It included utilization of data from “Food 
Composition Table of Bangladesh” in order to assess protein, phosphorus, potassium and 





list food based on its phosphorous to protein ratio and potassium content, construct meal plan 
and formulate a “Bangladeshi Phosphorus Pyramid”, all of which could be used as a visual 
and user-friendly tool for the nutrition education of dialysis patients as well as of health care 
professionals and to improve existing renal-specific nutrition knowledge/food practice among 
the patients identified as having poor nutritional and health status. The booklet contained a 
translation of necessary nutrition related information and suggestions in the “Local (Bangla)” 
language as well as an analyses of 381 ethnic food items from the INFS data-base for renal-
specific nutrients: protein, sodium, potassium, and phosphorous. The booklet was generated 
in “Bangla” and then translated into English and cross-checked by bilinguists.  
Statistical Analysis: 
The software, Statistical package for social science (SPSS) version 26 (IBM, Chicago, 
IL, USA) was used for data analysis. Descriptive statistics of continuous variables were 
reported as mean±standard deviation (SD), median (Interquartile range, IQR), and  frequency 
or number (n) and percentage (%), depending on the distribution of variables. Categorical 
variables were presented as number (n) and pecentage. The normal distribution of continuous 
variables was assessed using Kolmogorov-Smirnov test. Differences between groups were 
analyzed using Student t test and Mann-Whitney’s U test for normally distributed and non-
normally distributed data, respectively. p < 0.05 was considered statistically significant. 
When there were more than two groups, a one way ANOVA (analysis of variance) test was 
used and in order to assess the difference among groups, Tukey’s Post Hoc test was used. 


































Figure 2-3. HDL Lipoprint subfraction band separation on polyacrylamide gel tube 
 
















Figure 2-4. LDL Lipoprint subfraction band separation on polyacrylamide gel tube 
 
















Figure 2-5. ISRNM Criteria for Clinical Diagnosis of PEW in CKD [132]. 
 
Source: A proposed nomenclature and diagnostic criteria for protein–energy wasting in acute and chronic 
kidney disease [132]. PEW:protein energy wasting, CKD: chronic kidney disease, BMI: body mass index, DEI: 
dietary energy intake, DPI: dietary protein intake. At least three out of the four listed categories (and at least one 
test in each selected category) must be satisfied for the diagnosis of kidney-disease related PEW. Optimally, 
each criterion should be documented on at least three occasions, preferably 2-4 weeks apart. aNot valid if 
concentrations are due to abnormally great urinary or gastrointestinal protein losses, liver disease, or 
cholesterol-lowering medicines. bA lower BMI might be desirable for certain Asian populations, weight must be 
edema-free mass, for example, post-dialysi dry weight. cMeasurement must be performed by a trained 
anthropometrist, dCreatinine appearance is influenced by both muscle mass and meat intake, eCan be assessed 
by dietary diaries and interviews, or for protein intake by calculation of normalized protein equivalent of total 









CHAPTER 3 SPECIFIC AIM I: RESULTS-CURRENT NUTRITION AND HEALTH 
STATUS OF HEMODIALYISIS PATIENTS IN A SPECIALYZED RENAL 
HOSPITAL IN BANGLADESH 
Results. 
Overall Nutrition and Health Status of Bangladeshi Hemodialysis patients 
Table 3-1. demonstrated the mean values for demographic and clinical parameters. 
Data were collected from a total of 133 MHD patients in the present study, of which, 65 were 
males (49%) and 68, females (51%). The mean age for all patients was 50±13 years. Among 
all patients, 17% were in the “young adult” range of 18 to 35 years old, 45% were in the 
“middle-aged adult” range of 36 to 55 years old, and 38% were in the “older adult” range of 
more than 55 years old [133]. 
In this study, sixty-two percent (n=81) of patients underwent twice weekly dialysis. 
Average duration of dialysis was 3.8±0.4 hours. Mean dialysis vintage was 30±24.3 months. 
Hypertension (HTN) was reported to be the predominant causes of developing ESRD (39%), 
followed by HTN along with either diabetic nephropathy (DN) (28%) or chronic 
glomerulonephritis (CGN) (18%). Other (8%) reasons reported by the patients were-ADPKD 
(Adult polycystic kidney disease), postpartum complication, or unknown reason.  
Table 3-2 demonstrated anthropometric assessments including measurement of Body 
mass index (BMI) from height and post-dialysis weight of a patient using the Quetelet’s 
index [108]. BMI was calculated for 119 patients out of 133 patients as we had missing data 
for post-dialysis weight (n=13) and height (n=14). that, the mean BMI for all patients was 
24.1±5.2 kg/m2. Among all patients, 12% were in the “under-weight” range of less than 18.5 





“over-weight” category of 25-29.9 kg/m2, and 13% were in the “obese” range of more than 
30 kg/m2 [134].    
Another anthropometric assessment was the measurement of muscle mass on 131 out 
of 133 patients. Hand-grip strength was measured for all 133 patients. The mean values for 
mid-arm circumference (MAC), triceps skinfold (TSF), mid-arm muscle circumference 
(MAMC) and hand-grip strength (HGS) among all patients were 26.5±5.2 cm, 15.6±8.4 mm, 
21.6±3.6 cm and 19.3±7.5 kg respectively.  
Table 3-2 also demonstrated biochemical parameters which were analyzed in the 
hospital laboratory and available data were collected for the following parameters- TIBC or 
total iron binding capacity (n=89), urea reduction ratio (URR%) (n=92), sodium (n=116), 
potassium (n=121), serum albumin (n=105), phosphorous (n=108), ferritin (n=92), Kt/V 
(n=57).  The mean values for these biochemical parameters were-TIBC, 242.2±63.9 mg/dL; 
URR%, 64.6±10.3; sodium (Na), 135.8±4 mEq/L; potassium (K), 5±0.7 mEq/L; phosphorous 
(P), 4.4±2.2 mg/dL; serum albumin, 3.7±0.6 g/dL; ferritin, 496.7±442.8 ng/ml; 18 patients 
with ferritin >2000 ng/ml; Kt/V, 1.3±0.4 respectively.  
Table 3-3. showed the plasma lipid profile and subfraction values of the study cohort. 
Nine patients were excluded from the analysis due to high TAG values (839.3±273.8 mg/dL) 
of more than 600 mg/dL because Friedwald equation for LDL-C estimation is not reliable if 
TAG level is high [135]. Another eight patients were excluded due to missing plasma sample. 
Therefore, data for 116 plasma samples are presented in the results of both lipid profile and 
subfraction.  
The mean values for total cholesterol (TC), triglycerides (TAG), low-density 
lipoprotein (LDL-C) and high- density lipoprotein (HDL-C) were 154±40 mg/dL, 179±95 





TAG, and HDL-C are <200 mg/dL, <150 mg/dL, and >40 mg/dL. The average ratio of 
TC/HDL-C, LDL-C/HDL-C, and TAG/HDL-C were 4.9±1.8, 2.7±1.2, and 6.1±4.2 
respectively. Lipid subfraction analyses revealed that, means values for VLDL, IDL-C, and 
LDL diameter were 36.1±12.6 mg/dl, 52.1±15.4 mg/dL, and 267.7±8 A0. Mean values for 
large, intermediate, and small LDL particle sizes were 19.4±8.2 mg/dL, 11.2±7.1 mg/dL, and 
5.6±8.4 mg/dL respectively and mean values for large, intermediate, and small HDL particle 
sizes were 12.5±8.1 mg/dL, 17.4±4.7 mg/dL, and 4.6±2.4 mg/dL respectively. 
Studies sugeested a TAG to HDL-C ratio of more than 3.8 as an indicator of 
“dyslipidemia”[136]. Table 3-4 showed that, of the 116 patients, 74 patients had TAG/HDL-C 
ratio of more than 3.8 and could be considered as dyslipidemias, 42 had a ratio of less than 
3.8 and considered as normal. Dyslipidemia patients had significantly higher TC, TAG and 
significantly lower HDL-C as compared to those with normal. LDL particle diameters were 
significantly lower in dyslipidemia patients. Dyslipidemia patients also had significantly 
higher cholesterol in small and intermediate sized LDL particles and higher cholesterol in 
large LDL particles. Dyslipidemia patients had significantly less cholesterol in large and 
intermediate sized HDL particles. 
Table 3-5 showed the classification of dyslipidemia (DL) based on ATP (Adult 
Treatment Panel) III guideline [137], where DL is characterized by the presence of one or 
more of the following three criteria-i. HDL-C<40mg/dL, ii. LDL-C>100 mg/dL and iii. 
TAG>150 mg/dL as mixed DL or ‘MD’, presence of no criteria as normal or ‘N’, and 
presence of all three criteria as atherogenic DL or ‘AD’. Based on this guideline, 19 patients 
were ‘N’ (including 18 type A, 1 Int), 81 were ‘MD’ (48 Type A, 21 Type B, 12 Int) and 16 
patients were ‘AD’ (2 Type A, 12 Type B and 2 Int). ‘AD’ patients had significantly higher 





while compared to ‘MD’ and ‘N’ patients. As compared to normal patients, AD patients had 
3-fold higher TC, and 2-fold higher LDL-C, 1.5-fold higher TAG and 1.5-fold lower HDL-C. 
Significantly altered profiles were also apparent in the LDL and HDL sub-fractions. Normal 
HD patients had significantly less cholesterol in small and intermediate sized LDL particles 
and small sized HDL particles. Normal HD patients also had significantly more cholesterol in 
large and intermediate sized HDL particles while compared to both AD and MD patients. 
Table 3-6 demonstrated the comparison among patients having LDL phenotype A, B, 
and Intermediate. Of the 116 patients, 68 patients had LDL phenotype A, 33 had Type B and 
rest 15 had Intermediate type LDL pattern. Type B patients had significantly higher TC, TAG, 
VLDL, IDL-C, and LDL-C and significantly lower HDL-C as compared to those with pattern 
A and significantly higher TAG and Non-HDL-C compared to Intermediate LDL phenotype. 
LDL particles diameters were significantly lower in both type B and intermediate cases. Type 
B patients had significantly higher cholesterol in small and intermediate sized LDL particles 
and lower cholesterol in large LDL particles. Type B patients also had significantly less 
cholesterol in large and intermediate sized HDL particles and more cholesterol in small sized 
HDL particles. 
Overall, in KFHRI, Table 3-7 showed that, 70% of dialysis patients were MD and 
14% were AD. Only 16% of overall study cohort were having a normal (N) lipid profile 
based on laboratory analyses. Considering LDL-pattern, 59% patients had LDL-phenotype A, 
28% had phenotype B, and 13% had intermediate type LDL-pattern. Among AD patients, 
75% had LDL phenotype B. Based on TAG/HDL-C ratio, 64% of patients were DL with a 
ratio of >3.8. Of them, 77% were MD, and 22% were AD. Among 36% patients with a ratio 





Our study, for the first time revealed an approximate picture of dietary intake among 
Bangladeshi dialysis patients via analyzing a one-day 24-hour diet recall form. At first, one-
day 24-hour diet recall data were collected from 112 out of 133 patients in both 2017 and 
2018, from which energy, macronutrients and micronutrient intakes were analyzed. From 
these 112 patients, whose diet data were analyzed, 68 patients were identified as “acceptable 
reporters” (61%). 
Table 3-8 demonstrated that, the mean calorie intake and average dietary energy 
intake (DEI) were 1434±491 kcal and 23.7±6.6 kcal/kg BW/day. The mean protein intake 
and average dietary protein intake (DPI) were 54±22 g and 0.9±0.3 g of protein/kg BW/day. 
Mean phosphorous (P) to protein ratio was 16.3±3.8 mg of phosphorous/ g of protein. 
Among other macronutrients, mean carbohydrates intake was 208.5±69.5g, for which 
the recommendation is relying on body weight, average total fiber intake was 16.7±6.7 g, 
which is below the recommendation of 20-25g/day, average fat intake was 42.9±20.2, where, 
major portion, 15.6±9.4 g came from poly unsaturated fatty acids (PUFA), average 
cholesterol intake was 224±151 mg, which is slightly higher than the recommendation of 
<200 mg/day.  
Average intakes of fat-soluble vitamins- except vit A intake were far below the 
K/DOQI guideline. Mean intakes for water-soluble vitamins fall mostly within the guidelines 
provided by K/DOQI for hemodialysis patients.  Average intakes of minerals were all within 
the guideline for HD patients. Only zinc intake was below recommendation.  
Table 3-9. showed findings from the health-related questionnaire that were used in the 
present study. The mean MIS score among all patients was 6±3, a high score indicating 





existing among study cohort. In case of RLS form, “0” point means “no symptom”, 1-10 
points meaning “mild symptom”, 11-20 points meaning “moderate symptom”, 21-30 points 
meaning “severe symptoms”, and 31-40 points meaning “very severe symptoms”. The mean 
RLS score for this study cohort was 17.2±8.4 among 63 patients, indicating moderate 
symptoms of restless leg symptoms prevailed. In case of RLS, patients who reported ‘0’ as 
response were excluded from the analysis. In case of KD-QoL, the two domain “physical 
health composite” score was 37.7±11.1 and “mental health composite” score was 44.7±9.9. 
Here, a lower score indicates malnourished patients. The mean score for the other two 
components such as-burden of kidney disease and effects of kidney disease were 30±26.4 and 
64.3±17.5.  
Analyses based on Dialysis Frequency: 2x weekly vs 3x weekly dialysis 
 Based on dialysis frequency, Table 3-10 showed that, 129 patients’ data were 
analyzed, of which, a total of 81 patients (36 male and 45 female) underwent 2x weekly 
dialysis and 48 patients (25 male and 23 female) underwent 3x weekly dialysis. Significant 
difference was observed in terms of dialysis vintage, higher for patients on 3x weekly dialysis 
37.5±24.4 months, compared to those on 2x weekly dialysis, 25.5±23.5 months. Causes of 
developing ESRD showed similar trend in both groups. Significant differences were found in 
terms of mean MAC and MAMC, which were higher in patients undergoing 3x weekly 
dialysis.  
Table 3-11 demonstrated the average URR % value was higher in patients undergoing 
2x weekly dialysis (67%) than in patients on 3x weekly dialysis (63%), whereas the K/DOQI 





on 2x weekly dialysis had a ferritin value of >2000 ng/ml, mean ferritin value was lower for 
2x weekly patients.  
Although no significant differences were observed in terms of lipid profile and 
subfraction between these two groups of patients, those on 3x weekly dialysis had a higher 
TAG, TC and LDL-C values and a slightly lower HDL-C values compared to their 2x weekly 
counterparts (Table 3-12). Based on TAG/HDL-C ratio, 59% patients on 2x weekly dialysis 
had dyslipidemia, whereas, 74% patients on 3x weekly dialysis had DL. Based on LDL-
pattern, 3x weekly patients possess more atherogenic type B and intermediate type LDL 
compared to their 2x weekly counterparts (Table 3-13).  
Dietary analyses evaluated that, patients who underwent 3x weekly dialysis had a 
significantly higher intake of protein, water, and potassium, compared to those on 2x weekly 
dialysis which reflect the fact that, less dietary restriction was imposed on 3x weekly group 
(Table 3-14). No statistically significant differences were found in terms of health and 
nutrition questionnaire between these two groups (Table 3-15).  
Table 3-16 demonstrated the median values of parameters that were statistically 
significant between 2x weekly vs 3x weekly patients. In overall analyses, significant 
differences were found in case of dialysis vintage, MAC, MAMC, URR%, Ferritin, Intakes of 
protein, water, and potassium.  
Analyses based on Male vs Female 
While analyzing data based on gender, in table (Table S1), we found that, mean age 
for both male and female was same. However, male patient developed ESRD and start on 
dialysis at an early age compared to their female counterparts. Significant differences were 





male, 25.5±23.5 months. Around 66% of female patients underwent twice weekly dialysis, 
whereas 58% of male patients did so. Causes of developing ESRD showed similar trend for 
both groups where HTN was predominant, followed by HTN along with either DN or CGN. 
Significant differences were observed between the gender for BMI and mean MAC 
and TSF which were higher in female while the muscle strength was higher in male. Mean 
values of sodium and serum albumin were lower in female, and URR (%), and Kt/V were 
higher in female (Table S2) compared to their male counterparts. In case of male patients, 
average URR% was only 61%.  
Lipid and lipoprotein subfraction analyses showed that, TC, TAG, LDL-C, Non-
HDL-C and VLDL were significantly higher in case of female patients. In female, higher 
amount of cholesterol were present in large and intermediate LDL-particles. Based on 
TAG/HDL-C ratio of more than 3.8, 70% of female patients had dyslipidemia (DL), whereas 
58% of male patients had DL (Table S3). 
Significant differences were observed between gender in terms of calorie, DEI, 
protein, DPI, P/kg BW, carbohydrates, total fiber, fat and PUFA intakes, all of which were 
higher in male, Average intakes of vit A, B1, B3, folate and vit C intakes and mean intakes 
for phosphorous, potassium, zinc, and magnesium were also higher in male (Table S4).  
No significant differences were found in case of MIS, RLS and ADAT scores, except 
that, the mean MIS score was a little higher for female than those of male patients. 
Significant differences were found in case of first two components of KD-QoL score-physical 







Analyses based on Dialysis vintage: <2 years vs >2 years: 
114 patients’ data were analyzed, of which, 61 patients were on dialysis for ≤2 years 
and 53 patients were on dialysis for >2 years. Significant differences were observed between 
dialysis vintage (less than or equal to two years vs more than two years of dialysis) in case of 
mean values for age and muscle mass and muscle strength,  and TIBC, all of which were 
higher among patients on >2 years of dialysis (Supp. Table 6 and supp. table 7). No 
significant differences were observed in terms of lipid profile and subfraction except VLDL 
which was lower in patients on >2 years of dialysis and small HDL-C, lower in patients on ≤2 
years of dialysis (Table S8). Based on TAG/HDL-C ratio, 62% patients had dyslipidemia (≤2 
years) and 66% patients had dyslipidemia (>2 years). No significant differences were 














Tables and Figures 
Tables. 
Table 3-1: Demographics and clinical parameters  
 All patients 
Age in years (n) 50±13 (133) 
Young adult (18-35), n (%) 22 (17%) 
Middle-aged adult (36-55), n (%) 60 (45%) 
Older adult (>55), n (%) 51 (38%) 
Dialysis duration (hr) (n) 3.8±0.4 (119) 
Dialysis vintage (mon) (n) 30.0±24.3 (123) 
Dialysis frequency, n (%)  
Thrice a week 48 (36%) 
Twice a week 81 (61%) 
Once a week 1 (1%) 
Causes of ESRD, n (%)  
HTN 52 (39%) 
HTN and DN 37 (28%) 
HTN and CGN 24 (18%) 
Others 10 (8%) 
Missing data 10 (8%) 
Data were collected from the number of patients indicated in parentheses. Values are Mean ±SD and n or 
%.HTN: Hypertension, DN: Diabetic nephropathy, CGN: Chronic glomerulonephritis, Other: 2 APKD, 5 







Table 3-2: Anthropometric and biochemical parameters 
 All patients Reference value 
Height (cm) 159±9 (119)  
Dry weight (Kg) 60.5±12.5 (120)  
BMI (kg/m2) 24.1±5.2 (119)  
BMI Category, n (%)   
Underweight, <18.5 14 (12%)  
Healthy-weight, 18.6-24.9 62 (52%)  
Overweight, 25-30 28 (24%)  
Obese, >30 15 (13%)  
HGS (Kg) 19.3±7.5 (133)  
MAC (cm) 26.5±5.2 (131)  
TSF (mm) 15.6±8.4 (131)  
MAMC (cm) 21.6±3.6 (131)  
TIBC (mg/dL) 242±64 (89) 300-400 [139] 
URR % 65±9 (91) > 65 [140] 
Na (mEq/L) 135.8±4.0 (116) 135-146 [141] 
K (mEq/L) 5.0±0.7 (121) 3.5-5.3 [142-144] 
P (mg/dl) 4.4±2.2 (108)  
Albumin (g/dL) 3.7±0.6 (105) 3.8-5.0 [145] 
Ferritin (ng/ml) 497±443 (74) 5-275 [146] 
Ferritin >2000ng/ml (n) 18  
Kt/V 1.3±0.4 (57) 1.2-1.3 [147, 148] 
Data were obtained from patient medical records. Values are Mean ± SD (n). HGS: Hand grip strength, MAMC: 
Mid-arm muscle circumference. TSF: Triceps skinfold, BMI: Body mass index. URR%: Urea reduction rate. 










Table 3-3: Lipid profile and lipid subfraction 
 All (116) 
TC (mg/dl) 154±40 
HDL-C (mg/dl) 35±11 
TG (mg/dl) 179±95 






VLDL (mg/dl) 36±13 
IDL (mg/dl) 26±7 
Large LDL (mg/dl) 19.4±8.2 
Inter. LDL (mg/dl) 11.2±7.1 
Small LDL (mg/dl) 5.6±8.4 
Mean LDL size (Å) 268±8 
Large HDL (mg/dl) 17.4±4.7 
Inter. HDL (mg/dl) 12.5±8.1 
Small HDL (mg/dl) 4.6±2.4 
Data were analyzed for the number of patients indicated in parentheses. Values are Mean + SD and n or %. TC: 
Total Cholesterol, HDL-C: High density lipoprotein, TAG: Triglycerides, LDL-C: Low density lipoprotein. 














Table 3-4. Distribution of patients based on TAG/HDL-C ratio 
 TAG/HDL-C<3.8 (42) TAG/HDL-C> 3.8 (74) 
TC (mg/dL) 143.5±33.3 a 160.6±41.9 a 
TAG (mg/dL) 100.7±30.7 a 222.7±91.1 a 
Non-HDL-C (mg/dL) 99.2±30.4 a 131.7±39.2 a 
VLDL (mg/dL) 30.2±9.7 a 39.4±12.9 a 
IDL-C (mg/dL) 48.0±14.1 a 54.4±15.7 a 
HDL-C (mg/dL) 44.3±10.5 a 28.9±6.9 a 
Large HDL-C (mg/dL) 19.0±8.5 a 8.7±4.9 a 
Intermediate HDL-C (mg/dL) 20.9±3.8 a 15.4±3.9 a 
Small HDL-C (mg/dL) 4.2±2.4 4.8±2.3 
LDL-C (mg/dL) 79±28.4 87.2±31.9 
Large LDL-C (mg/dL) 21.4±8.9 a 18.2±7.5 a 
Intermediate LDL-C (mg/dL) 7.3±5.8 a 13.5±6.8 a 
Small LDL-C (mg/dL) 0.9±2.3 a 8.3±9.3 a 
LDL diameters (angstroms) 272.7±2.9 a 264.6±8.4 a 
TC/HDL-C 3.3±0.8 a 5.7±1.6 a 
LDL-C/HDL-C 1.9±0.7 a 3.1±1.2 a 
TAG/HDL-C 2.4±0.8 a 8.1±3.9 a 
Non-HDL-C/HDL-C 2.3±0.8 a 4.7±1.6 a 
Data were analyzed for the number of patients indicated in parentheses from 116 patients at Kidney Foundation 
Hospital and Research Institute. Values are Mean + SD (n). TC: Total Cholesterol, HDL-C: High density 
lipoprotein, TAG: Triacylglycerol/triglycerides, LDL-C: Low density lipoprotein. This table indicates values 
from both Lipoporint and from enzymatic assays in plasma. TAG/HDL-C>3.8 means dyslipidemia. Mean 
values sharing a common superscript were significantly different from each other using a one-way ANOVA 











Table 3-5. Distribution of patients based on Dyslipidemia (DL) (ATP III Guideline-2013) 
 AD [16 (14%)] MD [81 (70%)] N [19 (16%)] 
TC (mg/dL)  213.9±30.7 a, b 145.5±33.2 a 142.5±27.4 b 
TAG (mg/dL) 277.4±98.0 a, b 178.0±86.3 c, a 97.3±33.7 b, c 
HDL-C (mg/dL)  30.6±5.2 b 31.4±9.2 c 50.9±7.7 b, c  
Non-HDL-C (mg/dL)  183.3±29.6 a, b 114.1±29.5 c, a 91.6±27.2 b, c 
VLDL (mg/dL)  52.8±12.7 a, b 34.4±10.3 a 29.3±9.8 b 
IDL-C (mg/dL) 73.4±13.7 a, b 49.4±12.7 a 45.7±12.7 b 
Large HDL-C (mg/dL)  6.6±2.9 a, b 10.8±6.2 c, a 24.4±7.0 b, c 
Inter. HDL-C (mg/dL)  18.0±2.4 b 16.1±4.4 c 22.5±3.7 b, c 
Small HDL-C (mg/dL) 5.9±2.6 b 4.5±2.3 3.8±2.1 b 
LDL-C (mg/dL)  127.8±23.4 a, b 78.5±26.1 a 72.1±24.1 b 
Large LDL-C (mg/dL) 22±6.2 18.4±7.9 21.0±10.3 
Inter. LDL-C (mg/dL)  17.7±5.1 a, b 11.2±6.9 c, a 6.0±4.8 b, c 
Small LDL-C (mg/dL)  18.6±11.2 a, b 4.3±5.9 a 0.5±0.9 b 
LDL diameters (A0)  260.3±7.0 a, b 267.6±7.8 c, a 273.4±2.6 b, c 
TC/HDL-C  7.2±6.1.5 a, b 4.9±1.4 c, a 2.8±0.6 b, c 
LDL-C/HDL-C  4.3±1.1 a, b 2.6±1.0 c, a 1.5±0.5 b, c 
TAG/HDL-C  9.4±3.9 a, b 6.4±4.0 c, a 1.9±0.7 b, c 
Non-HDL-C/HDL-C  6.2±1.5 a, b 3.9±1.4 c, a 1.8±0.6 b, c 
Data were analyzed for the number of patients indicated in parentheses from 116 patients. Values are Mean + 
SD and [n (%)]. TC: Total Cholesterol, HDL-C: High density lipoprotein, TAG: Triacylglycerol/triglycerides, 
LDL-C: Low density lipoprotein, TAG/HDL-C>3.8 means dyslipidemia/DL. Atherogenic DL (AD): presence of 
the three condition-HDL-C<40 mg/dl, TAG>150 mg/dl, and LDL-C>100 mg/dl; Mixed DL (MD): presence of 
one of the three condition-HDL-C<40 mg/dl, TAG>150 mg/dl, and LDL-C>100 mg/dl; Normolipidemic: 
absence of the three condition-HDL-C<40 mg/dl, TAG>150 mg/dl, and LDL-C>100 mg/dl. Mean values 
sharing a common superscript were significantly different from each other using a one-way ANOVA followed 
by post-hoc Tukey’s test.  This table indicates values from both Lipoporint and from enzymatic assays in 
plasma. All values are significantly different with a p-value of <0.001 except small HDL-C and small LDL-C 
which are significantly different with a p-value of <0.05. Only Large LDL-C is not significantly different 








Table 3-6. Distribution of patients based on LDL-pattern 
 Type A (68) Intermediate (15) Type B (33) 
TC (mg/dL)  142.5±32.6 a 153.1±29.5 179.6±45.9 a 
TAG (mg/dL)  139±61.1 a 159.0±56.4 c 268.8±107.1 a, c 
LDL-C (mg/dL)  76.3±28.0 a 90.5±26.4 97.8±33.4 a 
Non-HDL-C (mg/dL)  104.1±30.1 a 122.3±27.5 c 151.6±42.2 a, c 
VLDL (mg/dL)  31.5±10.0 a 37.1±6.8  45.1±14.6 a 
IDL-C (mg/dL)  48.5±13.2 a 51.5±10.1 59.9±18.8 a 
Large LDL-C (mg/dL)  21.5±8.7 a 18.2±6.1 15.5±6.2 a 
Inter. LDL-C (mg/dL)  8.4±6.4 a, b 15.5±5.7 b 15.2±6.2 a 
Small LDL-C (mg/dL)  0.7±1.0 a, b 4.2±1.8 b, c 16.5±8.5 a, c 
LDL diameters (A0)  272.4±2.5 a, b 267.0±0.8 b, c 257.8±8.0 a, c 
TC/HDL-C  4.0±1.3 a, b 5.2±1.2 b, c 6.6±1.6 a, c 
LDL-C/HDL-C  2.1±1.0 a, b 3.1±1.1 b 3.6±1.1 a 
TAG/HDL-C  4.2±2.6 a 5.4±1.9 c 10.2±4.7 a, c 
Non-HDL-C/HDL-C  3.0±1.2 a, b 4.2±1.2 b, c 5.6±1.6 a, c 
HDL-C (mg/dL)  38.5±11.8 a, b 30.7±7.6 b 28±7 a 
Large HDL-C (mg/dL)  16.1±8.3 a, b 9.2±4.1 b 6.5±4 a 
Inter. HDL-C (mg/dL)  18.4±4.8 a 17.0±4.1 15.6±4.1a 
Small HDL-C (mg/dL)  3.9±2.1a 4.6±2.1 5.9±2.4 a 
Data were analyzed for the number of patients indicated in parentheses from 116 patients at Kidney Foundation 
Hospital and Research Institute. Values are Mean + SD (n). TC: Total Cholesterol, HDL-C: High density 
lipoprotein, TAG: Triacylglycerol/triglycerides, LDL-C: Low density lipoprotein. Mean values sharing a 
common superscript were significantly different from each other using a one-way ANOVA followed by post-
hoc Tukey’s test.  This table indicates values from both Lipoporint and from enzymatic assays in plasma. Type 
A: atheroprotective, Type B: atherogenic, Intermediate: both. All values are significantly different with a p-









Table 3-7. KFHRI patients based on LDL pattern and DL (TAG/HDL-C ratio and ATP III 
Guideline-2013) 










LDL-pattern     
Type A 68 (59%) 2 (13%) 48 (59%) 18 (95%) 
Type B 33 (28%) 12 (75%) 21 (26%) 0 (0%) 
Intermediate 15 (13%) 2 (13%) 12 (15%) 1 (5%) 
DL-TAG/HDL-C     
TAG/HDL-C<3.8 42 (36%) - 24 (57%) 18 (43%) 
TAG/HDL-C>3.8 74 (64%) 16 (22%) 57 (77%) 1 (1%) 
Data were analyzed for the number of patients indicated in parentheses. Values are n or %. TC: Total 
Cholesterol, HDL-C: High density lipoprotein, TAG: Triglycerides, LDL-C: Low density lipoprotein. Type A: 
athero-protective profile, Type B: atherogenic profile, Intermediate: has characteristics of both A and B.   
TAG/HDL-C>3.8 means dyslipidemia or DL. Atherogenic DL (AD): presence of the three condition-HDL-
C<40 mg/dl, TAG>150 mg/dl, and LDL-C>100 mg/dl; Mixed DL (MD): presence of one of the three condition-
HDL-C<40 mg/dl, TAG>150 mg/dl, and LDL-C>100 mg/dl; Normolipidemic: absence of the three condition-












Table 3-8: Dietary Analysis for Acceptable Reporters (AR) 
Parameters AR (68) KDOQI Guidelines 
Calories (Kcal) 1434±491 Based on BW 
DEI/kg BW/day 23.7±6.6 30-35 kcal/kg BW/day 
Protein (g) 54±22 Based on BW 
DPI/kg BW/day 0.9±0.3 1.2 g/ kg BW/day 
P mg/kg BW /day 14.2±5.3 10-17 mg/kg BW /day 
Phosphorous: Protein 16.3±3.8 <12 mg/g of protein 
Carbohydrates (g) 209±70 Based on BW 
Total Fiber (g) 16.7±6.7 20-25 g/day 
Fat (g) 43±20  
SFA (g) 8.4±4.3  
MUFA (g) 8.4±4.5  
PUFA (g) 15.6±9.4  
Cholesterol (mg) 224±151 <200 mg/day 
omega 6: omega 3 10.8±5.6 4:01 
Water (ml) 1417.5±642.3 750-1500 ml/day 
Vitamin A-IU 1016±1311 700-900 IU 
Vitamin D-IU 47±40 600 IU 
Vitamin E-a-Toco (mg) 2.2±1.5 15 mg 
Vitamin K (µg) 12.9±32 90-120 µg 
Vit B1 (mg) 0.7±0.3 1.1-1.2 mg 
Vit B2 (mg) 1.1±1.7 1.1-1.3 mg 
Vit B3 (mg) 13.7±5.4 14-16 mg 
Vit B6 (mg) 11.8±29.6 13-17 mg 
Vit B12 (µg) 1.6±1.6 2.4 µg 
Biotin (µg) 10±9.7 30 µg 
Folate (µg) 135±184 1000 µg 
Vit C (mg) 88±72 75-90 mg/day 
Dietary Calcium (mg) 435.4±260 <1000 mg 
Iron (mg) 15.4±14.5 Individualized 
Dietary Phosphorous (mg) 867.3±422 1000 mg 
Potassium (mg) 1411.6±564 Individualized 
Dietary Sodium (mg) 2043±924 <2400 mg/day 
Zinc (mg) 8±4.5 15 mg 
Magnesium (mg) 227±90 200-300 mg/day 
The data is reported for all acceptable reporters. Values are as Mean ± SD. DEI: Dietary energy intake, DPI: 
Dietary protein intake. SFA: Saturated fat, MUFA: Monounsaturated fat, PUFA: Poly unsaturated fat. IU: 






Table 3-9. Health and Nutrition Questionnaire 
 All patients 
MIS Score 6±3 (88) 
ADAT Score 3.7±1.6 (57) 
RLS Score 17.2±8.4 (63) 
KD-QoL  
SF-12 Physical Health Composite 37.7±11.1 (86) 
SF-12 Mental Health Composite 44.7±9.9 (86) 
Burden of Kidney Disease 30.0±26.4 (89) 
Effects of Kidney Disease 64.3±17.5 (79) 
Data were collected from the number of patients indicated in parentheses. Values are Mean ±SD (n). MIS [46]: 
Malnutrition inflammation score. A score >5 indicates malnourished The MIS has 10 components, each with 
four levels of severity, from 0 (normal) to 3 (very severe). The sum of all 10 MIS components ranges from 0 
(normal) to 30 (severely malnourished); higher score reflects a more severe degree of malnutrition and 
inflammation. ADAT [124]: Appetite and diet analysis tool. Scale: 1 = very good, 2 = good, 3 = fair, 4 = poor 
and 5 = very poor. RLS [126]: Restless leg syndrome. medical doctor. Scale: 0, None; 1 – 10, Mild RLS; 11-20, 
Moderate RLS, 21-30 Severe RLS, 31-40 Very Severe RLS. Patients reporting score ‘0’ were excluded from 














Table 3-10. Demographic and anthropometric parameters: 2x vs 3x weekly dialysis 
 2x weekly  3x weekly  
Gender, M/F (n) 36 / 45 (81) 25 / 23 (48) 
Age in years (n) 49±13 (81) 52±13 (48) 
Dialysis duration (hr) (n) 3.8±0.4 (76) 3.8±0.3 (43) 
Dialysis vintage (mon) (n) 25.5±23.5a (77) 37.5±24.4a (46) 
Causes of ESRD, n (%)   
HTN 33 (41%) 19 (40%) 
HTN and DN 22 (27%) 15 (31%) 
HTN and CGN 14 (17%) 9 (19%) 
Others 7 (9%) 3 (6%) 
Missing data 5 (6%) 2 (4%) 
Height (cm) 157±9 (76) 161±10 (41) 
Dry weight (Kg) 59±12 (77) 63±13 (41) 
BMI (kg/m2) 23.9±4.9 (76) 24.7±5.9 (41) 
HGS (Kg) 19.5±8.0 (81) 19.0±7.0 (48) 
MAC (cm) 25.8±4.8a (79) 28.2±5.6a (48) 
TSF (mm) 15.0±7.9 (79) 17.3±9.1 (48) 
MAMC (cm) 21.1±3.4a (79) 22.7±3.7a (48) 
Data were collected from the number of patients indicated in parentheses. Values are Mean ±SD (n) and n or %. 
HGS: Hand grip strength, MAMC: Mid-arm muscle circumference. TSF: Triceps skinfold, BMI: Body mass 
index. HTN: Hypertension, DN: Diabetic nephropathy, CGN: Chronic glomerulonephritis, Other: APKD, 
kidney stone, Unknown, postpartum complication; genetic, ESRD: End-stage renal disease. Mean values 








Table 3-11. Biochemical parameters: 2x vs 3x weekly dialysis 
 2x weekly 3x weekly Reference value 
TIBC (mg/dL) 231±56 (49) 255±71 (40) 300-400 [139] 
URR % 67±8a (50) 63±9a (40) > 65 [140] 
Na (mEq/L) 136±4 (70) 136±4 (45) 135-146 [141] 
K (mEq/L) 5.0±0.7 (75) 5.0±0.8 (45) 3.5-5.3 [142-144] 
P (mg/dl) 4.5±2 (62) 4.3±2.5 (45)  
Albumin (g/dL) 3.7±0.7 (60) 3.7±0.4 (44) 3.8-5.0 [145] 
Ferritin (ng/ml) 376±360a (38) 601±476a (35) 5-275 [146]  
Ferritin >2000ng/mL (n)  12 6  
Kt/V 1.4±0.3 (30) 1.2±0.5 (27) 1.2-1.3 [147, 148] 
Data were obtained from patient medical records. Values are Mean ± SD (n). Mean values sharing a common 
superscript were significantly different from each other using a one-way ANOVA(p<0.05).  URR% : Urea 














Table 3-12. Lipid profile and Lipid subfractions: 2x vs 3x weekly dialysis.  
 
2x weekly (75) 3x weekly (39) 
TC (mg/dl) 153±41 160±38 
HDL-C (mg/dl) 35±12 34±9 
TG (mg/dl) 169±90 198±105 
LDL-C (mg/dl) 84±32 86±28 
TC/HDL-C 4.9±2.0 4.9±1.4 
LDL-C/HDL-C 2.7±1.3 2.7±1.0 
Non-HDL-C 118±40 126±38 
Non-HDL-C/HDL-C 3.9±2.0 3.9±1.4 
TG/HDL-C 6.0±4.5 6.4±3.8 
VLDL (mg/dl) 36±13 37±12 
IDL (mg/dl) 52±17 53±13 
Large LDL (mg/dl) 19.3±8.5 19.3±7.3 
Inter. LDL (mg/dl) 10±7 13±7 
Small LDL (mg/dl) 4.9±7.8 7.4±9.4 
Mean LDL size (Å) 268.0±8.5 266.4±7 
Large HDL (mg/dl) 13±8.7 11.4±7 
Inter. HDL (mg/dl) 17±5.2 18±3.4 
Small HDL (mg/dl) 4.6±2.3 4.7±2.3 
Data were analyzed for the number of patients indicated in parentheses. Values are Mean + SD and n or %. TC: 
Total Cholesterol, HDL-C: High density lipoprotein, TAG: Triglycerides, LDL-C: Low density lipoprotein. 
Type A: athero-protective profile, Type B: atherogenic profile, Intermediate: has characteristics of both A and 












Table 3-13. Dyslipidemia: 2x vs 3x weekly dialysis.  
Dyslipidemia (DL) 2x weekly 3x weekly 
TAG/HDL-C<3.8 31 (41%) 10 (26%) 
TAG/HDL-C>3.8 44 (59%) 29 (74%) 
LDL-Pattern   
Type A 50 (67%) 16 (41%) 
Type B 20 (27%) 13 (33%) 
Intermediate 5 (7%) 10 (26%) 
Data were analyzed for the number of patients indicated in parentheses. Values are Mean + SD and n or %. TC: 
Total Cholesterol, HDL-C: High density lipoprotein, TAG: Triglycerides, LDL-C: Low density lipoprotein. 
Type A: athero-protective profile, Type B: atherogenic profile, Intermediate: has characteristics of both A and 


















Table 3-14. Dietary analysis for Acceptable Reporters: 2x vs 3x weekly dialysis. 
Parameters 2x weekly (41) 3x weekly (27) KDOQI Guidelines 
Calories (Kcal) 1364±393 1540±604 Based on BW 
DEI/kg BW/day 23.5±7.5 25.0±7.5 30-35 kcal/kg BW/day 
Protein (g) 49±16a 61±27a Based on BW 
DPI/kg BW/day 0.8±0.3 1.0±0.4 1.2 g/ kg BW/day 
P mg/kg BW/day 14.0±4.7 15.0±7.0 10-17 mg/kg BW /day 
Phosphorous: Protein 17.0±3.7 15.4±3.7 <12 mg/g of protein 
Carbohydrates (g) 201±64 220±76 Based on BW 
Total Fiber (g) 16±7 18±6 20-25 g/day 
Fat (g) 40±14 47±27  
SFA (g) 7.8±3.5 9.2±5.3  
MUFA (g) 7.9±4.2 9.0±4.8  
PUFA (g) 15.0±7.7 16.7±11.5  
Cholesterol (mg) 233±158 210±140 <200 mg/day 
omega 6: omega 3 11.0±5.6 10.4±5.7 4:01 
Water (ml) 1288±603b 1614±661a 750-1500 ml/day 
Vitamin A-IU 1036±1424 987±1145 700-900 IU 
Vitamin D-IU 52±40 40±38 600 IU 
Vitamin E--Toco (mg) 2.0±1.1 2.6±2.0 15 mg 
Vitamin K (µg) 9.0±19.5 19.0±44.4 90-120 µg 
Vit B1 (mg) 0.7±0.2 0.8±0.4 1.1-1.2 mg 
Vit B2 (mg) 0.8±0.4 1.4±2.6 1.1-1.3 mg 
Vit B3 (mg) 12.4±5.0 15.6±5.4 14-16 mg 
Vit B6 (mg) 14±34 8±22 13-17 mg 
Vit B12 (µg) 1.6±1.8 1.7±1.4 2.4 µg 
Biotin (µg) 9.8±10.6 10.3±8.0 30 µg 
Folate (µg) 105±68 179±277 1000 µg 
Vit C (mg) 75±71 109±71 75-90 mg/day 
Dietary Calcium (mg) 438±276 431±238 <1000 mg 
Iron (mg) 16±16 15±13 Individualized 
Dietary Phosphorous (mg) 821±277 938±577 1000 mg 
Potassium (mg) 1281±447a 1610±667a Individualized 
Dietary Sodium (mg) 1938±683 2203±1199 <2400 mg/day 
Zinc (mg) 7.5±3.4 8.8±5.8 15 mg 
Magnesium (mg) 217±60 241±91 200-300 mg/day 
The data is reported for all acceptable reporters. Values are as Mean ± SD. DEI: Dietary energy intake, DPI: 
Dietary protein intake. SFA: Saturated fat, MUFA: Monounsaturated fat, PUFA: Poly unsaturated fat. IU: 
International Unit, vit: vitamin, Toco-: tocopherol. Mean values sharing a common superscript were 







Table 3-15. Health and Nutrition Questionnaires: 2x vs 3x weekly dialysis 
  
2x weekly   3x weekly 
MIS Score 5.8±3.1 (48)  6.0±2.7 (39)  
ADAT Score 3.7±1.6 (30) 3.7±1.5 (27) 
RLS Score 15.9±8.7 (36) 17.6±7.1 (25) 
KD-QoL  
  
SF-12 Physical Health Composite 37.8±11.3 (47)  37.6±11.1 (39)  
SF-12 Mental Health Composite 45.7±8.9 (47)  43.4±11.0 (39)   
Burden of Kidney Disease 31.5±27.2 (49) 28.1±25.6 (40) 
Effects of Kidney Disease 67.3±16.5 (45) 60.3±18.2 (34) 
Data were collected from the number of patients indicated in parentheses. Values are Mean ±SD.  
MIS [46]: Malnutrition inflammation score. A score >5 indicates malnourished The MIS has 10 components, 
each with four levels of severity, from 0 (normal) to 3 (very severe). The sum of all 10 MIS components ranges 
from 0 (normal) to 30 (severely malnourished); higher score reflects a more severe degree of malnutrition and 
inflammation. ADAT [124]: Appetite and diet analysis tool. Scale: 1 = very good, 2 = good, 3 = fair, 4 = poor 
and 5 = very poor. RLS [126]: Restless leg syndrome. medical doctor. Scale: 0, None; 1 – 10, Mild RLS; 11-20, 
Moderate RLS, 21-30 Severe RLS, 31-40 Very Severe RLS. Patients reporting score ‘0’ were excluded from 

















Table 3-16: Demographic, Biochemical and Anthropometric differences between 2X and 3X 
weekly dialysis (IQR for significant differences) 
 2x weekly 3x weekly 
Dialysis Vintage (months) 
(n) 
17 (9-33) 34 (16-51) 
MAC (cm) 25.1 (22.4-28.9) 27.9 (23.9-30.5) 
MAMC (cm) 21.0 (18.2-23.9) 22.6 (19.8-24.9) 
URR% 67.5 (61.7-73.6) 63.4 (56.8-68.5) 
Ferritin (ng/mL) 288 (138-429) 473 (173-960) 
Protein (g) 45 (39-55) 53 (44-76) 
Water (ml) 1312 (780-1692) 1473 (1144-1856) 
Potassium (mg) 1260 (932-1416) 1579 (1195-1798) 
Data was collected for 129 patients at Kidney Foundation Hospital and Research Institute. The data reported is 
for number of patients for which the parameters were available. Values are Mean + SD (n). MAC: Mid Arm 
Circumference, MAMC: Mid Arm Muscle Circumference, URR%: Urea Reduction Ratio. Values are reported 
as Mean ± SD.  Statistical analysis was done using one-way ANOVA. All the reported parameters were 
significantly different between the groups (p<0.05). IQR: Interquartile range. Values for the IQR are represented 












CHAPTER 4 SPECIFIC AIM II RESULTS- TO DOCUMENT THE PREVALENCE 
OF PEW BASED ON ISRNM CRITERIA IN BANGLADESHI HEMODIALYSIS 
PATIENTS 
Results. 
Table 4-1 showed that, data for body mass index (BMI) were available for 119 out of 
133 patients (89%), of which 58 patients (49%) had a BMI of less than 23 kg/m2,  which is 
considered as the 1st criteria of PEW diagnosis. Data for mid-arm muscle cirmference 
(MAMC) were available for 131 out of 133 patients (98%), of which 75 patients (57%) had 
MAMC value, 10% below the 50th percentile of reference population, and this is considered 
to be the 2nd criteria for PEW diagnosis.  
Data for serum albumin were available for 105 out of 133 patients (79%), of which 64 
patients (61%) had serum albumin of less than 3.8, considered to be one of the two option for 
the 3rd criteria of PEW diagnosis. Data avilable for serum total cholesterol were available for 
116 out of 133 patients (87%), of which, only 6 patients (5%) had a value less than 100 
mg/dl-2nd option for the 3rd criteria of PEW diagnsis. However, use of serum cholesterol level 
of <100 mg/dl is rarely found among different studies to be used as a marker of detecting HD 
patients with malnutrition.  
Thus, in Table 4-2,we found  116 out of these 133 patients (87%) had all three 
required criteria needed to the analysis of PEW diagnosis, of which 21 patient met 3 criteria 
(18%)- considered as having PEW. Therefore the prevalence of PEW in this study cohort is 
18% without considering dietary intake. 
When we included 4th criteria, that is “Dietary energy and protein intake for at least 
two consecutive months”, only one day 24-hour diet recall data were available, from which, 
considering DEI <25 kcal/kg body weight/day or DPI<0.8 g/kg body weight/day, we found 





this study cohort is 25% including diet data. Another 26 out of 116 patients met 2 criteria 
(23%) and are considered at risk of having PEW. Around 36% (40) patients met only one 
criteria- mild prevalence of malnutrition and 41% patients met no criteria (46). We also found 
that, 17 out of 133 patients had one or two missing values (13%). Therefore, inspection of 
data revealed that the number of PEW patients identified was an underestimate and the figure 
may be as high as 40%. 
Based on PEW versus Non-PEW patients-we analyzed our data for 116 patients, of 
which, 21 PEW and 95 Non-PEW patients. Table 4-3 showed the demographic and clinical 
parameters between PEW vs Non-PEW, where, 14 out of 21 PEW patients were male (67%), 
and 41 out of 95 Non-PEW patients were male (43%). PEW patients were younger with mean 
age of 48±17 years compared to Non-PEW patients with age of 50±12 years. Average 
dialysis vintage in case of PEW patients, 32±32 months was higher compared to Non-PEW 
patients, 29±22 months. On an average, 62% of PEW patients and 64% of Non-PEW patients 
underwent twice weekly dialysis. While causes of ESRD among PEW patients were 38% due 
to hypertension (HTN) and chronic glomerulonephritis (CGN), 33% due to HTN, 19%-HTN 
and diabetic nephropathy (DN) and other-5%. Among Non-PEW patients, causes of 
developing ESRD were reported as HTN 44%, HTN and DM 31%, HTN and CGN 14% and 
other 9%. HTN and CGN seemed to be the major causes of developing ESRD among patients 
with PEW.  
Table 4-4 demonstrated statistically significant differences in terms of anthropometric 
and biochemical parameters between PEW vs Non-PEW patients. In case of BMI (20±2.4 
kg/m2 vs 25.2±5.2 kg/m2), MAC, TSF and MAMC (19.4±2.3 cm vs 22.2±3.8 cm). Only in 
case of hand grip strength, no significant difference was found. Biochemical evaluations 





3.8±0.5 g/dl. Statistically significant difference was observed only in case of serum albumin. 
Serum TIBC level was found lower among PEW patients, 228.1±55.4 mg/dL compared to 
non-PEW patients, 247.7±62.6 mg/dL, and serum Ferritin level was found higher among 
PEW patients, 724.1±569.1 ng/ml compared to Non-PEW patients, 482±423 ng/ml. 
Table 4-5 demonstrated the median values for all anthropometric and biochemical 
parameters between PEW and Non-PEW groups where we found that, 50% of PEW patients 
had BMI of 20.2 kg/m2 with 25% of them had BMI of ≤17.4 kg/m2 (Quartile 1) and 25% had 
BMI of ≥22.1 kg/m2 (Quartile 3), whereas, 50% of Non-PEW group had a BMI of 24.2 kg/m2 
with 25% had BMI of ≤21.2 kg/m2 in Quartile 1 (a BMI<23 kgm2 is one of the four criteria 
for PEW diagnosis) and 25% had BMI of ≥27.5 kg/m2. For MAMC, median values for PEW 
patients was lower than their Non-PEW counterparts (18.7 cm vs 22.3 cm) and in case of 
Non-PEW group, 25% of them were having MAMC of ≤19.6 cm (Quartile 1) which is lower 
than PEW patients with MAMC of ≥21.4 (Quartile 3). Median value for TIBC in PEW 
patients was lower than Non-PEW patients (225 mg/dL vs 239 mg/dL), and both were lower 
compared to the recommended value of 300 to 400 mg/dL. Additionally, 25% of Non-PEW 
patients had TIBC of ≤212 mg/dL (Quartile 1) which is even lower than the median TIBC 
value of PEW patients. 25% of both PEW and Non-PEW patients had a median value of 
URR, lower than 65% (recommendation) and a bit higher for PEW patients than their Non-
PEW counterparts (62% vs 59%). Median values for serum albumin between these two 
groups were 3.7 g/dL vs 3.8 g/dL with 25% of Non-PEW patients having serum albumin of 
only ≤3.5 g/dL (Quartile 1), lower than the median value for PEW patients. However, median 
values for Ferritin is higher for PEW patients than Non-PEW group, which further confirm 
the prevalence of malnutrition and 25% of Non-PEW patients had Ferritin value of 749.3 





In table 4-6, a statistically significant, moderately strong and positive correlation was 
found between muscle mass and muscle strength of patients, who met 3 criteria for PEW 
(n=21), not among Non-PEW group, and a moderately strong and negative correlation 
between age and grip strength was only seen among Non-PEW group in the present study. 
Also, a positive association was found between body mass index and muscle strength in both 
PEW and non-PEW group.  
While doing lipid profile and subfraction analyses among study cohort, of the 116 
patients, we analyzed the data for 108 patients, in which, 21 PEW patients and 87 Non-PEW 
patients.  Table 4-7 showed that, on average, among PEW patients, LDL and HDL 
cholesterol of 72±28 and 38±15 mg/dl, and among non-PEW patients, 88±31 and 34±10 
mg/dl, respectively. Non-PEW patients had significantly higher TC, TAG and LDL-C as 
compared to those with PEW patients.  
Ratio of TC/HDL-C, LDL-C/HDL-C and TAG/LDL-C all were significantly lower 
among PEW patients. LDL particles diameters were significantly higher in PEW patients. 
PEW patients had significantly lower cholesterol in small sized LDL particles and 
significantly more cholesterol in large sized HDL particles and less cholesterol in small sized 
HDL particles. 
Table 4-8 showed that, dyslipidemia (DL), defined as TAG/HDL-C ratio of >3.8, was 
prevalent among 43% of PEW patients and 68% of non-PEW patients. DL, defined by ATP 
III guidelines, no PEW patients had atherogenic DL, (Non-PEW-17%), while almost 76% 
PEW patients had mixed DL (Non-PEW-68%), with 24% of the PEW patients were normal 
(Non-PEW-15%). Based on LDL-pattern, 81% PEW and 54% of Non-PEW patients had an 
LDL phenotype A (atheroprotective), 10% PEW and 31% Non-PEW had type B 





Table 4-9 demonstrated the median values of lipid profile and subfraction between 
these two groups. Here we found that, 25% of Non-PEW patients had median values which is 
lower than the median values of 50% of PEW patients in terms of HDL-C, TAG, LDL-C, 
large and small HDL particles, IDL-C, Large and intermediate LDL particles, mean LDL size 
and ratios of TAG/HDL-C, TC/HDL-C, LDL-C/HDL-C, and Non-HDL-C/HDL-C, that 
means these 25% (Quartile 1) had susceptibility to develop malnutrition as well. Based on 
TAG/HDL-C ratio, 25% of PEW patients had a ratio of ≥6.6 (Quartile 3), which is higher 
than 3.8 and 25% of Non-PEW patients had a ratio of ≥8.1 (Quartile 3), also higher than 3.8, 
indicating prevalence of dyslipidemia (DL) in both groups. 
Table 4-10 showed that, while comparing nutrient intakes among 66 acceptable 
reporters, 14 were PEW and 52 patients were Non-PEW patients, it was found that, 
differences were present between these two groups in terms of calorie intake (1289 kcal vs 
1476 kcal), carbohydrates and total fiber intakes, total fat, saturated fat, MUFA, PUFA 
intakes (lower in PEW patients), vitamin A, E, B1, B2 and folate intakes and dietary calcium 
intake (lower in PEW patients), but no statistically significant differences were found. In this 
study, inadequate intakes of calorie and protein were also found among non-PEW patients. 
Overall, no significant differences in dietary intakes were observed between PEW and Non-
PEW patients except dietary calcium intake (lower among PEW patients). However, while 
compared to K/DOQI guidelines, both PEW and Non-PEW groups showed lower intake in 
terms of DEI (dietary energy intake), DPI (dietary protein intake), total fiber, fat soluble 
vitamins (except vitamin A), water soluble vitamins and zinc. Higher phosphorous to protein 
ratio and omega-6 to omega-3 fatty acid ratios were also observed compared to the reference 





Table 4-11 demonstrated median values of both macro and micronutrient intakes 
between two groups. Here we found that, 25% of our Non-PEW patients’ intakes of calorie, 
protein, phosphorous, carbohydrates, total fiber, fat, water, vitamins and minerals (Quartile 1) 
were lower than the median values of their PEW counterparts. Median values for DEI and 
DPI were also lower in Non-PEW patients compared to their PEW counterparts (25 kcal/kg 
BW/day vs 22 kcal/kg BW/day and 0.9 g vs 0.8 g/kg BW/day). Median values for 
phosphorous to protein and omega 6 to omega 3 fatty acid ratios were also found higher 
among non-PEW group. Therefore, we postulated that, both groups were found to be 
deprived of adequate dietary intake in the present study. 
Table 4-12 showed a statistically significant and higher malnutrition inflammation 
score (MIS) of 7.6 was found among PEW patients compared to a lower score of 5.6 in their 
non-PEW counterparts. From this point, we can further predict that, the number of PEW 
patients identified in this study might be an underestimate. No significant differences were 
observed in terms of ADAT and self-reported RLS score between these two groups. 
However, while analyzing four components KD-QoL (self-reported) questionnaire, 
significant differences were observed in terms of 1st two components such as- Physical 
(43.7±12.5 vs 37.3±10.4 ) and Mental Health composite score (50.1±7.5 vs 43.9±9.6) 
between these two groups and PEW group had a higher score, therefore, a low score 
indicating malnutrition [130]. No significant differences were observed in case of other two 
components (Burden and Effects of Kidney Disease). 
Table 4-13 demonstrated the median values of MIS, ADAT, RLS and KD-QoL 
between two groups where we found that, 25% of Non-PEW patients had an MIS of ≥7.0 
(Quartile 3) which is like the median value for PEW group. Additionally, 25% of Non-PEW 

































Tables and Figures 
Tables. 





1. Body mass index n (%) 3.a. Sr Albumin (g/dl) n (%) 
BMI data available 119 (89%) Sr. Albumin data available 105 (79%) 
BMI<23 kg/m2 58 (49%) Sr. albumin<3.8 g/dl 64 (61%) 
2. Mid-arm muscle circumference 
(MAMC) 
n (%) 3.b. Sr. Total cholesterol 
(mg/dl) 
n (%) 
MAMC data available 131 (98%) Sr. TC data available 116 (87%) 
MAMC 10% below the ref 
population 
75 (57%) TC<100 mg/dl 6 (5%) 
Data were collected from 133 patients. Values are n or percentage (%). ESRD: End stage renal disease. PEW: 
Protein energy wasting, ISRNM: International society for renal nutrition and metabolism. Anthropometric 
criteria include, 1. BMI<23 kg/m2, 2. MAMC below 10th% of the 50th percentile of MAMC for reference US 
population, Biochemical criteria include-3a. Sr. Albumin<3.8 g/dL or 3b. Sr Total cholesterol<100 mg/dl, which 












Table 4-2: Prevalence of PEW based on ISRNM criteria 
Matched Criteria for PEW n (%) 
All criteria present 116 (87%) 
PEW-3 criteria matched 21 (18%) 
At risk PEW-Only 2 criteria matched 26 (23%) 
Only 1 criterion matched 40 (36%) 
No criteria matched 46 (41%) 
Including diet, patients with PEW 33 (25%) 
Data were collected from 133 patients at Kidney Foundation Bangladesh. Values are n or percentage (%). 
ESRD: End-stage renal disease. PEW: Protein energy wasting, ISRNM: International society for renal nutrition 
and metabolism. Anthropometric criteria include, 1. BMI<23 kg/m2, 2. MAMC below 10th% of the 50th 
percentile of MAMC for reference US population, Biochemical criteria include-3a. Sr. Albumin<3.8 g/dL or 3b. 
Sr Total cholesterol<100 mg/dl. For 3 criteria matched, 116 patients had no missing values for BMI, MAMC 
and Sr. albumin or total cholesterol. That is why, 116 patients who had all anthropometric and biochemical 















Table 4-3: Demographics and clinical parameters. PEW versus Non-PEW 
 All PEW Non-PEW 
Gender, M/F (n) 55 / 61 (116) 14 / 7 (21) 41 / 54 (95) 
Age in years (n) 50±13 (116) 48±17 (21) 50±12 (95) 
Dialysis duration (hrs) (n) 3.8±0.4 (110) 3.9±0.3 (19) 3.8±0.4 (91) 
Dialysis vintage (mon) (n) 30±24 (115) 32±32 (20) 29±22 (95) 
Dialysis frequency, n (%)    
Thrice a week 41 (35%) 7 (33%) 34 (36%) 
Twice a week 74 (64%) 13 (62%) 61 (64%) 
Once a week 1 (1%) 1 (5%) 0 (0%) 
Causes of ESRD, n (%)    
HTN 49 (42%) 7 (33%) 42 (44%) 
HTN and DN 33 (28%) 4 (19%) 29 (31%) 
HTN and CGN 21 (18%) 8 (38%) 13 (14%) 
Others 10 (9%) 1 (5%) 9 (9%) 
Missing data 3 (3%) 1 (5%) 2 (2%) 
Data were collected from the number of patients indicated in parentheses. Values are Mean ±SD and n or 
percentage (%) from 116 patients, of which 21 PEW and 95 non-PEW patients. HTN: Hypertension, DN: 
Diabetic nephropathy, CGN: Chronic glomerulonephritis, Other: 4 Unknown, 1 postpartum complication; 1 
genetic, 2 APKD, 1 DN and CGN. ESRD: End-stage renal disease. PEW: Patients having protein-energy 
wasting based on ISRNM criteria, Non-PEW: Patients without PEW. No significantly differences were found 










Table 4-4: Anthropometric and biochemical parameters: PEW versus Non-PEW  
 All PEW Non-PEW References 
Height (cm) 158.5±9.3 (116) 159.7±8.0 (21) 158.3±9.6 (95) 
 
Dry weight (kg) 60.6±12.6 (116) 51.0±8.9a (21) 62.7±12.3a (95) 
 
BMI (kg/m2) 24.2±5.2 (116) 19.9±2.4a (21) 25.2±5.2a (95) 
 
HGS (kg) 19.8±7.4 (116) 20.2±7.9 (21) 19.7±7.3 (95) 
 
MAC (cm) 26.6±5.2 (116) 22.3±2.4a (21) 27.5±5.2a (95) 
 
TSF (mm) 15.8±8.2 (116) 9.3±3.8a (21) 17.2±8.2a (95) 
 
MAMC (cm) 21.7±3.7 (116) 19.4±2.3a (21) 22.2±3.8a (95) 
 
TIBC (mg/dL) 244.1±61.5 (81) 228.1±55.4 (15) 247.7±62.6 (66) 300-400 [139] 
URR % 65.3±8.8 (83) 66.6±9.7 (16) 65.0±8.6 (67) > 65 [140] 
Na (mEq/L) 136.1±3.8 (107) 136.5±2.5 (19) 136.0±4.1 (88) 135-146 [141] 
K (mEq/L) 5.0±0.7 (112) 5.1±0.7 (20) 5.0±0.7 (92) 3.5-5.3 [142-
144] 
P (mg/dl) 4.5±2.2 (100) 4.7±2.6 (18) 4.5±2.1 (82) 
 
Albumin (g/dl) 3.7±0.6 (97) 3.5±0.6a (20) 3.8±0.5a (77) 3.8-5.0 [145] 







F>2000ng/ml 15 6 9 
 
Kt/V 1.3±0.4 (55) 1.4±0.4 (11) 1.3±0.4 (44) 1.2-1.3 [147, 
148] 
Data were collected from 116 patients of which 21 PEW and 95 Non-PEW patients. Biochemical data were 
obtained from patients’ medical record. Values are Mean + SD (n). BMI: Body mass index, HGS: Hand grip 
strength, MAC: Mid-arm circumference, TSF: Triceps skin fold, MAMC: Mid-arm muscle circumference, 
TIBC: Total iron binding capacity. F: Ferritin. Mean values sharing a common superscript were significantly 
different from each other using a one-way ANOVA(p<0.05).  URR %: Urea reduction rate. Na: Sodium, K: 







Table 4-5: Anthropometric and biochemical parameters: PEW versus Non-PEW based on 
Percentile distribution (IQR)  
 PEW Non-PEW Reference value 
Height (cm) 160 (153-165.5) 158 (150165)  
Dry weight (kg) 54 (42.8-57.5) a 62 (53-70) a  
BMI (kg/m2) 20.2 (17.4-22.1) a 24.2 (21.2-27.5) a  
HGS (kg) 20.9 (13.3-24.6) 18.3 (14.3-23.9)  
MAC (cm) 21.5 (21.1-23.5) a 27.4 (23.7-30.2) a  
TSF (mm) 9.8 (6.5-12.3) a 17.3 (10.8-22.5) a  
MAMC (cm) 18.7 (17.6-21.4) a 22.3 (19.6-24.5) a  
TIBC (mg/dL) 225 (172-250) 239 (212-280) 300-400 [139] 
URR% 65.5 (61.6-75.3) 65.4 (59.0-70.9) > 65 [140] 
Na (mEq/L) 136 (135-138) 137 (134-139) 135-146 [141] 
K (mEq/L) 5.1 (4.8-5.7) 4.9 (4.5-5.4) 3.5-5.3 [142-144] 
P (mg/dl) 5.1 (1.9-6.6) 4.8 (2.7-5.9)  
Albumin (g/dl) 3.7 (3.4-3.7) a 3.8 (3.5-4.0) a 3.8-5.0 [145] 
Ferritin (ng/ml) 549.5 (125.1-1400.3) 345.4 (156.0-749.3) 5-275 [146] 
F>2000ng/ml 6 9  
Kt/V 1.3 (1.2-1.6) 1.2 (1.1-1.4) 1.2-1.3 [147, 148] 
Data is reported for 116 patients of which 21 were PEW and 95 were Non-PEW patients based on ISRNM 
guidelines. Biochemical data were obtained from patient’s medical records. IQR: Interquartile range. Values for 
IQR are represented as Median (Quartile 1-Quartile 3). BMI: Body mass index, HGS: Hand grip strength, MAC: 
Mid-arm circumference, TSF: Triceps skin fold, MAMC: Mid-arm muscle circumference, TIBC: Total iron 
binding capacity. F: Ferritin. URR %: Urea reduction rate. Na: Sodium, K: Potassium, P: Phosphorous. Mean 








Table 4-6: Correlation of muscle mass with BMI and muscle strength among PEW patients 
and age with muscle strength and BMI with muscle mass among Non-PEW patients 
 
MAMC (cm) Age (years) BMI (kg/m2) HGS (kg) 
PEW (21)     
MAMC (cm) 1 0.109 R=0.544* R=0.648** 
Age (years) 0.109 1 0.424 -0.260 
BMI (kg/m2) R=0.544* 0.424 1 0.357 
HGS (kg) R=0.648** -0.260 0.357 1 
Non-PEW (95) 
    
MAMC (cm) 1 R=0.235* R=0.630** 0.154 
Age (years) R=0.235* 1 R=0.286** R=-0.276** 
BMI (kg/m2) R=0.630** R=0.286** 1 -0.107 
HGS (kg) 0.154 R=-0.276** -0.107 1 
Data were collected from patients at Kidney Foundation Bangladesh.; values were for 21 PEW and 95 Non-
PEW patients; MAMC: Mid-arm muscle circumference, HGS: Hand Grip Strength in Kilograms. *p<0.05 or 
















Table 4-7: Lipid profile and subfraction analysis: PEW versus Non-PEW 
 ALL (108) PEW (21) Non-PEW (87) 
TC (mg/dl) 155±40 136±34a 160±40a 
HDL-C (mg/dl) 35±11 38±15 34±10 
TAG (mg/dl) 177.6±97.4 131.4±50.1a 188.7±102.8a 
LDL-C (mg/dl) 85±31 72±28a 88±31a 
Non-HDL-C 121±40 98±28a 126±40.5a 
TC/HDL-C 4.9±1.8 3.9±1.1a 5.1±1.8a 
Non-HDL-C/HDL-C 3.9±1.8 2.9±1.1 4.1±1.8 
LDL-C/HDL-C 2.7±1.2 2.0±0.8 a 2.8±1.3a 
TAG/HDL-C 6.0±4.0 4.2±2.7 a 6.4±4.1 a 
Large HDL (mg/dl) 12.4±8.1 16.4±10.1a 11.4±7.3 a 
Intermediate HDL (mg/dl) 17.5±4.4 18.2±6.0 17.3±4.0 
Small HDL (mg/dl) 4.7±2.4 3.3±2.1a 5.0±2.3 a 
VLDL (mg/dl) 36.4±12.8 29.7±10.2 a 38.1±12.8 a 
IDL-C (mg/dl) 52.3±15.2 45.1±11.1 a 54±15.5 a 
Large LDL (mg/dl) 19.4±8.2 19.8±7.0 19.3±8.5 
Intermediate LDL (mg/dl) 11.3±7.0 9.3±5.3 11.8±7.3 
Small LDL (mg/dl) 5.6±8.4 1.7±2.9 a 6.5±9.1 a 
Mean LDL size (Å) 268±7 271±3 a 267±7 a 
Data were analyzed for the number of patients indicated in parentheses. Values are Mean + SD and n or %. TC: 
Total Cholesterol, HDL-C: High density lipoprotein, TAG: Triacylglycerol/triglycerides, LDL-C: Low density 
lipoprotein, Type A: athero-protective profile, Type B: atherogenic profile, Intermediate: has characteristics of 

















Table 4-8: Dyslipidemia: PEW versus Non-PEW 
 All PEW Non-PEW 
Dyslipidemia (DL)    
TAG/HDL-C ratio<3.0 40 (37%) 12 (57%) 28 (32%) 
TAG/HDL-C ratio>3.8 68 (63%) 9 (43%) 59 (68%) 
DL-ATP III Guideline, 2013    
Atherogenic DL (AD) 15 (14%) 0 15 (17%) 
Mixed DL (MD) 75 (69%) 16 (76%) 59 (68%) 
Normolipidemic (N) 18 (17%) 5(24%) 13 (15%) 
LDL-Pattern, n (%)    
A 64 (59%) 17 (81%) 47 (54%) 
B 29 (27%) 2 (10%) 27 (31%) 
Intermediate 15 (14%) 2 (10%) 13 (15%) 
Data were analyzed for the number of patients indicated in parentheses. Values are Mean + SD and n or %. TC: 
Total Cholesterol, HDL-C: High density lipoprotein, TAG: Triacylglycerol/triglycerides, LDL-C: Low density 
lipoprotein, Type A: athero-protective profile, Type B: atherogenic profile, Intermediate: has characteristics of 






















Table 4-9: Lipid profile and Lipid Subfractions between PEW and Non-PEW groups based 
on Percentile distribution (IQR) 
 PEW (21) Non-PEW (87) 
TC (mg/dl) 128 (106-158) a 154 (133-184) a 
HDL-C (mg/dl) 34.4 (26.1-47.2) 32 (26-40) 
TAG (mg/dl) 129.6 (97.2-183.0) a 171.6 (120.1-224.7) a 
LDL-C (mg/dl) 73.5(51.0-90.2) a 83.5 (67.3-103.2) a 
Non-HDL-C 94 (77-119) a 118 (97-150) a 
TC/HDL-C 3.9 (3.2-4.6) a 4.7 (3.8-6.3) a 
Non-HDL-C/HDL-C 2.9 (2.2-3.6) 3.7 (2.8-5.3) 
LDL-C/HDL-C 2.0 (1.6-2.5) a 2.5 (1.9-3.5) a 
TAG/HDL-C 3.4 (2.0-6.6) 5.7 (3.2-8.1) 
Large HDL (mg/dl) 14.0 (11.0-20.5) a 9.0 (6.0-16.0) a 
Intermediate HDL (mg/dl) 18.0 (14.0-22.5) 18.0 (14.0-20.0) 
Small HDL (mg/dl) 3 (2-5) a 5 (3-7) a  
VLDL (mg/dl) 27 (24-33) a 36 (29-45) a 
IDL-C (mg/dl) 44 (36-55) a 50 (43-62) a 
Large LDL (mg/dl) 18 (14-24) 18 (13-25) 
Intermediate LDL (mg/dl) 9.0 (5.5-13.5) 11.0 (6.0-17.0) 
Small LDL (mg/dl) 0 (0-2) a 2 (0-10) a 
Mean LDL size (Å) 272a (270-273) a 268 (263-273) a 
Data is reported for 108 patients of which 21 were PEW and 87 were Non-PEW patients based on ISRNM 
guidelines. IQR: Interquartile range. Values for IQR are represented as Median (Quartile 1-Quartile 3). TC: 
Total Cholesterol, HDL-C: High density lipoprotein, TAG: Triacylglycerol/triglycerides, LDL-C: Low density 
lipoprotein, Type A: athero protective profile, Type B: atherogenic profile, Intermediate: has characteristics of 











Table 4-10. Dietary Analysis for acceptable reporter: PEW and Non-PEW 
Parameters All (66) PEW (14) Non-PEW (52) KDOQI Guidelines 
Calories (Kcal) 1436±498 1289±285 1476±537 Based on BW 
DEI/kg BW/day 23.7±6.6 24.0±5.3 24.0±7.0 30-35 kcal/kg BW/day 
Protein (g) 54.0±22.0 55.0±20.4 53.7±22.4 Based on BW 
DPI/kg BW/day 0.9±0.3 1.0±0.3 0.8±0.3 1.2 g/ kg BW/day 
P mg/kg BW/day 14.2±5.4 14.5±3.2 14.2±6.0 10-17 mg/kg BW /day 
P: Protein 16±4 15±4 17±4 <12 mg/g of protein 
Carbohydrates (g) 209±71 188±41 215±76 Based on BW 
Total Fiber (g) 17±7 15±4 17±7 20-25 g/day 
Fat (g) 43±21 36±13 45±22  
SFA (g) 8.4±4.4 6.6±3.3 8.8±4.5  
MUFA (g) 8.4±4.5 6.8±3.6 8.8±4.7  
PUFA (g) 15.6±9.5  13±7a 16.3±10a  
Cholesterol (mg) 223±153 177±132 236±157 <200 mg/day 
omega 6: omega 3 10.8±5.7 10.0±6.7 11.0±5.5 4:01 
Water (ml) 1419±644 1500±704 1395±633 750-1500 ml/day 
Vitamin A-IU 1033±1328 835±1106 1087±1386 700-900 IU 
Vitamin D-IU 47±40 30±36 51±40 600 IU 
Vitamin E (mg) 2.2±1.6 1.9±0.8 2.3±1.7 15 mg 
Vitamin K (µg) 13±32 15±19 13±33 90-120 µg 
Vit B1 (mg) 0.7±0.3 0.6±0.2 0.8±0.4 1.1-1.2 mg 
Vit B2 (mg) 1.1±1.7 0.7±0.2 1.2±2.0 1.1-1.3 mg 
Vit B3 (mg) 13.7±5.4 15.0±5.0 13.3±5.5 14-16 mg 
Vit B6 (mg) 12.0±30.0 8.0±15.3 13.3±32.8 13-17 mg 
Vit B12 (µg) 1.6±1.7 1.5±1.1 1.7±1.8 2.4 µg 
Biotin (µg) 10.2±9.7 9.8±8.9 10.3±10.0 30 µg 
Folate (µg) 136±187 96±61 147±208 1000 µg 
Vit C (mg) 87±72 66±44 94±77 75-90 mg/day 
Dietary Ca (mg) 738±263 316±145a  471±279a  <1000 mg 
Iron (mg) 16±15 12±8 17±16 Individualized 
Dietary P (mg) 868±428 792±215 888±469 1000 mg 
Dietary K (mg) 1412±571 1282±369 1447±612 Individualized 
Dietary Na (mg) 2054±929 1876±731 2101±976 <2400 mg 
Zinc (mg) 8.1±4.6 7.4±3.0 8.2±4.9 15 mg 
Magnesium (mg) 226±92 208±58 232±98 200-300 mg 
The data is reported for all acceptable reporters. Values are as Mean ± SD. DEI: Dietary energy intake, DPI: 
Dietary protein intake. SFA: Saturated fat, MUFA: Monounsaturated fat, PUFA: Poly unsaturated fat. IU: 
International Unit, vit: vitamin, Vit E: alpha tocopherol. BW: body weight. Ca: calcium, Na: sodium, K: 
Potassium, P: Phosphorous. Mean values sharing a common superscript were significantly different from each 






Table 4-11. Dietary Analysis for acceptable reporters between PEW and Non-PEW groups 
based on Percentile distribution (IQR) 
 
PEW (14) Non-PEW (52) KDOQI 
Calories (Kcal) 1218 (1078-1488) 1316 (1159-1657) Based on BW 
DEI/kg BW/day 25 (19-28) 22 (19-27) 30-35 kcal/kg BW/day 
Protein (g) 46 (42-75) 48 (40-60) Based on BW 
DPI/kg BW/day 0.9 (0.8-1.3) 0.8 (0.6-1.1) 1.2 g/ kg BW/day 
P mg/kg BW/day 15 (11.8-16.7) 12.6 (10.0-17.3) 10-17 mg/kg BW /day 
P: Protein 14 (11.4-17.8) 16.5 (13.8-19.3) <12 mg/g of protein 
Carbohydrates (g) 186 (148-226) 194 (167-247) Based on BW 
Total Fiber (g) 14 (12-16) 15 (13-21) 20-25 g/day 
Fat (g) 37 (25-45) 40 (32-53)  
SFA (g) 6.7 (3.3-10.5) 8.1 (5.7-11.6)  
MUFA (g) 6.6 (3.4-9.8) 7.7 (5.6-11.1)  
PUFA (g) 10.7a (7.2-18.4) 14.9a (9.3-20.6)  
Cholesterol (mg) 164 (52-292) 196 (136-380) <200 mg/day 
omega 6: omega 3 8.9 (7.4-13.2) 12.0 (8.0-13.8) 4:01 
Water (ml) 1563 (959-1777) 1431 (851-1759) 750-1500 ml/day 
Vitamin A-IU 527 (166-789) 703 (439-1043) 700-900 IU 
Vitamin D-IU 28 (1.2-47) 45 (12-80) 600 IU 
Vitamin E (mg) 1.9 (1.3-2.4) 1.9 (1.3-2.8) 15 mg 
Vitamin K (µg) 5.2 (2.9-15.3) 5.3 (3.0-9.5) 90-120 µg 
Vit B1 (mg) 0.6 (0.5-0.7) 0.7 (0.6-0.9) 1.1-1.2 mg 
Vit B2 (mg) 0.7 (0.5-0.8) 0.9 (0.6-1.2) 1.1-1.3 mg 
Vit B3 (mg) 14.5 (11.0-19.8) 12 (9.5-15.2) 14-16 mg 
Vit B6 (mg) 0.8 (0.5-6.5) 0.8 (0.6-1.2) 13-17 mg 
Vit B12 (µg) 1.1 (0.7-2.2) 1.4 (0.9-1.7) 2.4 µg 
Biotin (µg) 7 (3.9-11.6) 9.4 (3.9-13.1) 30 µg 
Folate (µg) 82.0 (44.0-163.0) 97.3 (74.3-159.6) 1000 µg 
Vit C (mg) 53 (32-87) 70 (36-116) 75-90 mg/day 
Dietary Ca (mg) 340 (172-431) a 418 (246-614) a <1000 mg 
Iron (mg) 9 (6-16) 11 (8-16) Individualized 
Dietary P (mg) 728 (632-1022) 774 (644-993) 1000 mg 
Dietary K (mg) 1320 (890-1568) 1298 (1018-1734) Individualized 
Dietary Na (mg) 1604 (1227-2675) 1939 (1424-2575) <2400 mg 
Zinc (mg) 7.0 (5.2-8.5) 6.3 (5.2-11.0) 15 mg 
Magnesium (mg) 196 (158-250) 208 (176-250) 200-300 mg 
The diet data is reported for the acceptable reporters for the two groups. IQR: Interquartile range. Values for 
IQR are represented as Median (Quartile 1- Quartile 3). DEI: Dietary energy intake, DPI: Dietary protein intake. 
SFA: Saturated fat, MUFA: Monounsaturated fat, PUFA: Poly unsaturated fat. IU: International Unit, vit: 
vitamin, Vit E: alpha tocopherol. BW: body weight. Ca: calcium, Na: sodium, K: Potassium, P: Phosphorous. 






Table 4-12: Different health and Nutrition related Questionnaire: PEW versus Non-PEW 
 PEW Non-PEW 
MIS Score 7.6±3.1 (14) a 5.3±2.7 (66) a 
ADAT Score 3.0±1.1 (10) 3.7±1.6 (43) 
RLS Score 14.4±8.1 (10) 17.3±8.1 (46) 
KD-QoL   
SF-12 Physical Health Composite 43.7±12.5 (15) a 37.3±10.4 (64) a 
SF-12 Mental Health Composite 50.1±7.5 (15) a 43.9±9.6 (64) a 
Burden of Kidney Disease 35.4±23.5 (15) 28.1±26.9 (66) 
Effects of Kidney Disease 72.6±19.1 (13) 63.5±16.2 (18) 
Data were collected from the number of patients indicated in parentheses. Values are Mean ±SD (n). Mean 
values sharing a common superscript are statistically significant to each other using a one-way ANOVA. 
MIS [46]: Malnutrition inflammation score. A score >5 indicates malnourishment. MIS has 10 components, 
each with four levels of severity, from 0 (normal) to 3 (very severe). The sum of all 10 MIS components ranges 
from 0 (normal) to 30 (severely malnourished); higher score reflects a more severe degree of malnutrition and 
inflammation. ADAT [124]: Appetite and diet analysis tool. Scale: 1 = very good, 2 = good, 3 = fair, 4 = poor 
and 5 = very poor. RLS [126]: Restless leg syndrome. medical doctor. Scale: 0, None; 1 – 10, Mild RLS; 11-20, 
Moderate RLS, 21-30 Severe RLS, 31-40 Very Severe RLS. Patients reporting score ‘0’ were excluded from 
















Table 4-13: Different health and Nutrition related Questionnaire: PEW versus Non-PEW 
based on Percentile distribution (IQR) 
 PEW Non-PEW 
MIS Score 7.0 (5.8 - 9.5) a 5.0 (3.0-7.0) a 
ADAT Score 3.0 (2.0 - 4.0) 3.0 (3.0-4.0) 
RLS Score 13.0 (6.8-20.0) 16.5 (10.0-23.5) 
KD-QoL   
SF-12 Physical Health Composite 47.7 (27.8-53.6) a 36.4 (28.3-44.6) a 
SF-12 Mental Health Composite 50.1 (43.8-55.0) a 44.6 (36.4-51.3) a 
Burden of Kidney disease 37.5 (18.8-56.3) 18.8 (6.3-45.3) 
Effects of Kidney disease 78.1 (51.6-90.6) 64.1 (50.0-75.0) 
Data were collected from the number of patients indicated in parentheses. Values are IQR: Interquartile range. 
Values for the IQR are represented as Median (Quartile 1 – Quartile 3). MIS [46]: Malnutrition inflammation 
score. A score >5 indicates malnourishment. MIS has 10 components, each with four levels of severity, from 0 
(normal) to 3 (very severe). The sum of all 10 MIS components ranges from 0 (normal) to 30 (severely 
malnourished); higher score reflects a more severe degree of malnutrition and inflammation ADAT [124]: 
Appetite and diet analysis tool. Scale: 1 = very good, 2 = good, 3 = fair, 4 = poor and 5 = very poor. RLS [126]: 
Restless leg syndrome. medical doctor. Scale: 0, None; 1 – 10, Mild RLS; 11-20, Moderate RLS, 21-30 Severe 
RLS, 31-40 Very Severe RLS. KD- QoL[130] Subscale scores range from 0 to 100, with lower scores indicating 















CHAPTER 5 SPECIFIC AIM III RESULTS: TO DEVELOP CULTURALLY 
ACCEPTABLE RENAL-SPECIFIC NUTRITION INFORMATION AND 
EVALUATES ITS IMPACT ON PATIENTS’ RENAL NUTRITION-RELATED 
KNOWLEDGE 
Results. 
At the beginning, a color-coded table was made (Table 5-1), based on which all 381 
foods were separated based on their protein, potassium, phosphorous and phosphorus to 
protein(mg/g) ratio in ‘low’, ‘medium’, ‘high’, and ‘very high level’ [85] according to NKF 
guideline. The ethnic Bangladeshi foods were separately analyzed from different food groups 
like cereals and their products, pulse, legumes, and their products, vegetables and their 
products, leafy vegetables, starchy roots, tubers, and their products, nuts, seeds, and their 
products, spices, condiments, and herbs, fruits, fish, shellfish and their products, meat, 
poultry, and their products, eggs and their products, milk and milk products, fats and oils, and 
beverages with their nutrient content which were documented in a recently published ‘Food 
composition table of Bangladesh’[111]. Table 5-2 presented data of some renal-friendly 
Bangladeshi food stuffs which were analyzed based on protein, phosphorus, phosphorus to 
protein ratio, potassium, and sodium content in raw food (mostly) that are thought to be the 
major concern in case of the dietary management of patients having chronic kidney disease.  
Then, a phosphorus pyramid in accordance with “International Phosphorous pyramid” 
was generated with locally acceptable food items which were derived from the former 
analysis of all 381 food stuffs (Figure 5-1) and table 5-3 showed the explanation of that 
newly developed Bangladeshi Phosphorous pyramid. 
In table 5-4. the recommended intakes of energy, protein and phosphorous were 





30 kcal of energy/kg body weight/day, 1.2 g of protein/kg body weight/day and 10-17 mg of 
phosphorous/kg body weight/day according to NKF/KDOQI guideline[149].  
In table 5-5, foods from meat, egg, fish and legumes were listed based on their 
phosphorous (P) to protein ratio and separated as ‘eat more’ if the ratio is <15 mg of P/g of 
protein and ‘eat less’ if the ratio is >15 mg of P /g of protein. 
Table 5-6 showed the list of food from fruits and vegetables in which potassium is 
present in low, moderate and high amount based on guideline per 100 g of food. Here we 
found that, boiling reduces potassium content of some vegetables, such as- boiled radish and 
cabbage has low potassium compared to raw radish and cabbage. Then in table 5-7, some tips 
for reducing potassium content through cooking procedure was provided[150]. 
Then approximately 150 commonly consumed Bangladeshi dishes were used for 
recipe construction and analysis of nutrient using Esha Food Processor software (Figure 5-2). 
After that, a one-day (1800 kcal for a 60 kg man-30 kcal/kg body weight/day according to 
NKF K/DOQI Guideline) sample menu (Table 5-8) and 7-day renal-friendly sample menu 
was designed/prepared based on this analysis (Table 5-9), so that it could be used later to 
design a calorie and protein adjusted “Food plate” for each meal for individual patient. With 
sample menu, list of local sorted out food items based on potassium content, phosphorous to 
protein ratio as well as a local ‘Phosphorous Pyramid’ was provided so that, a patient could 
select food based on individual need.  
Finally all of these information were incorporated in the booklet which basically had 
two parts-one part includes “translation of necessary nutrition related information and dietary 
suggestion in “Bengali” and another part includes “analysis of 381 ethnic Bangladeshi food 





protein, sodium, potassium, phosphorous, phosphorous to protein ration. English version of 
that booklet was also prepared and checked by bilingual specialists in this field (Figure 5-3). 
The booklet was then verified from the Institute of Nutrition and Food Science (INFS), 




















Tables and Figures 
Tables 
Table 5-1. Recommended cut-off points of renal-specific nutrients [149]. 
Nutrient/100 g of Food Low Medium High Very High 
Phosphorus to protein ration (mg/g) < 12 mg/g 12-15 mg/g >15 mg/g 
 
Protein (g) <20 g (20-50) g >50 g 
 
Phosphorus (mg) <50 mg 50-150 mg >150 mg 
 
Potassium (mg) <100 mg 101-200 mg 201-300 mg >300 mg 
















Table 5-2. A snapshot of renal-specific nutrient analysis using Food Composition Table, 














Beverages Sugar cane juice 0.7 6.0 8.6 25.0 7.0 
Beverages  Jaggery liquid, date palm 0.3 15.0 b50.0  
  
Cereals Vermicelli, boiled 3.9 38.0 9.7 49.0 4.0 
Cereals Semolina, wheat, raw 10.9 a105.0  9.6 a158.0  5.0 
Cereals Vermicelli, wheat, raw 8.9 a92.0  10.3 a140.0  8.0 
Cereals Rice flakes, water soaked 2.0 39.0 b19.5  45.0 1.0 
Fish Pangas, w/o bones, raw 15.9 a130.0  8.2 a169.0  46.0 
Fish Boal, w/o bones, raw 15.4 a134.0  8.7 a146.0  63.0 
Fish Calbasu, w/o bones, raw 17.0 a141.0 8.3 b287.0 100.0 
Fish Prawn, raw 18.2 a133.0 7.3 c355.0 93.0 
Fish Stripped snake-head, raw 17.7 a130.0 7.3 c362.0 50.0 
Fish Prawn, raw 17.6 a132.0 7.5 c352.0 92.0 
Fish Prawn, raw 18.8 a141.0 7.5 c375.0 98.0 
Fish Stone roller, raw 15.3 a124.0 8.1 c834.0 35.0 
Fish Giant tiger prawn, raw 16.5 a141.0 8.5 c423.0 117.0 
Fruits Hog plum, raw 1.1 11.0 10.0 a175.0 1.0 
Fruits Pineapple, ripe, raw 1.0 9.0 9.0 a175.0 13.0 
Fruits Pineapple, ripe, raw 0.8 7.0 8.8 a122.0 42.0 
Fruits Pineapple ripe, raw 0.8 7.0 8.8 a122.0 42.0 
Fruits Palmyra palm, raw 0.6 20.0 b33.3 
  
Fruits Bullocks Heart, ripe, raw 1.4 10.0 7.1 c495.0 6.0 
Greens or 
leaves 




Amaranth leaves, red, 
boiled, w/o salt 
5.3 34.0 6.4 a154.0 53.0 
Greens or 
leaves 
Indian spinach, boiled, 
w/o salt 
3.1 37.0 11.9 a123.0 69.0 
Greens or 
leaves 
Fenugreek leaves, raw 4.4 a51.0 11.6 31.0 76.0 
Greens or 
leaves 











Bottle gourd leaves, raw 2.5 28.0 11.2 b276.0 41.0 
Greens or 
leaves 
Cassava leaves, raw 4.7 36.0 7.7 c303.0 22.0 
Greens or 
leaves 
Bengal dayflower, leaves,  2.0 19.0 9.5 c473.0 21.0 
Greens or 
leaves 
Colocasia leaves, green 4.0 40.0 10.0 c764.0 47.0 
Milk Milk, human, colostrum 2.0 14.0 7.0 70.0 47.0 
Meat Lamb/mutton, meat, 
moderately fat, raw 
18.5 a150.0 8.1 a136.0 41.0 
Milk Milk, human, mature 1.2 15.0 b12.5 56.0 16.0 










Pulses Lentil, boiled, w/o salt 13.6 a115.0 8.5 b234.0 16.0 
Spices Lemon peel, raw 1.6 12.0 7.5 a160.0 6.0 
Spices Coriander leaves, raw 3.3 30.0 9.1 c396.0 58.0 
Vegetables Gourd, pointed, raw 2.0 18.0 9.0 a148.0 28.0 
Vegetables Gourd, bitter, boiled 2.3 20.0 8.7 a141.0 33.0 
Vegetables Gourd, bitter, raw 2.1 20.0 9.5 a182.0 36.0 
Vegetables Gourd, pointed, boiled 2.3 18.0 7.8 a115.0 26.0 
Vegetables Bean, scarlet, runner 3.9 34.0 8.7 b220.0 trace 
Vegetables Plantain, raw 2.0 21.0 10.5 b242.0 4.0 
Vegetables Chili green, raw 2.8 30.0 10.7 b282.0 12.0 
Vegetables Carrot, boiled, w/o salt 1.1 39.0 b35.5 81.0 40.0 
Vegetables Okra, boiled, w/o salt 1.7 21.0 b12.4 99.0 24.0 
Vegetables Amaranth, stem, raw 0.9 30.0 b33.3 
  
Vegetables Pumpkin, boiled, w/o salt 2.2 23.0 10.5 c371.0 13.0 
Here, the colomn for ‘Protein (g)’ and ‘Sodium or Na (mg)’ and all values that have no ‘superscript’ are in 
desirable or safe range, superscript a indicates ‘moderately desirable’, b indicates ‘not desirable’ and c indicates 









Table 5-3. Explanation of Bangladeshi Phosphorus pyramid 
 Foods to be eaten from different Food groups 
Level#1. Whole grain cereals and oil seeds:  roti, bhaat, suji, semai, porota, polao, 
khichuri, pawruti, soybean oil, palm oil, sesame oil, olive oil, ghee 
(vegetable/cow). 
Level#2. Vegetables: leafy vegetables such as, lal shak, pui shak, lau shak, methi shak, 
and vegetables like, pointed gourd, plantain, bitter gourd, teasle gourd, beans, 
pumpkin, okra, green and boiled tomato. 
Level#3. Plant protein: lentil, grass pea, pea, green gram 
Level#4. Animal protein: Different types of fish such as- ayre, shorputi, pangas, boal, 
white rupchada, mrigel, ilish, chital, rui, katla, magur, shol (no small fish) 
and egg white, chicken, beef, mutton, goat meat. 
Level#5. Fruits and beverages: pineapple, lichi, lemon, black berry, bel, amra, papaya, 
mango (langra), pears, guava, sugarcane juice, soymilk, licker tea. 
Level#6. Use sparingly: dairy products, spices, too much oily or greasy foods, nuts, 
hard cheese, egg yolk, fast food or restaurant food, street food, foods with 
preservatives such as pickles, sauce and all types of processed foods. 
Explanation of Bangladeshi Phosphorous Pyramid. Boil foods to reduce their mineral content, including 
phosphorus (then discard the water). According to one study, boiling reduces phosphorus by 51% for 




















30 1.2 10 11 12 13 14 15 16 17 
For 50 kg BW 1500 60 500 550 600 650 700 750 800 850 
For 60 kg BW 1800 72 600 660 720 780 840 900 960 1020 
For 70 kg BW 2100 84 700 770 840 910 980 1050 1120 1190 
Phosphorous: 
Protein (mg/g) 
  8.3 9.3 10 10.8 11.7 12.5 13.3 14.2 














Table 5-5. List of fish, meat and legumes based on Phosphorous to Protein (P: Pro) Ratio (mg 
of P per g of Pro)[111] 
 Eat More (P:Pro of <15) Eat Less (P:Pro>15) 
Fish Ayre, Pangas, Rohu, White 
Rupchanda, Hilsha, *(Prawn, Shol, 
tatkini, Kalibaush, Shorputi, Boal, Poa, 
Thai Koi, Vetki, Lakkha, Silver carp, 
dried fish, Chital, narkeli chela, magur, 
katla, Gulsha, Bagda and Golda 
chingri) 
Black Rupchanda, Kanchki, Mola, 
Kholisha, Kajuli, *(Mrigel, Pabda, 
tilapia, Shing, Local Koi, Bacha, Bele, 
Foli, Taki, Parshe, Meni, Kakila, Puti, 
Chapila, Horina chingri) 
Meat and 
egg 
Chicken egg and meat, mutton, pork, 
*(goat meat, beef, buffalo meat, pork, 
duck meat, pigeon meat)  
Egg from Farm chicken, Duck egg, 
cheese, whole cow’s milk, sweet 




Lentil, green gram, peas, grass peas Chickpea/Bengal gram, Black gram 




















Table 5-6. Amount of potassium per 100 g of Fruits and vegetables[111] 




More (Above 201 
mg) 
Vegetables Radish (boil), 
green papaya 
(boil), cabbage 
(boil), okra (boil), 
carrot (boil) 
Cucumber, pointed gourd (boil), 
green papaya, radish, eggplant 
(boil), snake gourd, ash gourd, 
bottle gourd, sponge gourd, 
cabbage, bitter gourd (boil), 
teasle gourd, pointed gourd, 
carrot, plantain (boil), green and 
ripe tomato, black bean, 
eggplant, sweet potato (boil) 







sweet potato, potato, 
colocassia, taro, edd 
Greens/leaves Fenugreek/methi Indian spinach, red amaranth 
(boil), green amaranth leaves 
(boil) 
Water spinach, 
water cress, red 
amaranth, bottle 




Fruits Apple (w/o skin) Jamrul, apple, water-melon, 
pineapple, Carambola, pear, 
muskmelon, lichi, orange, 
pomegranate, black berry, 
























Table 5-7. How to Leach Potassium from tuberous Root Vegetables[150] 
 Cooking procedure 
#1 Wash and peel the vegetables and slice the vegetables into thin 
slices 
#2 Place the sliced vegetables in room temperature water. Use two 
times the amount of water to the amount of vegetable. 
#3 Bring the water to a boil and drain off the water and add fresh, 
room temperature water. 
#4 Use two times the amount of water to the amount of vegetables, 
bring the water to a boil again and cook until the vegetable is 
soft and tender. 


















Table 5-8. One-day Sample menu for a typical 60 kg dialysis patient containing 1800 kcal of 
energy and 72 g of protein 
 Food item Amount 
Breakfast Roti 3 pieces (30g/pc) 
Cooked mixed vegetables 1 cup (150g/cup) 
Egg boil (no yolk) 2 pcs 
Morning snacks Any fruit 1/3 cup (50 g) 
Lunch Bhaat 2.5 plate or medium bowl 
(160g/plate or medium 
bowl) 
Fried leafy vegetable 2/3 cup (100g) 
Fish curry 2 pcs (1 pc=1 match 
box=30g) 
Dshi thin daal(lentil) ½ cup (75g) 
Afternoon Snacks Licker tea 1 cup (150 ml) 
Vegetable 
pakora/pancake/shemi/suji/noodles 
2 to 3 pcs or 0.5 cup 
Dinner Roti 5 pcs (30g/pc) 
Chicken/Fish curry 2 pcs (30g/pc) 
Cooked mixed/single vegetable 0.5 cup (75g) 
Before bed Yogurt/skim milk 0.5 cup (75 ml) 
This sample menu was prepared based on NKF K/DOQI recommendation for a 60 kg HD patient using local 
food stuffs and along with this chart, a local ‘Phosphorous Pyramid’ as well as ‘list of local food stuffs sorted 
out based on renal-specific nutrient content’ were also given to patients so that they ca choose food item and 












Table 5-9. Seven-day Sample menu for dialysis patient 
Days Breakfast Snacks Lunch Snacks Dinner 
Sat Roti, vegetable, 












Sun Porota, suji 
halwa/daal curry, 
egg boil (no yolk) 
Any 
fruit 







Mon Pawruti, butter, 
licker tea, egg boil 
Any 
fruit 
Rice, mash veg, 

















Wed Roti, vegetable, 




khichuri, egg or 
meat curry 



















Fri Porota, vegetable, 





fish or chicken 
curry 


















Figure 5-1. The Phosphorous Pyramid for Bangladeshi Dialysis Patients. 
 
Here, box#1 and box#2 indicate ‘eat more’, box#3 and box#4 indicate ‘eat moderately’, box#5 indicates ‘eat 




























Figure 5-3. Nutrition Booklet, “Necessary Nutrition Information for the better heath of 
























CHAPTER 6 DISCUSSION 
Specific Aim I 
Methods to identify patients at risk for ESRD are a high priority in Bangladesh, where 
kidney transplants or dialysis options are limited and costly. Evidence from epidemiological 
studies showed that, anthropometric, biochemical, clinical, and dietary data together will help 
to get a better picture of health status among this population group. Nutrition intervention to 
delay the progression to ESRD is a promising and affordable strategy. However, data on 
nutritional status of Bangladeshi renal patients is limited and is not adequately documented. 
Very few studies conducted in Bangladesh among MHD patients did a nutritional screening 
following internationally accepted standard protocols and to the best of our knowledge, ours 
is a very first attempt in this context. This may also serve as a useful reference for future 
work in this field. Here we examine current health and nutritional status of hemodialysis 
(HD) patients. 
In present study, we evaluated demographics, anthropometric, biochemical, dietary 
and laboratory parameters in a group of patients on MHD in a specialized renal hospital as a 
representative of Bangladeshi MHD population. Then, we did subgroup of our patients based 
on gender, dialysis frequency, lipid biochemistry and dialysis vintage and explored our 
results.  
The most notable findings that evolve from our study is that, there is high prevalence 
of both mixed and atherogenic dyslipidemia (AD) among Bangladeshi patients on MHD. 
Dyslipidemia in CKD is related to high TG, low HDL-C and abnormal lipoprotein 
composition such as low cholesterol level predisposed to atherosclerosis and cardiovascular 





conducted in India among 159 CKD patients showed that, CKD patients had a significantly 
lower level of HDL-C and higher level of TC, TAG, VLDL and LDL-C compared to healthy 
subjects of same age [153]. Another study showed that, abnormal lipid metabolism was 
common in MHD patients in India that may contribute to high CVD morbidity and mortality 
[154]. There was little information on the prevalence of dyslipidemia in Bangladeshi MHD 
patients.  In the present study, 70% patients had mixed dyslipidemia and 14% had 
atherogenic dyslipidemia. European Best Practice Guidelines (EBPG) as well as K/DOQI 
recommended appropriate treatment of dyslipidemia for CKD patients with drugs and 
lifestyle modification as it triggers the risk of CVD among them [152, 155]. Data are needed 
to establish the prevalence of such patterns in a much larger cohort and establish criteria, if 
any, for patient management in Bangladesh.  
Previous studies showed that, CKD patients tend to develop CVD much higher than 
the general population due to the development of rapid atherosclerosis [156]. Dyslipidemia is 
a significant risk factor for CVD and is common among CKD patients, due to lowering HDL-
C and rising of TAG level and often improves after transplantation with increasing HDL-C 
level and lowering TAG level, shown in a study conducted on 60 patients[157]. We had also 
found a low HDL-C and a high TAG level in our study population. However, recent studies 
showed that, quality of HDL-C is more important rather than its quantity and a very high 
concentration of HDL-C could also triggers CVD risk [158]. A paradoxical association 
between high serum HDC-C concentration over time and high mortality rate in hemodialysis 
patients was found in one study, where it was demonstrated that both too low and too high 
HDL-C level could be the reason for CV mortality[159].  
In our study, we did a subfraction analysis to see the actual disturbance in lipoprotein 





LDL phenotype A (considered as atheroprotective, being larger and more buoyant) [160] had 
increased amount of cholesterol in their large HDL particles whether those with LDL 
phenotype B (considered as atherogenic, small, and denser) had small amount of cholesterol 
in their large HDL particles [161]. One study showed that, small LDL-particle size is an early 
sign of uremic dyslipidemia [162]. In our study, LDL-particle size is significantly small for 
patients with type B LDL compared to patients with LDL phenotype A. ‘Intermediate’ LDL-
pattern is the least described of three patterns, which carries the criteria of both A and B and 
often termed as [AB] and could be easily shifted to either A or B[163]. In our study, patients 
with phenotype [AB] also had a significantly small LDL-particle size compared to phenotype 
A. Thus, LDL pattern analysis could be clinically important for CKD patients and patients 
with LDL phenotype B need attention to reduce CVD events. 
Analysis of HDL particle size may also be considered clinically important to predict 
CVD risk in patients in general. In HD patients, large HDL is more abundant whereas in 
normal persons, small HDL is more abundant, which may be responsible for high risk of 
atherosclerosis among this patients[164]. In one study, it was found that, presence of more 
small HDL particle is associated with high risk of CVD mortality [165]. However, in some 
study, it was found that, the small but dense protein-rich HDL-C is thought to carry 
antioxidant and anti-inflammatory cardioprotective benefits, compared to the large buoyant 
HDL with large amount of cholesterol[166]. In our study, significantly large amount of 
cholesterol was found in the small HDL particle for patients with LDL phenotype B. 
Additionally, with a decline in kidney function, there is also evidence in changing the protein 
composition of HDL particle as a metabolic derangement[167].  
Another important finding that was evolved from our study is that, majority of our 





well as other macro and micronutrients for hemodialysis patients. In this study, we assessed a 
one-day 24-hour diet recall and consider the results from 61% of acceptable reporters to 
analyze their nutrient intakes. About 39% of our study patients were under-reporters, which is 
a common scenario among HD patients, especially in women and in those with a high BMI 
[168]. Previously, there was little documentation regarding a proper nutrient intake analysis 
of this specific population in Bangladesh. This is one of the very first attempts that has been 
made in Bangladesh. In the present study, it was observed that, most of the respondents were 
not aware of specific renal diet, their average calorie and protein consumption showed lower 
values than that is recommended by K/DOQI [149]. These values were below the 
recommendation provided by NKF/KDOQI for hemodialysis patients, where it was stated 
that, for hemodialysis patients, DEI should be 30-35 kcal/kg body weight/day and DPI should 
be 1.2 g/kg body weight/day [89, 149]. Studies showed that, both low protein intake and 
inflammation reduce the synthesis of albumin in body and further deteriorate the health status 
of patients[169].  
Inadequate intakes of important vitamins and minerals were also found which 
indicates that, the patients are deprived of adequate amount of anti-oxidant and anti-
inflammatory food intake, and are more prone to develop hypokalemia, anemia and 
electrolyte imbalance [170]. A significant number of dietary restrictions are imposed 
traditionally and consistently on MHD patients, whereas there is very little data to support 
their benefits. Recent studies indicate that dietary restrictions of phosphorus may lead to poor 
survival and nutritional status. Restricting dietary potassium may deprive dialysis patients of 
heart-healthy diets such as fruits and vegetables and thus lead to intake of more atherogenic 
diets [71, 171]. Zn deficiency can lead to perturbance in taste and smell that may often cause 





aluminum and possibly copper [173]. However, it is important to note that in dialysis 
patients, there is a high prevalence of antioxidant deficiency due to inadequate ingestion of 
antioxidant vitamins such as vitamins E, C, and carotenoids [97]. 
Resnicow et al.  in their paper, “Validation of Three Food Frequency Questionnaires 
and 24-Hour Recalls with Serum Carotenoid Levels in a Sample of African-American 
Adults” mentioned about the pros and cons of three different methods [174], that are used to 
determine food intake pattern among a group of people. These include, 24-hour recall method 
and food diaries (3 to 7 days diet record) for short-term diet information, and traditional FFQ 
(Food frequency questionnaire) for long-term diet information. Of them, 24-hours diet recall 
is easy, quick and convenient, though, it possesses some demerits such as, day-to day 
variability in nutrient intake, the importance of obtaining multiple recalls to estimate the 
usual intake in a reliable way, burden of patients, and literacy of the participants for correctly 
estimating the portion size. Literacy of the participants is more important in case of using 
Food Dairies [175]. In case of using FFQ, the amount of exact daily nutrient intake is only 
based on assumption and is also difficult to record [176], especially for elderly patients. And 
it must be accustomed for cross-culture applications [177]. 
Dietary intake evaluation is an important tool for dialysis patients which provides an 
insight of their nutrient intake and helps in the assessment of both nutritional adequacy and 
toxicity. Estimating dietary intake is challenging in patients with chronic diseases [178]. 
Through a proper dietary assessment, both nutritional adequacy and toxicity of a patient 
could be determined [179]. When less staffs and time is available in a clinical setting, it is 
difficult to conduct more formal assessment of nutritional intake analysis, a 24-hour recall 





In the United States and Canada there are significant restrictions for eating during 
hemodialysis treatment in dialysis clinics. Possible reasons reported include postprandial 
hypotension, aspiration risk, infection control and hygiene, dialysis staff burden, diabetes and 
phosphorus control, and financial constraints. However, in other countries such as Germany, 
Japan and many other Europeans and Asians nations, meal trays are regularly prepared and 
served during each hemodialysis treatment session. Palmer et al. proposed approaches to help 
patient learn and incorporate with individualized dietary restriction, such as-improving 
patient’s education, motivation, and identifying ways that help patient in adapting the dietary 
recommendation positively[180]. In Bangladesh, although, patients are allowed in taking 
food during dialysis, no emphasis has been put on the type and quality of food consumed. In 
such condition, provision of high-protein meals during hemodialysis could be a feasible, 
inexpensive, and patient-friendly, and an economically feasible strategy [181]. 
An additional finding observed in this study was that, we got an opportunity to 
explore our results based on dialysis frequency as more than half of our patient pool 
underwent 2x weekly dialysis which is not common in USA and Malaysia. Approximately 
62% of patients underwent 2x weekly dialysis and remaining 38% underwent 3x weekly 
dialysis in our patient pool. Minor differences were present between patients undergoing 2x 
weekly versus 3x weekly dialysis. A study conducted on 74 patients in Taiwan showed that, 
if patients on 2x weekly dialysis have sufficient urinary output, they maintain better dialysis 
adequacy and exhibit better preservation of their residual renal function (RRF), compared to 
those on 3x weekly dialysis [182]. Although we found that, patients undergoing thrice weekly 
dialysis were more prone to both atherogenic and mixed dyslipidemia in our study, this 
become contrary to another study conducted in Bangladesh, where it was found that, twice 





Dietary analyses evaluated that, patients who underwent 3x weekly dialysis had a 
significantly higher intake of protein, water, and potassium, compared to those on 2x weekly 
dialysis which reflect the fact that, less dietary restriction was imposed on 3x weekly group.  
However, a cross-sectional study conducted among 142 patients in Thailand showed that, 
there was no significant differences in terms of dietary intake between 2x weekly vs 3x 
weekly patients [183]. 
In Bangladesh, hemodialysis prescription is empiric, which may lead to under-dialysis 
and other related complications. A lot of patients go on a “need to go” basis of dialysis. In 
some clinics, due to high volume of patients, dialysis times are cut down to accommodate 
more patients. In some places rather than KFHRI, there is lack of trained manpower in 
dialysis unit, some dialysis facilities also do not have water treatment facilities, which was 
also common in Pakistan dialysis facilities[184]. Another important issue is the assessment of 
dialysis adequacy for patients who are on dialysis either 2x or 3x weekly. In India, only 20% 
of patients underwent 3x weekly dialysis with a Kt/V<1 for most patients [185]. Kt/V is a 
number that is used to calculate dialysis adequacy, where ‘K’ stands for dialyzer clearance of 
urea, ‘t’ stands for dialysis time and ‘V’ stands for volume of urea distribution that is 
approximately equal to a patient’s total body water. In Bangladesh, same problem existed as a 
patient may missed the regular dialysis schedule due to shifts running late, late arrival due to 
transportation issue, time of dialysis each day that was not recorded properly, missing 
sessions etc. Increasing dialysis session from 2x weekly to 3x weekly is not always an option 
due to increasing number of patients and inadequate number of dialysis machines. Although 
the yearly expenses of HD are much lower in developing countries (such as- 30 times lower 
in India compared to the US), patients often do not have enough money to bear the costs, 





educational and understanding level and financial condition is often critical that they cannot 
afford 3x weekly dialysis. Most patients live far away from dialysis centers and they had to 
travel a long distance by spending extra money from their already broken economic status, 
that makes them even missing their regular dialysis session for at least once a month, if 
otherwise feeling better. Overall, insufficient number of Kidney disease care hospitals result 
in overcrowding and long awaiting time for patients, and lack of access to dialysis treatment 
results in premature death of patients. Cumulative approach along with health care system 
reform and research as well as necessary steps from Government level could play a crucial 
role to improve the overall situation. 
In most developed countries, frequency of hemodialysis was anchored to thrice-
weekly regimens. Health policy in developed countries like the USA and UK usually covers 
the cost of renal replacement therapy and thus makes patients choose the best treatment 
option once they were diagnosed to have ESRD [187]. But this situation is not practical for 
developing countries where it is a matter of scarce facilities and poor socioeconomic status of 
majority of inhabitants. Patients were getting limited and no treatment support from the 
Government [16]. In developing countries, approximately three-fourths of ESRD patients 
undergo twice weekly dialysis [183]. In India, most patients undergo twice weekly dialysis 
and only 20% of patients undergo thrice weekly dialysis. Although, increasing the frequency 
of dialysis improves the quality of life (QoL), it is not an option here due to pressure from too 
many patients and inadequate numbers of dialysis machines [188]. Though, some recent data 
suggests that, frequent hemodialysis accelerates residual renal function decline, and 
infrequent regimens may provide better preservation of native kidney function. In this study-
62% of patients undergo twice a week dialysis and 38% performed thrice a week dialysis. In 





weekly therapy had a two-fold higher risk in mortality compared to those on thrice weekly 
dialysis [189]. However, in a subgroup analysis of the HEMO study, women experienced a 
survival benefit with higher dialysis dose whereas men did not[190]. Thus, prescribing 
specific dialysis frequency using an approach instead of a “one size fits all” strategy, and 
assessing its effects across Bangladeshi renal populations could be an emerging field for 
future research.  
The effects of kidney damage cause problems in all organ system [191]. Previous 
studies suggest that, in Bangladesh, 40% of ESRD is due to glomerulonephritis 31% due to 
diabetic nephropathy, and 15% due to hypertension [5]. A recent study showed that, 
prevalence of CKD is alarmingly high in hypertensive patents and is a hidden cause of 
developing glomerular diseases[192]. CGN is another common cause of ESRD around the 
world and is associated with high rates of inflammation[193].  Diabetic nephropathy (DN)-
another leading cause of ESRD and is also a well-known complication of diabetes mellitus 
(DM). It may arises from uncontrolled hypertension, dyslipidemia, hyperglycemia, smoking 
as well as family history of DM [194]. If we look at our neighboring countries, we found that, 
DN, followed by CKD of unknown cause and CGN were common causes of developing 
ESRD in India. On the other hand, obstructive uropathy (22%), followed by reflux 
nephropathy (13%) and CGN (11%) were the common causes in Pakistan[184]. In this study, 
major causes of developing ESRD was reported to be hypertension following HTN along 
with either diabetic nephropathy or chronic glomerulonephritis. 
Overnutrition is a major problem in the general population and a serious risk of 
metabolic syndrome, cardiovascular disease with an increase in death risk. However, in 
malnourished CKD patients, this relationship is different, especially in those who undergo 





epidemiology” [195-197], where, survival rates among patients improve if they have a higher 
BMI [198-200]. In present study, the average BMI of patients was reported to be 24.1±5.2 
kg/m2, however, 12% with less than 18.5 kg/m2 and 13% of them were having a BMI of >30 
kg/m2. Kalantar-Zadeh et al. also demonstrated that, a U-shaped BMI between <25 kg/m2 and 
≥35 kg/m2 is associated with poor outcomes in CKD patients[201].  
Mid arm muscle circumference (MAMC) is another important measure as low muscle 
mass is related to poor survival, reflecting poor nutritional status, and inflammation [202]. 
Average MAMC in this study was reported to be 21.6±3.6  cm which is also similar to the 
value reported by Tashkandi et al. in HD patients from Saudi Arabia[120]. Studies in the 
general population showed that, muscle strength is inversely related with inflammation and 
oxidative stress [203]. Currently, there are no standardized tables of grip strength for HD 
population. And the reference HGS value in kg for a 55-year old right-handed male is 
21.7[204, 205], which is not appropriate for dialysis patients. However, the mean age and 
HGS in Kg of the study population were 50 years and 19 Kg, which shows similar, but a 
lower trend compared to what was found among healthy adult population. The value is also 
similar to HGS among hemodialysis population of comparable age in Saudi Arabia reported 
by Tashkandi et al. [120]. Stenvinkel et al. showed a negative association between hand grip 
strength (HGS) (surrogate of muscle strength) and age of the respondents [206].  
Serum transferrin could be measured by using serum TIBC (total iron binding 
capacity) and is considered as a marker of malnutrition in patients on MHD. One study 
showed that, MHD patients with a serum TIBC of >250 mg/dL had a high BMI and low 
serum ferritin level and thus a low risk of inflammation and death compared to patients with a 
low TIBC level[207]. In this study, mean TIBC was 242±64 mg/dL. [138]. Hypokalemia is 





potassium level of more than 5.0 mmol/L (our study). Moderate to severe hyperkalemia is 
defined as a potassium level of more than 5.5 mmol/L[144]. Studies showed that, high serum 
ferritin level of more than 250 ng/ml is associated with high risk of mortality among patients 
with CKD[208]. 74 of our study patients had a ferritin level of 496.7±442.8 ng/ml and 18 
patients had a ferritin of >2000 ng/ml. In order to measure dialysis adequacy, URR% is the 
most used tool along with Kt/V. However, both has its own limitation and is not applicable to 
all dialysis facilities. URR (%) reflected dialysis adequacy. If the  URR% is more than 65 
(recommended by Kidney Disease Outcome and Quality Initiative, K/DOQI) , then it is 
thought that, dialysis was adequate [138, 148]. In our data, URR% was approximately 65% 
on an average. Standard Kt/V can also be used as an important tool to modify twice weekly 
dialysis sessions and to provide better quality of life to the patients in India where patients 
live far away from dialysis centers and had to spend additional money to travel to these 
centers [185]. One study conducted among 25 HD patients in Turkey showed that, both 
URR% and single-pool Kt/V reduced if the patients were given food during dialysis[147].  
ADAT form has a five-point scale, where, “1=very good’, “2=good’, “3=fair’, 
“4=poor’, and “5=very poor’. One study showed that, malnourished patient tends to develop 
poor appetite during the course of disease progression [123]. In our study, it was found ‘fair’ 
to ‘poor’. KD-QoL is an easy to use tool that can be use in the outcome assessment programs 
for dialysis patients [129]. It is also a clinically adequate and inexpensive method that gives a 
balanced estimation of nutritional status in dialysis patients [131]. Studies showed that, low 
health-related quality of life among patients with CKD is more associated with CVD events 






Specific Aim II 
 We found that, majority of our patient had a nutrient intake below the K/DOQI 
recommendation for hemodialysis patients. Additionally, poor muscle mass and muscle 
strength as well as abnormal biochemical parameters lead us to further analyze our data to 
diagnose patients having malnutrition or protein energy wasting (PEW). PEW in 
hemodialysis patients is prevalent worldwide, so as in Bangladesh, affecting their morbidity 
and mortality. Despite having numerous important consequences of PEW to CKD patients 
such as-a negative impact on patients’ prognosis, complications, management, quality of life 
as well as in health economics, it is not being considered as a clinical priority in many parts 
of the world and is often undetected and untreated. Increased awareness of PEW in CKD 
begins with identifying the prevalence of PEW among CKD patients. In 2018, a review paper 
was published by ISRNM, where malnutrition-inflammation score (MIS) cut-off point of ≥5 
was used to identify the prevalence of PEW in overall CKD population worldwide and 
proposed that, 28% to 54% of MHD patients have PEW globally [63] where no data was 
available for Bangladesh. Data on nutritional status of Bangladeshi dialysis patients 
(specifically those with PEW) is limited to the best of our knowledge. Therefore, an 
appropriate, cost-effective and reliable detection method is highly warranted in order to 
assess the prevalence of this comorbid condition among Bangladeshi MHD patients. In this 
study, we found the prevalence of PEW among MHD patients was 18% using criteria 
provided by ISRNM for PEW diagnosis, which is one of the very first studies conducted in 
Bangladesh. 
A recent study in Bangladesh [25], which was conducted in Kushtia district stated 
that, 57% of their study population had a BMI <23 kg/m2, which correlates with the result 





Additionally, 57% patients showed lower MAMC compared to the values that are 10% below 
the 50th percentile reference population and 61% had a serum albumin of <3.8 g/dL. Similarly 
a recent study conducted in Indonesia among HD patients showed that, 66% of patients had a 
lower MAMC and serum albumin of <3.8 g/dL [106] that correlates with our observation. 
There are several reasons why low muscle mass is related to poor survival., such as, lower 
muscle mass may reflect poor nutritional status, and a level of inflammation [202]. Honda et 
al. showed a significant increase of inflammation (CRP≥10 mg/l) in HD patients with low 
lean-body mass determined by DEXA[210]. Again, muscle mass is the compartment in the 
body where uremic toxins are distributed in HD patients. Gotch et al. stated that, total body 
water and muscle mass are strongly correlated, and muscle mass is the main location of 
intracellular water. Therefore, patients with lower muscle mass indicates a high level of 
uremic toxins [211]. Thus, presence of muscle-wasting, inflammation and comorbidities 
contribute to an additional burden of physiological derangement in this group of patients.  
Sarcopenia is a disease that is found among elderly population who have loss of 
muscle mass and strength [212]. Studies also showed that, in patients with chronic disease, 
there is hormonal changes, increment of proinflammatory factors, and accumulation of 
reactive oxygen species, which lead to muscle atrophy at even younger age [213]. Studies on 
general population showed that, muscle strength is inversely related with inflammation and 
oxidative stress[203], but no study was done among renal population. Though a statistically 
significant, moderately strong and positive correlation was found between muscle mass and 
hand grip strength of PEW patients in the present study, which indicates that, with the 
severity of malnutrition, patients experienced frailty- loss of muscle mass and strength, thus a 
diminished physiological function [214, 215]. No previous study found in Bangladesh have 





Hypoalbuminaemia is another diagnostic criteria to determine the prevalence of 
malnutrition and half of dialysis patients having a serum albumin level of less than 3.8 g/dl, 
show a two fold increase in mortality rate [39]. Although serum albumin is reduced due to 
inadequate dietary protein intake, inflammation is mainly responsible for its reduction due to 
a decrease in synthesis and transfer to extravascular space [216]. Low serum albumin is one 
of the strongest forecaster of mortality in HD patients[217]. In our study, the average serum 
albumin levels for PEW and Non-PEW patients were 3.5±0.6 g/dL and 3.8±0.5 g/dl 
respectively, indicating that, majority of our patients were suffering from hypoalbuminemia. 
However, measurement of serum albumin is not a routine biochemical procedure in most of 
the renal clinic in Bangladesh and we speculate that, if it is made as a mandatory assessment 
along with necessary anthropometric assessment following standardized protocol in all HD 
clinic in Bangladesh, it could be easier to capture the true picture of the prevalence of PEW in 
these population. 
Both low TIBC and high Ferritin values found in this study indicates the prevalence 
of malnutrition and inflammation with a higher death risk in this PEW cohort and also among 
Non-PEW cohort [207, 218]. Increased metabolic and regulatory derangements such as-
acidosis, inflammation, hormonal and electrolyte imbalance take place in patients with 
ESRD. All these lead to the development of hyper catabolism and negative nitrogen balance 
and at this point, patient experience anorexia, poor appetite and other gastrointestinal 
disorders which decrease their food intake and increase their loss of muscle protein. Presence 
of other comorbidities like hypertension, diabetes and often CVD significantly increased their 
mortality risk and thus make their condition worst [219].  
TC, TAG, LDL-C, all are lower in PEW patients-attributed to malnutrition and 





patients[220] and a synergistic relationship between malnutrition, inflammation and oxidative 
stress is responsible for rapid development of atherosclerosis in ESRD patients [221]. 
Approximately, 76% of PEW patients were suffering from mixed dyslipidemia and 43% 
PEW patients were having dyslipidemia based on TAG/HDL-C ratio, which suggest that, 
both PEW and dyslipidemia were prevalence side by side in MHD patients in this specialized 
renal hospital. 
Close monitoring of a patient’s nutritional status, dietary modification and counselling 
based on his physiological condition could be one of the preventive strategies to preserve 
health in malnourished dialysis patients[222]. A prospective cohort study was conducted 
among 809 patients who participated in NIED study [223] (Nutritional and Inflammatory 
Evaluation in Dialysis) for 63 months where it was found that, the MIS is correlated with 
nutritional status, quality of life, inflammation and mortality prediction among chronic HD 
patients and improving the MIS may improve their clinical outcomes [224]. 
Based on, 4th diagnostic criteria for PEW by ISRNM, theoretically, an HD patient 
with a dietary energy intake (DEI) below 25 kcal/kg body wt./day and a dietary protein intake 
(DPI) below 0.8 g/kg body wt./day for at least 2 consecutive months need to be considered. 
In this study, a one-day 24-hour diet recall data were analyzed for 112 patients, of which 68 
patients were considered as acceptable reporters (61%). Considering one occasion of dietary 
information (that has been done in present study), 38 patients (56%) had a dietary energy 
intake (DEI) below 25 kcal/kg body wt./day and 30 patients (46%) had dietary protein intake 
(DPI) below 0.8 g/kg body wt./day. More data are required to validate this result. However, 
average dietary energy intake (DEI) was 24 kcal/day and dietary protein intake (DPI) was 
1.0g/day in case of PEW patients which were below the recommended intakes of 30-35 





Kidney Foundation (NKF)/Kidney Disease Outcome and Quality Initiative (KDOQI) 
guidelines [151, 225]. Amongst all patients (PEW and Non-PEW) protein intakes of 54±22 
g/day and energy intakes of 1436±498 kcal/day were noted. Although we did not assess diet 
intake in normal non-dialysis patients in this study, previous data from a normal urban 
population in Bangladesh revealed protein intake estimates of 68-78 g/day, with energy 
intake estimates of 2142 to 2394 kcal/day [226]. Studies showed that, compromised dietary 
energy and protein intake among hemodialysis patients leads to the development of 
malnutrition along with duration of dialysis [227, 228]. 
No significant differences were observed in other components of health-related 
questionnaires, (which might be due to the small number of PEW patients) with the exception 
of MIS score and two components of KD-QoL (PCS and MCS) between PEW and non-PEW 
patients (Both had higher values for PEW patients). However, an MIS score of > 5 is 
considered as an indicator of the prevalence of malnutrition in many studies and a higher 
score of KD-QoL indicates malnutrition. From this point of view, we can further predict that, 
the number of PEW patients identified in this study might be an underestimate. 
PEW is the consequence of various mechanisms intrinsic to CKD, including 
undernutrition, systemic inflammation, comorbidities, hormonal imbalances, the dialysis 
practice, and magnitudes of uremic toxicity. It may instigate infection, cardiac events, frailty, 
and depression, but these impediments may also upsurge the extent of PEW [59]. 
Sabatino et al. in 2016, proposed the following “Nutrition approach” for HD patients 
having PEW[222]: 
1. Early nutrition intervention should be targeted for PEW patients when their energy 





body weight/day up to 35 kcal/kg body weight/day and 1.1 g/kg body weight/day- in 
order to make up accelerated muscle catabolism. 
2. Individualized nutrition counseling is needed at a regular basis in order to provide 
them with correct dietary information, assessing and reassessing their eating habits, 
helping them to increase their food intake with adjustment in excess phosphorous, 
potassium and sodium intake at the same time, and 
3. Help patients to avoid unnecessary fasting during acute illness or hospitalization and 
due to dialysis schedule. 
However, if the causes of developing PEW in CKD patients is not linked to poor 
dietary intake but to poor clinical condition, then the patients may not respond to the dietary 
therapy, that is high calorie and protein intake [70]. 
For now, we conclude that, based on ISRNM criteria as gold-standard, prevalence of 
PEW in this specialized renal hospital is 18% and the number could be more or up to 40% if 
all data were available at this point. If this is the scenario in an Urban renal-specialized 
hospital in Bangladesh, it is obvious that, many more hemodialysis patients were also 
suffering from PEW all over the country. In summary, our nutrition assessment protocol and 
PEW diagnosis criteria from ISRNM are comparatively easy, quick, inexpensive and reliable 
which enables malnourished or PEW hemodialysis patients to be identified and put on 
nutrition intervention trials. If PEW remains undiagnosed, it will make the situation of 
Bangladeshi MHD patients even worst. Now, it is high time to plan and implement the 
strategies to diagnose PEW patients undergoing hemodialysis and recommend additional care 
for them to improve their health status, which will ultimately impact on a better survival of 






Specific Aim III 
In order to understand the impact of the provision of targeted renal-specific nutrition 
information among a group of disadvantageous dialysis population as well as to support diet 
counseling among Bangladeshi dialysis patients, the culturally acceptable ‘Nutrition Booklet’ 
was developed. For educating MHD patients, a renal-friendly food pyramid and more 
particularly a phosphorus pyramid was prepared as an educational tool and incorporated in 
the ‘Booklet’ as because most Bangladeshi people are not aware of the existence of a renal 
food pyramid and to the best of our knowledge, there is no food pyramid as well as 
phosphorus pyramid available for renal patients in Bangladesh. Attempts had also been taken 
in order to improve Patients’ knowledge regarding proper dialysis diet and nutrition. 
Thorough analysis of Bangladeshi common food list [111] was done to address the gap in 
knowledge between the patients and nutritionist in field level.  
Studies previously done in this field showed that effective renal-specific knowledge 
among patients could reduce the deterioration of renal function among patients at early stages 
of renal disease [69], and also reduce the incidence of diet related comorbidities such as 
hypertension, hyperphosphatemia, hypo and hyperkalemia among chronic kidney disease 
patients[67, 94]. Studies also showed that, patients with chronic disease having nutrition 
counseling were shown to have a positive outcomes, compared to patients who did not 
receive any counseling by analyzing height, weight, recent laboratory data, past medical 
history, 24-hour diet recall both before and after nutrition counseling [68]. 
In some study, it was found that, interactive educational intervention could improve 






Only big city hospitals have dietitians in Bangladesh who provide nutrition and food 
related advise to all patients in general. There is mostly no renal dietitian to the best of our 
knowledge. Patients often seemed confused on what food to select among wide varieties of 
local foods and ends up selecting the wrong one or none. Thus, their food intake became 
inappropriate, that lead them to the vicious cycle of malnutrition and further complicate their 
health. For this study, the renal-specific nutrition booklet was only developed for Bangladeshi 
MHD patients and made feasible to use in practice as an educational tool to improve their 
selection of food items as well as adherence towards renal-specific diet practice. Future 
research is needed to observe the impact of this booklet in a large group of Bangladeshi 
hemodialysis patients. 
Limitation of the study 
This study has several limitations, which are highlighted to facilitate future studies by 
other groups. Firstly, data were collected from one hospital in Dhaka, and likely may not be 
representative of the country. Secondly, only a 24hr diet recall was captured, limitations of 
which have been discussed by others. Third, home-cooking involved numerous recipes, all of 
which may not have been captured by the patients. Fourth, while Bangladesh Food 
composition tables were used, these are not exhaustive, and no software captures this 
information. Fifth, diet data were not collected for dialysis day and may not reflect the usual 
intake of patients. Sixth, logistic support for such studies are hampered by lack of trained 
support staff, renal dietitians, and a general lack of nutritional knowledge of patients and 






Our study though has several strengths. First, we were able to capture anthropometric, 
dietary, and biochemical parameters from the same set of patients, which is one of the first 
from Bangladeshi ESRD patients to the best of our knowledge. Second, a coordinated 
training effort across Malaysia, Bangladesh and US ensured uniform protocols for diet and 
anthropometric assessment. The latter were modeled on the protocols of ISAK. Third, the 
presence of overseas personnel to supervise and train local staff in data collection helped 
facilitate logistic support. Fourth, the fact that, the hospital had patients whose typical care 
included twice or thrice weekly dialysis, allowed us to detect some initial data on individuals 
receiving twice/thrice weekly dialysis. Fifth, our lipid analyses extended beyond serum 















CHAPTER 7 ADDITIONAL TASK AS A PILOT SKIM TO EDUCATE AND TRAIN 
RENAL NUTRITION SUPPORT PERSONNEL IN A RESOURCE-POOR FACILITY   
Individuals with expertise in renal nutrition and associated aptitude in nutrition 
assessment are scarce in resource-poor countries. In order to disseminate detailed renal-
specific nutrition education to each dialysis patients and their family members, and later, 
throughout Bangladesh, involvement of properly trained and skilled manpower with a 
background of renal nutrition-related research turns out to be an important part of the study. 
Taking necessary permission from the appropriate authorities, students in nutrition 
background from one of the reputed government STEM universities in Bangladesh were 
involved at this point. A renowned specialized Bangladeshi renal hospital and the department 
of Nutrition and Food Science, Wayne State University, USA were also involved and actively 
cooperate to resolve this issue. Attempts were made to generate trained manpower in order to 
facilitate research work in renal nutrition field in a resource-poor country, like Bangladesh. 
The purpose was to educate and train a group of graduate students (in nutrition) with basic 
skills to assist renal staff in nutrition and anthropometric assessments in a hospital providing 
dialysis services in Dhaka, Bangladesh, who could be utilized to help out improving the 
health and nutritional status of Bangladeshi dialysis patients in near future. A total of 50 
graduate students (in Nutrition) from a research University, “Noakhali Science and 
Technology University” participated in a pilot training program from November 2018 till 
March 2019 that involves 3 phases.  
First stage involved online lectures via Skype from the USA on selected topics. 
Lectures totaled 6-8 hours of contact time and allowed for interactive exchanges. There is an 
11 hours of differnce in local time schedule between USA and Bangladesh, for which in 
USA, the training schedule was from 6.30 AM till 10 A.M and in Bangladesh, it was from 





materials were also provided to the participants regarding an overview of the basic 
information on kidney disease, complication related to CKD and its possible management, 
anthropometric and dietary assessment, malnutrition among CKD patients, use of different 
health related questionnaire to detrmine health outcomes, lipid metabolism in CKD or ESRD 
patients as well as the precess of doing nutrition related reseach among dialysis patients.  
In the second phase, half of the participants were divided into five groups and each 
group rotated in KFHRI in Dhaka providing renal services to make them understanding of 
how to work in a clinical setting for  a 7-10 days period from January to February, 2019. 
KFHRI is a perfect clinical settingfor Bangladesh perspective. It is a specilized renal hospital 
with both laboratory and dialysis facilities at the same place as well as facilities for renal 
transplant. Admitted patients were provided cooked food over there as because it has its oen 
kitchen and canteen facilities. At the same time, this hospital is also served as a research and 
training institute on chronic kidney disease and has collaboration with renowned hospitals 
and universities throughout the world. In one word, students got an opportunity to see the 
whole picture related to renal disease treatment and research in one single place. Students 
were provided real-life exposures to patients, medical staff and dietitians as well as the 
opportunity to work and view nutritional services in the cafeteria. They observed different 
units of the whole hospital, took pictures of different packed foods, sold in the canteen, 
measured and document the weight od both raw and cooked food ingredients from the 
kitchen in a scientific way, performed self-reported 24-hour diet recall practice, learnt how to 
collect anthropometric data and attended “ward round” with the doctors for two days of their 
foundation training period and observed how dialysis patients were being treated based on 
their different signs and symptoms, both biochemical and clinical. They also observed how to 





In the third stage, seven students who had completed both online and on-site rotation, 
and upon recommendations from the hospital director, were selected to receive additional 
training. Then they were given additional 2-days of hand-on training by the Experts in this 
field on March, 2019.  
Through the whole process, students learnt research ethics, techniques of interviewing 
patients and completion of food diaries. They collected photographs and videos of cooking 
procedure as well as foods prepared and served in the cafeteria to create recipes,  
standardized serving sizes and prepared nutrition information for hospital staff. Students were 
trained in anthropometric assessments from ISAK certified personnel, nutritional assessment 
by Dietitians with accreditations from Australia, Malaysia and USA. Students were also 
trained to analyze data using “NutriPro” software. which was done for the 1st time in 
Bangladesh to analyze dietary data to the best of our knowledge. Based on successful 
performance, 7 students were “certified” and co-opted to assist in an ongoing clinical 
research study where they subsequently assisted the lead researchers with data collection. 
From an initial pool of 50 students-7 (14%) were successfully trained to assist researchers in 
an ongoing clinical trial.  
This pilot training program also helped increase awareness of renal nutrition amongst 
students, hospital staff and patients. While mechanisms are developed between Universities 
and renal facilities to expand this program in Dhaka and formalize certification process, this 
simple model may be a cost-effective way to increase pool of trained “technicians” in renal 
research in resource-poor settings. It has successfully developed qualified health research 
supporting personnel in renal nutrition research field and the perceived impact of this pilot 
program had created a positive impact among experts in renal nutrition as well as 





increase the number of qualified research personnel in renal nutrition field, especially in low 
income developing countries like Bangladesh in order to conduct quality research in future in 
this field. 
There are gaps in research, care, and policy that severely compromised our ability to 
improve the outcomes of patients with CKD worldwide. The goal of ISN (International 
Society of Nephrology) for the community is-at least 30% of all people with CKD should be 
involved in relevant clinical trials by 2030 which might greatly improve secondary 
prevention and treatment of CKD [229]. There are high demand in capacity building training 
programs in the field of dissemination and implementation research, which had been found 
based on a NIH (National Institute of Health) workshop in 2013[230]. The development of 
renal registries in resource-poor countries could be an important step forward in documenting 
current disease burden and changes. Therefore, it is high time to close gaps and reduce the 
burden of CKD worldwide. If such pilot training could be arranged in future, research 
personnel who got certificates from such program (International Accreditation) could be 
further utilize for successful initiation and completion of multinational clinical trial focusing 











CHAPTER 8 CONCLUSION AND RECOMMENDATION 
To summarize, in the first study (specific aim I), the purpose was to examine current 
health and nutritional status of hemodialysis (HD) patients in a specialized renal hospital in 
Dhaka, Bangladesh. Methods to identify patients at risk for ESRD are a high priority in 
Bangladesh, where kidney transplants/dialysis options are limited and costly. Nutrition 
intervention to delay progression to ESRD is a promising and affordable strategy. However, 
data on nutritional status of Bangladeshi dialysis patients is limited and is not adequately 
documented. We assessed 133 patients (49% male) at the Kidney Foundation Hospital and 
Research Institute (in 2017 and 2018) based on different anthropometric, biochemical, and 
clinical parameters. Lipid profiles and subfractions were analyzed and patients with DL were 
characterized using ATP (Adult Treatment Panel) III guideline. Malnourished patients were 
identified using criteria from the International Society of Renal Nutrition and Metabolism 
(ISRNM). Results revealed patient characteristics: Age 50±13 years, dialysis vintage 30± 24 
months, 62% twice weekly dialysis, with causes of ESRD- hypertension (HTN) 42%, HTN 
and diabetes 28%, HTN and chronic glomerulonephritis 19%. Anthropometric and 
biochemical evaluations revealed; BMI 24.1± 5.2 kg/m2, mid-arm muscle circumference 
21.6± 3.6 cm, serum albumin 3.7± 0.6 g/dL. Laboratory analyses revealed: low density 
lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) of 
84.2±30.8 and 34.5±11.2 mg/dL, respectively, with 59% of the patients having LDL 
phenotype A, 28% -LDL phenotype B. Type B patients had significantly higher total 
cholesterol, triglycerides (TG), and LDL-C and significantly lower HDL-C as compared to 
those with pattern A. Type B patients also had significantly less cholesterol in large and 





on TG to HDL-C ratio>3.8, ~64% patients were DL, while based on ATP III guideline, ~70% 
patients had mixed DL and ~14% patients had atherogenic DL.  
In the second study, PEW was assessed by the presence of 3 out of 4 standard criteria 
(as per the ISRNM) and was found prevalent in 21 patients (18%). Another 23% of patients 
were considered at risk for PEW (presence of 2 criteria). The figures may be underestimates 
as only one clinic was evaluated. Although these are some of the first measurements reported 
from Dhaka, additional data from a cross section of dialysis patients in Bangladesh are 
needed, prior to formulating strategies for nutrition and life-style interventions. 
In the third pilot study for specific aim III, attempts were taken to develop an 
educational tool for improving renal-specific nutrition knowledge among Bangladeshi 
dialysis patients in the form of a “Nutrition booklet”. Provision of renal-specific nutrition 
knowledge may help renal patients make more informed food choices. This may be especially 
important in resource-poor settings where nutritional support is a low-priority amongst 
health-care providers. The booklet was certified by Kidney Foundation Hospital and 
Research Institute, Dhaka (for its clinical content) and the INFS for its nutrition information, 
and was developed only for Bangladeshi dialysis patients and made feasible to use in practice 
as an educational tool to improve their selection of food items as well as adherence towards 
renal-specific diet practice.  
As an additional task as a pilot scheme, attempts were made to educate and train a 
group of graduate students (in nutrition) with basic skills to assist renal staff in nutrition and 
anthropometric assessments in a hospital providing dialysis services in Dhaka, Bangladesh. 
Individuals with expertise in renal nutrition and associated aptitude in nutrition assessment 
are scarce in resource-poor countries. Students learnt research ethics, techniques of 





of cooking procedure as well as foods prepared and served in the cafeteria to create recipes,  
standardized serving sizes and prepared nutrition information for hospital staff. Students were 
trained in anthropometric assessments from personnel certified by the International Society 
for Anthropometrics and Kinantiometry, nutritional assessment by Dietitians with 
accreditations from Malaysia and USA. Students were trained to analyze data using 
“NutriPro” software. From an initial pool of 50 students-7 (14%) were successfully trained to 
assist researchers in an ongoing clinical trial. This pilot training program also helped increase 
awareness of renal nutrition amongst students, hospital staff and patients. While mechanisms 
are developed between Universities and renal facilities to expand this program in Dhaka and 
formalize certification process, this simple model may be a cost-effective way to increase 
pool of trained “technicians” in renal research in resource-poor settings in near future. 
Due to epidemiological transition, existing disease pattern changed from 
communicable and infectious diseases to non-communicable and chronic diseases in 
Bangladesh and CKD contributes to the later a lot. There is a rising trend in the incidence and 
prevalence of kidney diseases in Bangladesh. Besides the well-known risk factors like 
hypertension, diabetes, obesity, glomerular diseases, genetic and other unknown emerging 
risk factors might play a role in the initiation and progression of this disease. Though 
numerous researches are ongoing worldwide based on CKD, Bangladesh is still far behind. In 
context of Bangladesh, lots of information is still missing. Despite some efforts, reliable and 
consistent data concerning various aspects of CKD is unknown.  
Besides these, large-scale, countrywide survey and epidemiological and clinical 
research should be conducted to determine different aspects of CKD in Bangladesh so that we 
can combat the widespread of CKD more efficiently in future. CKD prevention should be 





education program that is currently taken into consideration in developed countries [231]. 
Mass media can play role to build up awareness about CKD. Approaches like screening for 
hypertension, diabetes, malnutrition or protein-energy wasting and dyslipidemia should be 
made feasible to general people. Formulation of appropriate policy and emphasis on 
preventive strategies could help to combat CKD in our country.  
Additionally, a 3 Day Diet Record should be collected from different renal hospitals 
(both public and private) and analyzed to grasp a better picture of CKD Diet intake pattern in 
Bangladesh. Promotion of healthy lifestyles such as-moderation in salt use, cessation of 
smoking/tobacco use, limit intakes of high sugar or fatty food, processed and fast foods 
should be taken place in every parts of the country. Food labelling should be introduced to 
help consumers choose what they should buy. Food adulteration should be monitored more 
strictly. Moreover, collaborative research with international organization should be 
undertaken to explore still unidentified risk factors unique to develop CKD. Formation of a 
Bangladeshi FFQ (Food frequency questionnaire), specific for renal patients would also be 














APPENDIX A. SUPPLIMENTARY TABLES 
Table S1. Demographic and clinical parameters (Male vs Female) 
 Male Female 
Age in years (n) 50±14 (65) 50±12 (68) 
Young adult (18-35), n (%) 12 (18%) 10 (15%) 
Middle-aged adult (36-55), n (%) 30 (46%) 30 (44%) 
Older adult (>55), n (%) 23 (35%) 28 (41%) 
Dialysis duration (hr) (n) 3.8±0.4 (76) 3.8±0.3 (43) 
Dialysis vintage (mon) (n) 25.5±23.5a (77) 37.5±24.4a (46) 
Dialysis frequency, n (%)   
Thrice a week 25 (40%) 23 (34%) 
Twice a week 36 (58%) 45 (66%) 
Once a week 1 (2%) 0 
Causes of ESRD, n (%)   
HTN 26 (40%) 26 (38%) 
HTN and DN 14 (22%) 23 (34%) 
HTN and CGN 12 (18%) 12 (18%) 
Others 4 (6%) 6 (9%) 
Missing data 9 (14%) 1 (1%) 
Data were collected from the number of patients indicated in parentheses. Values are Mean ±SD and n or %. 
HTN: Hypertension, DN: Diabetic nephropathy, CGN: Chronic glomerulonephritis, Other: 2 APKD, 5 
Unknown, 1 postpartum complication; 1 genetic, 1 DN and CGN. ESRD: End-stage renal disease. Mean values 








Table S2. Anthropometric and biochemical parameters (Male vs Female) 
 Male Female Reference value 
Height (cm) 166±7 a (56) 152±6 a (63)  
Dry weight (Kg) 62.4±10.5 (58) 58.5±13.9 (63)  
BMI (kg/m2) 22.7±3.3 a (56) 25.4±6.2 a (63)  
Underweight, <18.5, n (%) 6 (11%) 8 (13%)  
Healthy-weight, 18.6-24.9, n (%) 37 (66%) 25 (40%)  
Overweight, 25-30, n (%) 12 (21%) 16 (25%)  
Obese, >30, n (%) 1 (2%) 14 (22%)  
HGS (Kg) 23.6±7.6 a (65) 15.3±4.6 a (68)  
MAC (cm) 25.3±4.1 a (65) 27.7±5.9 a (66)  
TSF (mm) 11.5±5.8 a (65) 19.7±8.7 a (66)  
MAMC (cm) 21.7±3.0 (65) 21.6±4.0 (66)  
TIBC (mg/dL) 252.8±67.1 (40) 233.4±60.5 (49) 300-400 [139] 
URR % 61±8 a (41) 68±8 a (50) > 65 [140] 
Na (mEq/L) 137±3.4 a (56) 134.8±4.3 a (60) 135-146 [141] 
K (mEq/L) 5±0.6 (56) 4.9±0.8 (65) 3.5-5.3 [142-144] 
P (mg/dl) 4.3±2.2 (49) 4.5±2.3 (59)  
Albumin (g/dL) 3.8±0.6 a (48) 3.6±0.5 a (57) 3.8-5.0 [145] 
Ferritin (ng/ml) 550.9±441.6 (33) 453.1±444.3 5-275 [146] 
Ferritin >2000ng/mL (n) 8 10  
Kt/V 1.1±0.2 a (28) 1.5±0.5 a (29) 1.2-1.3 [147, 148] 
Data were obtained from patient medical records. Values are Mean ± SD. Mean values sharing a common 
superscript were significantly different from each other using a one-way ANOVA(p<0.05). HGS: Hand grip 
strength, MAMC: Mid-arm muscle circumference. TSF: Triceps skinfold, BMI: Body mass index. URR%: Urea 









Table S3. Lipid profile and Lipid subfractions (Male vs Female) 
 Male (56) Female (60) 
TC (mg/dl) 139±32 a 169±41 a 
HDL-C (mg/dl) 33±11 36±11 
TG (mg/dl) 158±86 a 197±100 a 
LDL-C (mg/dl) 75±25 a 93±33 a 
TC/HDL-C 4.7±1.7 5.0±1.8 
LDL-C/HDL-C 2.3±1.1 2.9±1.4 
Non-HDL-C 106±32 a 133±41 a 
Non-HDL-C/HDL-C 3.7±1.7 4.0±1.8 
TG/HDL-C 5.9±4.7 6.2±3.7 
VLDL (mg/dl) 32±11 a 40±13 a 
IDL (mg/dl) 23±6 a 28±8 a 
Large LDL (mg/dl) 17.3±8.2 a 21.2±7.7 a 
Inter. LDL (mg/dl) 9.8±5.7 a 12.6±8.0 a 
Small LDL (mg/dl) 4.5±5.9 6.7±10.1 
Mean LDL size (Å) 267±9 268±7 
Large HDL (mg/dl) 11.1±7.6 13.7±8.4 
Inter. HDL (mg/dl) 16.8±4.7 17.9±4.6 
Small HDL (mg/dl) 4.8±2.3 4.4±2.4 
Dyslipidemia (DL)   
TAG/HDL-C<3.8 24 (43%) 18 (30%) 
TAG/HDL-C>3.8 32 (57%) 42 (70%) 
LDL-Pattern   
Type A 34 (61%) 34 (57%) 
Type B 16 (29%) 17 (28%) 
Intermediate 6 (11%) 9 (15%) 
Data were analyzed for the number of patients indicated in parentheses. Values are Mean + SD. TC: Total 
Cholesterol, HDL-C: High density lipoprotein, TAG: Triglycerides, LDL-C: Low density lipoprotein. Type A: 
athero-protective profile, Type B: atherogenic profile, Intermediate: has characteristics of both A and B.  Mean 







Table S4. Dietary analysis for Acceptable Reporters (Male vs Female) 
Parameters Male (39) Female (29) KDOQI Guidelines 
Calories (Kcal) 1594±577 a 1218.6±204 a Based on BW 
DEI/kg BW/day 25.2±7.6 a 21.7±4.2 a 30-35 Kcal/kg BW/day 
Protein (g) 60±24.7 a 46.2±13.1 a Based on BW 
DPI/kg BW/day 0.9±0.3 a 0.8±0.2 a 1.2 g/ kg BW/day 
P mg/kg body wt. /day 15.3±6.4 a 13±3 a 10-17 mg/kg BW/day 
Phosphorous: Protein 16.4±4 16.1±3.6 <12 mg/g of protein 
Carbohydrates (g) 233±79 a 175±33 a Based on BW 
Total Fiber (g) 19.2±7.7 a 13.4±2.8 a 20-25 g/day 
Fat (g) 47.5±24.2 a 36.7±10.6 a  
SFA (g) 9±4.7 7.5±3.7  
MUFA (g) 9.2±4.5 7.3±4.2  
PUFA (g) 18±11 a 12.6±5.2 a  
Cholesterol (mg) 232±157.2 213.2±143.3 <200 mg/day 
omega 6: omega 3 11.5±6.1 9.8±4.8 4:01 
Water (ml) 1506.5±643.5 1298±632 750-1500 ml/day 
Vitamin A-IU 1290.7±1605.7 a 647.3±607.7 a 700-900 IU 
Vitamin D-IU 47±37.8 47±42.5 600 IU 
Vitamin E-a-Toco (mg) 2.4±1.2 2±1.9 15 mg 
Vitamin K (µg) 23.3±38 14±20.1 90-120 µg 
Vit B1 (mg) 0.9±0.3 a 0.6±0.2 a 1.1-1.2 mg 
Vit B2 (mg) 1.3±2.2 0.8±0.3 1.1-1.3 mg 
Vit B3 (mg) 15.6±6 a 11.2±2.7 a 14-16 mg 
Vit B6 (mg) 8.9±24.4 15.6±35.7 13-17 mg 
Vit B12 (µg) 1.7±1.2 1.6±2.1 2.4 µg 
Biotin (µg) 12±11.6 7.3±5.4 30 µg 
Folate (µg) 175±234.2 a 80.5±40 a 1000 µg 
Vit C (mg) 104±79.8 a 67±55 a 75-90 mg/day 
Dietary Calcium (mg) 414.4±236.2 463.2±290.5 <1000 mg 
Iron (mg) 15.4±11.9 15.6±17.6 Individualized 
Dietary Phosphorous (mg) 978±519.6 a 718.3±140.7 a 1000 mg 
Potassium (mg) 1556.7±678 a 1216±262 a Individualized 
Dietary Sodium (mg) 2168±1094 1876±606 <2400 mg/day 
Zinc (mg) 9±5.1 a 6.7±3 a 15 mg 
Magnesium (mg) 251±108 a 195±43 a 200-300 mg/day 
The data is reported for all acceptable reporters. Values are as Mean ± SD. DEI: Dietary energy intake, DPI: 
Dietary protein intake. SFA: Saturated fat, MUFA: Monounsaturated fat, PUFA: Poly unsaturated fat. IU: 
International Unit, vit: vitamin, Toco-: tocopherol. BW: Body weight. Mean values sharing a common 






Table S5. Health and Nutrition Questionnaires (Male vs Female) 
 Male Female 
MIS Score 5.8±2.9 (40) 6.2±3.0 (48) 
ADAT Score 3.4±1.4 (28) 4.0±1.7 (29) 
RLS Score 15.0±8.3 (24) 18.5±8.3 (39) 
KD-QoL   
SF-12 Physical Health Composite 42.9±10.2 (39)a 33.4±10.1 (47)a 
SF-12 Mental Health Composite 47.3±9.6 (39)a 42.5±9.7 (47)a 
Burden of Kidney Disease 32.5±25.6 (40) 27.9±27.2 (49) 
Burden of Kidney Disease 67.8±18.6 (34) 61.6±16.3 (45) 
Data were collected from the number of patients indicated in parentheses. Values are Mean ±SD (n). Mean 
values sharing a common superscript are statistically significant using a one-way ANOVA (p<0.05). 
MIS [46]: Malnutrition inflammation score. A score >5 indicates malnourished The MIS has 10 components, 
each with four levels of severity, from 0 (normal) to 3 (very severe). The sum of all 10 MIS components ranges 
from 0 (normal) to 30 (severely malnourished); higher score reflects a more severe degree of malnutrition and 
inflammation. ADAT [124]: Appetite and diet analysis tool. Scale: 1 = very good, 2 = good, 3 = fair, 4 = poor 
and 5 = very poor. RLS [126]: Restless leg syndrome. medical doctor. Scale: 0, None; 1 – 10, Mild RLS; 11-20, 
Moderate RLS, 21-30 Severe RLS, 31-40 Very Severe RLS. Patients reporting score ‘0’ were excluded from 














Table S6. Demographic and anthropometric parameters (< 2 years vs >2 years dialysis) 
 < 2 years (65) >2 years (59) 
Age in years (n) 51.8±12.5 a (65) 47.3±12.6 a (59) 
Dialysis duration (hrs) (n) 3.7±0.4 (63) 3.8±0.3 (56) 
Height (cm) 158.4±8.8 (62) 158.6±10.1 (56) 
Dry weight (Kg) 60±12.4 (62) 60.9±12.8 (56) 
BMI (kg/m2) 24±5.2 (62) 24.3±5.3 (56) 
HGS (Kg) 18±6.9 a (65) 21±7.9 a (59) 
MAC (cm) 26.1±5.3 (64) 27.4±5.2 (58) 
TSF (mm) 16.8±8.6 (64) 15.3±8.5 (58) 
MAMC (cm) 20.8±3.6 a (64) 22.6±3.5 a (58) 
Data were collected from 124 patients (65 patients with dialysis vintage of less than or equal to 2 years and 59 
patients with more than 2 years). Values are Mean + SD (n). Mean values sharing a common superscript were 
significantly different from each other using a one-way ANOVA(p<0.05). HGS: Hand grip strength, MAMC: 













Table S7. Biochemical parameters (< 2 years vs >2 years dialysis) 
 
< 2 years (65) >2 years (59) Reference value 
TIBC (mg/dL) 219.7±50.8 a (36) 257.4±67.7 a (53) 300-400 [139] 
URR % 64.2±11.4 (38) 64.8±9.6 (54) >65 [140] 
Na (mEq/L) 136±3.6 (60) 135.5±4.4 (56) 135-146 [141] 
K (mEq/L) 5.1±0.7 (64) 4.9±0.8 (57) 3.5-5.3 [142-144] 
P (mg/dl) 4.1±2.4 (51) 4.7±2 (57) 
 
Albumin (g/dl) 3.6±0.7 (49) 3.7±0.4 (56) 3.8-5.0 [145] 
Ferritin (ng/ml) 503.7±383.7 (29) 492.2±481.1 (45) 5-275 [146] 
Kt/V 1.2±0.3 (18) 1.4±0.4 (39) 1.2-1.3 [147, 148] 
Data were obtained from patient medical records. Values are Mean ± SD. Mean values sharing a common 
superscript were significantly different from each other using a one-way ANOVA(p<0.05). TIBC: Total Iron 

















Table S8. Lipid profile and subfraction (< 2 years vs >2 years dialysis) 
 < 2 years (61) >2 years (53) 
TC (mg/dl) 158.5±42  152±35.9  
HDL-C (mg/dl) 36.7±12.2 a 32.6±8.9 a 
TG (mg/dl) 180±105.8 175.3±83.9 
LDL-C (mg/dl) 85.8±31 84.3±29.8 
TC/HDL-C (*4.0) 4.7±1.9 4.9±1.6 
LDL-C/HDL-C 2.6±1.2 2.8±1.2 
Non-HDL-C (mg/dl) 121.8±42.8 119.4±35.3 
Non-HDL-C/HDL-C  3.7±1.9 3.9±1.6 
TG/HDL-C 5.9±4.4 5.9±3.3 
VLDL (mg/dl) 38.9±13.7 a 33.4±10.6 a 
IDL (mg/dl) 53±15.7 52.3±14.1 
Large LDL (mg/dl) 18.4±7.1 20.8±9 
Intermediate LDL (mg/dl) 10.7±6.7 12.2±7.5 
Small LDL (mg/dl) 5.8±8.6 5.4±8.1 
Mean LDL size (Å) 267.9±6.8 267.9±6.6 
Large HDL (mg/dl) 13.7±9.1 11.1±6.7 
Intermediate HDL (mg/dl) 18.5±4.5 a 16.6±4 a 
Small HDL (mg/dl) 4.4±2.3 5±2.3 
Data were collected from the number of patients indicated in parentheses. Values are Mean ±SD. TC: Total 
Cholesterol, HDL-C: High density lipoprotein, TAG: Triglycerides, LDL-C: Low density lipoprotein. Mean 








APPENDIX-B INFORMED CONSENT FORM 
KIDNEY FOUNDATION HOSPITAL AND RESEARCH INSTITUTE  
WAYNE STATE UNIVERSITY, USA 
 
Name of the respondent: ----------------------------------------  Date: ----/----/ ----- 
 
I am Tanjina Rahman, a PhD student of Nutrition and Food Science, Wayne State 
University, USA. As a course requirement I am doing research on “Nutrition and Health 
Status of Hemodialysis Patients in Dhaka, Bangladesh”. 
 
I hereby would expect necessary information from you to complete the questionnaires. I 
would also like to assure that this data will be used only for the study purpose. If you feel any 
inconvenience you can stop the interview at any time. Your participation will not directly 
benefit you and will be volunteered. I would also like to mention that an additional 20ml 
blood will be taken from your routine blood draw for this research purpose if you participate 
in this study. 
I would appreciate your cooperation. If you agree to join the study, please sign at the space 
indicate below. 
All information will be kept confidential. 
Investigators signature & Date                                        Volunteer signature & Date 






APPENDIX-C CASE REPORT FORM (CRF) 








Personal Details & Medical History 
 
   
 
  
Hemodialysis Regimen      
Anthropometry, Body Comp & Muscle Strength      
Biochemical Data      
24 Hour Recall      
Appetite and Diet Assessment Tool (ADAT)      
Restless Legs Syndrome Rating Scale      
KDQOL      
 
 
Subject Number:  















ii. Inclusion Criteria 
iii. Exclusion Criteria 
iv. Personal Details & Medical History 
v. Hemodialysis Regimen 
vi. Anthropometry, Body Composition & Muscle Strength Test 
vii. Biochemical Data from HD Clinic 
viii. 24-hour Recall 
ix. Appetite and Diet Assessment Tool 




























1. Dr Harun Ur Rashid (PI) 
2. Dr. Tasnuva Kashem 




All information contained therein is strictly confidential and cannot be shared     



















1. Patient is willing and able to give informed consent for participation in the trial 
2. Male or Female, aged 18 years and above. Undergoing chronic hemodialysis 
treatment for more than 3 months (life expectancy > 1 year). 
3. Able and willing to comply with all trial requirements. 
4. Willing to allow his or her /Physician/Nephrologist/General Practitioner and 
consultant, if appropriate, to be notified of participation in the trial. 
 
 























1. Participants who have participated in another research trial involving an 
investigational product in the past 12 weeks 
2. History of functional kidney transplant 6 months before study entry; anticipated live 
donor kidney transplant over the study duration; 
3. Participants who are taking vitamin E- containing supplements >60 IU/d during the 
past 30 days 
4. History of poor adherence to hemodialysis or medical regimen 
5. Participants who are currently on active treatment for cancer, excluding basal cell 
carcinoma of the skin 
6. Participants who have been diagnosed as HIV/AIDS and/or on the anti-HIV therapy. 
(HIV seropositivity is not an exclusion criterion) 
7. Patients taking anti-inflammatory medication, except aspirin<325 mg/d, over the past 
30 days 
8. Female participant who is pregnant, lactating or planning pregnancy during the course 
of the trial 
9. Participants who are receiving nutritional support (i.e. enteral and intra-venous route) 
10. Patients using a temporary catheter for dialysis access at baseline or patients receiving 
a graft/fistula within the 6-month study period 
11. More than two hospitalizations within the last 90 days or one hospitalization within 
the 30 days preceding enrollment 
12. Any other significant disease or disorder which, in the opinion of their nephrologist, 
may either put the participants at risk because of participation in the trial, or may 
influence the result of the trial, or the participant's ability to participate in the trial. 
 
 










Dialysis Shift:  
Time of Dialysis Shift: _______am/pm; Duration: ___________ hrs. 
Gender:            M/F                    Age: ___________ years old. 
Date of Birth (dd/mm/yy): _______________ 
Ethnicity: Caucasian      African American    Hispanic/Latino 
                  Asian                Other: ________ 
 
MEDICAL HISTORY 
What is the cause of kidney failure? 
Unknown               Nephronophthisis 
Diabetes Mellitus      APKD (Adult Polycystic Kidney Disease) 
Hypertension              Gout Nephropathy 
HIV-Nephropathy      Toxic Nephropathy 
Kidney Stone SLE (Systemic Lupus Erythematosus) 
Glomerulonephritis                     Other: _____________   
Start Date of HD: (mm/yy) ____________ 
Kidney Transplantation?                          Yes                             No 
Parathyroid Gland removed?                   Yes                             No 
Current Diagnoses: Diabetes?                  Yes                             No 
Tobacco Use?                                           Yes                              No 
Hepatitis C?                                               Yes                             No 









Is the dialyzer reused? Yes, How often?   Times No 
 
Type of dialyzer membrane: Polysulfone Cellulose triacetate Other:     
 
Types of vascular graft being used: Arterio venous fistula 
Arteriovenous graft (AVG) Venous Catheter 
Type of dialysate buffer: Acetate 
Low calcium 
Normal Calcium High Calcium Bicarbonate 
 
APPETITE AND DIET ASSESSMENT TOOL (ADAT) 
 
1. During the past wee (7 days), how would you rate your appetite? 





2. Have you had a change of appetite in the past week (7 days?) 
0=no 
1=Yes 
3. If you answered ‘yes’ to #2, how has your appetite changed? 
1=Increased 








Target Weight (kg)  
Height (cm)  
Post dialysis weight (dry weight)  
Body Mass index (kg/m2)  
Average IDWG  
Average UFR  
Average BP  
 
MUSCLE STRENGTH 
Hand Grip Dynamometer 
Hand Grip Strength (kg) 
Left (L) or 
Right (R) hand 












        
 
BODY COMPOSITION -- MUSCLE MASS MEASUREMENTS 
 1st measure 2nd measure Mean 
Mid-arm circumference 
(cm) 
   








Renal Profile (Pre-Dialysis) Date Test Result Normal Range 
Pre BUN (mg/dL)    
Post BUN (mg/dL)    
Creatinine (mg/dL)    
Sodium (mEq/L)    
Potassium (mEq/L)    
Corrected Calcium (mg/dL)    
Phosphorus (mg/dL)    
Serum Albumin (g/dL)    
Total Cholesterol (mg/dL    
Triglycerides (mg/dL)    
HDL-C (mg/dL)    
LDL-C (mg/dL)    
Glucose (mg/dL)    
HgbA1C (g/dL)    
Hemoglobin (g/dL)    
Hematocrit (%)    
Serum Fe (μg/dL)    
Serum TIBC (μg/dL)    
TSAT (%)    
Ferritin (ng/mL)    
Kt/V    
URR    
nPCR (g/kg/day)    
hsCRP (mg/L)    







24-hour dietary recall Dialysis Day or Non-Dialysis day 
MealHome 






tsp. oz., g) 
Preparation Method 
(fried, grilled, roasted, 
stewed) 
Source of food 
(fresh, frozen, 
canned, etc.) 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      







MALNUTRITION INFLAMMATION SCORE (M.I.S.) 
(A) Patients’ related medical history 








No decrease in dry weight 
or weight loss <0.5 kg 
Minor weight loss 
(≥0.5 kg but < 1 kg) 
Weight loss more than 1 kg 
but <5% 
Weight loss> 5% 








Good appetite and no 
deterioration of the 
dietary intake pattern 
Somewhat sub-optimal solid 
diet intake 
Moderate overall decrease to 
full liquid diet 
Hypo-caloric liquid to 
starvation  








No symptoms with good 
appetite 
Mild symptoms, poor 
appetite or nauseated 
occasionally 
Occasional vomiting or 
moderate GI symptoms 
Frequent diarrhea or 
vomiting or severe 
anorexia 








Normal to improved 
functional capacity, 
feeling fine 
Occasional difficulty with 
baseline ambulation, or 
feeling tired frequently 
Difficulty with otherwise 
independent activities       
(e.g. going to bathroom) 
Bed/chair-ridden, or 
little to no physical 
activity 
 








On dialysis less than one 
year and healthy 
otherwise 
Dialyzed for 1-4 years, or 
mild co-morbidity 
(excluding MCC*) 
Dialyzed > 4years, or 
moderate co-morbidity 
(including one MCC*) 
Any severe, multiple 
co-morbidity (2 or 
more MCC*) 
 
(B) Physical Exam (according to SGA criteria) 








Normal Mild Moderate Severe 








Normal Mild Moderate Severe 
 
(C) Body mass index: 








BMI ≥ 20 kg/m2 BMI: 18 - 19.99 kg/m2 BMI: 16 – 17.99 kg/m2 BMI ≤ 16 kg/m2 
 
(D) Laboratory Parameters: 








Albumin ≥ 4.0 g/dL Albumin: 3.5 -3.9 g/dL Albumin: 3.0 – 3.4 g/dL Albumin ≤ 3.0 g/dL 








TIBC ≥ 250 mg/dL TIBC: 200 - 249 mg/dL TIBC: 150 - 199 mg/dL TIBC ≤ 150 mg/dL 
 







RESTLESS LEG SYNDROME RATING SCALE 
Have the patient rate his/her symptoms for the following ten questions. The patient and not 
the examiner should make the ratings, but the examiner should be available to clarify any 
misunderstandings the patient may have about the questions. Either the examiner or the 
patient may mark the answers on the form. 
1. How would you rate the RLS discomfort in your legs or arms? 
 






2. Overall, how would you rate the need to move around because of your RLS 
symptoms? 
 






3. Overall, how much relief of your RLS arm or leg discomfort do you get from moving 
around? 
 
(4) No relief 
(3) Slight relief 
(2) Moderate relief 
(1) Either complete or almost complete relief 
(0) No RLS symptoms and therefore question does not apply. 
 
4. Overall, how severe is your sleep disturbance from your RLS symptoms? 
 













5. How severe is your tiredness or sleepiness from your RLS symptoms? 
 






6. Overall, how severe is your RLS as a whole? 
 






7. How often do you get RLS symptoms? 
 
(4) Very Severe (This means 6 to 7 days a week) 
(3) Severe (This means 4 to 5 days a week) 
(2) Moderate (This means 2 to 3 days a week) 
(1) Mild (One day a week or less) 
(0) None 
 
8. When you have RLS symptoms, how severe are they on an average day? 
 
(4) Very Severe (This means 8 hours per 24 hours a day or more) 
(3) Severe (This means 3 to 8 hours per 24 hour a day) 
(2) Moderate (This means 1 to 3 hours per 24 hour a day 
(1) Mild (One hour per 24 hour a day) 
(0) None 
 
9. Overall, how severe is the impact of your RLS symptoms on your ability to carry out 
your daily affairs, for example, carrying out a satisfactory family, home, social, 
school, or work life? 
 







10. How severe is your mood disturbance from your RLS symptoms-for example angry, 














































































– and – 
Well-Being 
Kidney Disease and Quality of Life (KDQOL™-36) 
This survey asks for your views about your health. This information 
will help keep track of how you feel and how well you are able to 
do your usual activities. 
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Methods to identify patients at risk for ESRD are a high priority in Bangladesh, where 
kidney transplants/dialysis options are limited and costly. Every year, 35,000 to 40,000 
people reach ESRD in Bangladesh, but currently available facilities can hardly accommodate 
only 9000 to 10,000 new patients with twice weekly dialysis and the remaining 66% have no 
access to any kind of renal replacement therapy (RRT) in the form of dialysis or 
transplantation. Nutrition is an important factor in maintaining good health of hemodialysis 
patients. However, data on nutritional status of Bangladeshi dialysis patients is limited and is 
not adequately documented. The purpose of the first study (specific aim I and II) was to 
assess current health and nutritional status of hemodialysis (HD) patients in a specialized 
renal hospital in Dhaka, Bangladesh. We assessed 133 patients (49% male) at the Kidney 
Foundation Hospital and Research Institute (in 2017 and 2018) based on different 
anthropometric, biochemical, and clinical parameters. Lipid profiles and subfractions were 





Treatment Panel) III guideline. Patients were also analyzed based on 2x weekly versus 3x 
weekly dialysis in order to see if there were any significant differences between these two 
groups. Patients with protein-energy wasting (PEW) were identified using criteria from the 
International Society of Renal Nutrition and Metabolism (ISRNM). Therefore, we conclude 
that, in this specialized renal hospital, no significant differences were found based on dialysis 
frequency. However, both mixed and atherogenic DL were prevalent and 64% of patients 
were having DL based on TAG/HDL-C ratio. Prevalence of PEW was 18%, thus both DL 
and PEW were common among the study cohort. The figures may be underestimates as only 
one clinic was evaluated. If this is the scenario in an Urban renal-specialized hospital in 
Bangladesh, it is obvious that, many more hemodialysis patients were also suffering from DL 
and PEW all over the country. For specific aim III, we took an attempt to develop an 
educational tool for improving renal-specific nutrition knowledge among Bangladeshi 
dialysis patients in the form of a “Nutrition booklet” based on robust analysis of local Food 
compoition table and then incorporated key observations based on scientific basis into the 
booklet. Provision of renal-specific nutrition knowledge may help renal patients make more 
informed food choices. This may be especially important in resource-poor settings where 
nutritional support is a low-priority amongst health-care providers. The renal-specific 
nutrition booklet was developed only for Bangladeshi dialysis patients and made feasible to 
use in practice as an educational tool to improve their selection of food items as well as 
adherence towards renal-specific diet practice through this study. Additionally, we took 
initiative to educate and train a group of graduate students (in nutrition) with basic skills to 
assist renal staff in nutrition and anthropometric assessments in a hospital providing dialysis 
services in Dhaka, Bangladesh. The outcomes for both attempts were hopeful. Individuals 





resource-poor countries which limit the opportunity to conduct research in this field in order 
to find the hidden truth behind the occurrence and severity of disease. Therefore, attempts 
should be made to generate trained manpower in order to facilitate research work in renal 
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